Investigation of SAP, NPTX1 and their interaction on synaptic function and microglia activity and their possible role in Alzheimer's disease by Benway, TA
  
Investigation of SAP, NPTX1 and their 
interaction on synaptic function and 
microglia activity and their possible role in 
Alzheimer's disease 
 
Tiffanie Benway 
UCL 
 
Thesis submitted for partial fulfillment of the degree 
of Doctor of Philosophy 
 
May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 2	
Declaration  
 
 
I declare that the work presented herein is my own, except where indicated below. 
 
Immunohistochemistry for mouse models was performed in part by Angela Richard-
Loendt, and for human tissue was performed in part by Dr. Tammaryn Lashley. 
 
Brain dissections for RNA were performed by Dr. Dervis Salih, and the preparation of 
organotypic hippocampal slices from GFP-S mice was carried out by Dr. Damian 
Cummings. 
 
I generated Figures 3.1, 3.5*, 3.7 and 3.8 for my work as part of a previous 
publication (Cummings, Benway et al., 2017) 
*or co-generated with the co-first author of the paper 
 
 
 
 
 
Acknowledgements 
 
 
I would first like to thank Dr. Frances Edwards for not only providing me with the 
opportunity to work in her lab, but also for being such a supportive supervisor who 
always manages to make time for her students. 
 
A massive thank you to the post docs, Dr. Dervis Salih and Dr. Damian Cummings. In 
particular, I can’t thank you enough Dervis for your resounding patience and for 
taking the time to teach me so much, despite me probably asking you the same 
questions hundreds of times.  
 
A big thanks also to current and former lab members, particularly Zelah, Josh and 
Wenfei, who have helped to make the lab a fun place to work for all the years that 
I’ve been there! 
 
Lastly, I want to thank my family and friends, for whom I am immensely grateful to 
have in my corner. Thank you Sonia for being there, Pips for the countdowns and 
Heather for all of your help. And especially, thank you Zel, for supporting me through 
all of it. I’m not sure I would have made it without all the laughs (and the dinners!) 
that you provided. 
 
 
 
 
 
 
	 3	
Abstract 
 
 
The pentraxins comprise of a family of proteins that exist in the brain to modulate 
synaptic formation and plasticity, and in the periphery as part of the immune 
response. Both the peripheral pentraxin serum amyloid-P component (SAP) and the 
neuronal pentraxin 1 (NPTX1) have been implicated in Alzheimer’s disease (AD) and 
show up-regulation in AD brains. SAP is always found on amyloid plaques and is 
linked to amyloid fibril stability, while NPTX1 is present in dystrophic neurons in 
plaques and can mediate some of the effects of amyloid-beta (Aβ). Under conditions 
of blood-brain barrier compromise, SAP can also enter the brain and is capable of 
exerting effects on synaptic transmission. 
 
Results from the current study show that SAP is capable of forming complexes with 
the neuronal pentraxins.  Specifically, SAP can bind with NPTX1, NPTX2 and 
NPTXR when co-overexpressed in 293T cells. To investigate the effects that this 
complex may be having in the brain, SAP and NPTX1 were applied separately or 
simultaneously to primary neurons and to organotypics slices. To evaluate post-
synaptic effects, spine density after SAP and/or NPTX1 application was examined. 
NPTX1 application resulted in decreased spine density, but this effect was prevented 
by SAP. A similar blocking effect of NPTX1 by SAP was found in the microglia 
counts from organotypic cultures, where NPTX1 alone resulted in decreased 
microglia and NPTX1+SAP showed a reduced deficit. Application of both SAP and 
NPTX1 resulted in a decrease in the proportion of activated microglia, whereas the 
application of either pentraxin alone was not found to affect levels of activation. 
Therefore, while SAP alone has no effect, it can block the effect of NPTX1 in 
decreasing microglial numbers, and contribute to decreased activation levels when co-
applied with NPTX1. These results suggest that when SAP enters the brain it may be 
capable of exerting effects on synaptic transmission and immune response in the CNS 
via an interaction with the neuronal pentraxins. 
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Chapter 1 		
Introduction  
 
An introduction to the present study 
 
The present study concentrates on two members of the pentraxin family of proteins 
that have both been implicated in Alzheimer’s disease (AD): the neuronal pentraxin 
NPTX1 and the peripheral pentraxin SAP. While various studies have been performed 
on either SAP in the context of its interactions in the periphery, or NPTX1 in the 
context of its interactions in the CNS and/or with other neuronal pentraxins, no 
studies had previously examined the possible interactions between these two 
particular pentraxins. This raised the question whether, given the structural homology 
and the evidence that both pentraxins have been reported to be present on amyloid 
plaques, SAP and NPTX1 may be capable of interacting or somehow influencing the 
effects of one another in the CNS, and with focus on their possible roles in AD.  
 
To investigate this question, it was essential for our experiments that we first develop 
the tools with which to carry out our study most accurately. The reasoning for this 
was two-fold; 1) there is a significant degree of homology between each of the 
different pentraxins (Fig. 1.1), and 2) there exists contention in the field over the 
particular functions of certain pentraxins and the roles they play in pathological 
processes of the brain.  The aim of this thesis is to therefore confirm the localization 
of SAP and NPTX1 in the brains of AD patients, particularly in relation to one 
another, and then investigate the effects that each of the two pentraxins may be having 
in the brain at increased levels, either separately or together.  
 
While some of the evidence presented has recently been published in an article in 
which I am co-first author (Cummings, Benway et al., 2017), I have performed 
additional work that expands upon these results, and examines these two pentraxins in 
the context of AD pathology. To accomplish this, I focused on attributes comprising 
the hippocampus, as it is the brain structure most significantly affected in AD. The 
following thesis provides histological and molecular biological characterization in 
humans and mice, and also assesses the effects of SAP and NPTX1 on features of 
synaptic plasticity, the immune response, and, for SAP, behavior.  
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An introduction to the pentraxins 
 
The pentraxins are members of a phylogenically conserved multifunctional 
superfamily of proteins that are characterized by an evolutionarily conserved 200 
amino acid domain in the C-terminus and an eight amino acid long conserved 
pentraxin signature: HxCxS/TWxS (where x is any amino acid); (Garlanda et al., 
2005). This superfamily of proteins is defined by their structural organization of five 
identical subunits arranged covalently in pentameric radial symmetry (Osmand et al., 
1977). The pentraxins share a very high degree of sequence homology (Fig. 1.1), and 
they are divided into two subdivisions based upon the primary structure of their 
subunits: the long and the short pentraxins (Garlanda et al., 2005). The short, or 
classic, pentraxins are produced mostly in the liver and transported through the blood 
stream to other organs and tissues (Deban et al., 2011), while the long pentraxins are 
comprised mostly of a subset of neuronal proteins termed the neuronal pentraxins, 
which are expressed by neurons of the central nervous system (Schlimgen et al., 
1995). 
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Figure 1.1. The pentraxin share a significant degree of homology. Alignment of the 
protein sequences for APCS (SAP), CRP, NPTX1, NPTX2 and NPTXR, where asterisks 
identify the regions shared by the five pentraxins, modified from Clustal Omega. 
   Pentraxin          
Domain Start 
   Pentraxin 
   Domain End  
signature 
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The short pentraxins	 
 
The short (classic) pentraxin arm of the 
superfamily consists of acute phase C-
reactive protein (CRP), the first pentraxin 
identified in the late 1930s, and serum 
amyloid P component (SAP). CRP was 
first discovered in the blood of a patient 
with Streptococcus pneumonia, but could 
only be detected during the time when the 
patient was infected. CRP was 
subsequently found to be at high 
concentrations in the acute phase sera, 
where it induced the precipitation of the 
cell wall of a bacterial cell in the presence 
of calcium (Tillett and Francis, 1930). The 
other short and very closely related 
pentraxin SAP was first discovered by 
Cathcart et al. (1967) who coined the 
name P-component after finding a protein 
constituent of amyloid deposits in the 
body that was also related to normal 
plasma protein (Cathcart et al., 1965; 
Cathcart et al., 1967a; Cathcart et al., 
1967b). Using electron microscopy 
techniques, Bladen et al. (1966) 
independently discovered SAP in their 
study on amyloid extracts from the 
periphery, but misinterpreted the 
pentagonal molecular structure of SAP 
as aggregated rods that they believed 
to be the bulk of amyloid deposits. 
Figure 2.  
Figure 1.2. The orientations of the five subunits of 
SAP pentamer: A) the five a-helixes on the A face 
of the protein, B) the five double calcium binding 
sites on the B face of the protein (with white calcium 
atoms). This crystal structure of SAP was solved by 
Emsley et al. (1994), with the subunits packed into a 
radially symmetric pentameric disk approximately 
100-Å in diameter, 35-Å in depth, and a 20-Å pore in 
the center. Each subunit consists of 204 amino acids 
in a single polypeptide chain containing a disulfide 
bridge that links Cys36 and Cys95. There is also a 
complex oligosaccharide N-glycosylation site on 
Asn32, as well as a metal-binding site containing two 
calcium ions. Adapted from (Kolstoe and Wood, 
2010). 
  A 
  B 
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SAP was later isolated and independently characterized by Binette et al. (1974), who 
identified the molecule that the previous studies determined to have both a pentagonal 
unit (Bladen et al., 1966) and a P-component (Cathcart et al., 1967a).  
 
It has since been found that human SAP and CRP share 51% strict residue sequence 
identity, or upwards of 66% homology when conservative substitutions are taken into 
account (Emsley et al., 1994; Srinivasan et al., 1994a). These pentraxins have been 
conserved throughout vertebrate evolution, with several forms present in species as 
far back as the arachnid, Limulus polyphemus (the horseshoe crab), which has 
persisted for 250-300 million years (Robey and Liu, 1981). These proteins have 
retained their ligand specificity and subunit arrangement of five tightly arranged 
subunits in planar symmetry (Fig. 1.2), in what has been described as a “doughnut-
shaped ring” (Osmand et al., 1977), and there remains a significant level of similarity 
in the sequence of CRP and SAP orthologs among different mammal species 
(Bottazzi et al., 2010).  It has been posited that human CRP and SAP are likely 
products of gene duplication on 1q23.2, as there is a significant degree of overlap in 
precise ligand specificity, behavior as acute phase proteins, as well as deposition in 
amyloid (Srinivasan et al., 1994a). Both short pentraxins have also been found to 
circulate in the blood as single pentamers (Hutchinson et al., 2000). 
 
Physiological roles of short pentraxins  
 
CRP function was first demonstrated by the injection of typhoid vaccine into rabbit 
muscle to examine the pattern of its deposition. CRP was found to target dead and 
damaged cells for processing by the innate immune system (Kushner and Kaplan, 
1961). Both short pentraxins have since been found to bind to nuclear antigens 
released from damaged cells and affect their clearance and antigenic processing, 
specifically with CRP binding primarily to the small nuclear ribonucleoproteins 
(snRNPs) (Du Clos, 1989) and SAP binding to chromatin and native DNA (Du Clos, 
1996; Pepys and Butler, 1987). These pattern recognition molecules also interact with 
various ligands: CRP with apoptotic cells, microorganisms and lipoproteins, and SAP 
also with apoptotic cells, bacteria, lipopolysaccharide (LPS) and amyloid fibrils (Hind 
et al., 1985; Mulder et al., 2010; Noursadeghi et al., 2000).  
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Human SAP is produced in the liver at constitutive serum levels reported to average 
approximately 33 µg/mL in women and 43 µg/mL in men (Pepys et al., 1978). This is 
consistent with the later measures that reported average serum levels to be at 
approximately 40 µg/mL (Hicks et al., 1992). SAP is secreted into blood circulation 
and exhibits a diverse range of functions in mammals (Skinner & Cohen, 1988). 
Natively, SAP can bind to chromatin, DNA, amyloid fibrils, bacteria, 
glycosaminoglycans and complement components, polymorphonuclear neutrophil 
cells, and bacterial lipopolysaccaride. Specifically, human SAP, like CRP, has been 
shown to clear cellular debris by its high affinity binding to neutrophils, and 
subsequent degradation by neutrophil enzymes that yields a mixture of small peptides 
(Landsmann et al., 1994). 
 
As the use of mouse models is common practice in the examination of physiological 
conditions, and will be discussed later in this introduction, it is important to note that 
there are some properties of mouse SAP that differ from human SAP. Namely, while 
SAP is not an acute protein in humans, it is found to be a strong acute phase marker in 
mice (Pepys et al., 1979), meaning plasma concentrations fluctuate in response to 
injury or infection (Whicher and Westacott, 1992). Additionally, the affinity with 
which SAP binds to DNA and to amyloid in mice is reported to be significantly 
weaker in mice than in humans, with the latter demonstrated by the measurement of 
injected mouse SAP compared to human SAP that was localized to amyloid fibrils in 
mice	(Gillmore et al., 2004; Hawkins et al., 1988). Among different mouse strains the 
baseline levels of SAP have been reported to differ considerably (Le et al., 1982), but 
as an acute phase protein SAP has been shown to be induced by IL-6 (Pepys et al., 
1979). However, as in humans, SAP is capable of opsonizing molecules for 
phagocytosis by binding to FcyRs (Fc receptors that induce phagocytosis of marked 
microbes), and of activating the complement cascade of the immune system (Lu et al., 
2008; Mold et al., 2001). 	
The physiological protective role of SAP 
 
For the purposes of the current study, focus will be placed upon research performed 
on SAP, rather than CRP, given the evidence to be provided for its possible role in 
neurodegenerative disease. However, the similarity in structure of the two short 
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pentraxins is an important point to consider in the examination of our results. Prior to 
the examination of SAP’s possible role in disease however, it is critical to note that 
SAP plays a protective role in the homeostatic balance in the periphery, under normal 
conditions. As such, SAP has been shown to be a constituent of the glomerular 
basement membrane, which is an extracellular matrix of the selectively permeable 
glomerular filtration barrier separating the vasculature from the urinary space (Dyck 
et al., 1980a; Dyck et al., 1980b). In vivo studies have demonstrated that SAP can 
inhibit renal fibrosis by binding to cell debris and causing suppression of 
inflammatory macrophages through activation of FcγRI and the anti-inflammatory 
cytokine IL-10 (Castano et al., 2009). Moreover, SAP appears to aid in the protection 
against different types of infections; SAP knockout mice show higher susceptibility to 
bacterial infections including Streptococcus pneumonia (Noursadeghi et al., 2000), 
and SAP has also been reported to inhibit the influenza viral infection in vitro by 
disrupting the viral binding to hyaluronic acid (Job et al., 2013). The latter result was 
consistent with earlier in vitro and in vivo studies that found SAP to be vital in the 
inhibition of viral infection (Andersen et al., 1997; Horvath et al., 2001). 
 
The predominant mechanisms by which SAP acts to play a protective role in the 
periphery are via opsonization of targets for phagocytosis when bound to monocytes 
and neutrophils (Bharadwaj et al., 2001) or triggering the immune response via the 
activation of the complement cascade (Hicks et al., 1992; Ying et al., 1992a). While 
activation of complement is a key feature of the immune response to fight off 
pathogens and clear debris in the body, recent research has revealed that there are 
situations in which this protective function can go awry and lead to a disruption of the 
delicate state of homeostasis in an organism. As SAP has been shown to play a 
significant role in complement, it is important to consider whether it may also be 
involved in this disruptive process as well.  
  
SAP and the complement cascade 
 
The classical pathway of the complement system is an integral line of defense 
comprised of 35 plasma and cell surface proteins that are part of the humoral immune 
response (Fig. 1.3). Complement plays a major role in immunological and 
inflammatory processes by monitoring the system and directing the elimination of 
	 20	
foreign intruders, cell debris and apoptotic cells. In addition, this system acts in 
synaptic maturation and removal, angiogenesis, tissue regeneration and lipid 
metabolism (Sunyer et al., 1998). This pathway is activated by the versatile pattern 
recognition molecule (PRM) C1q, which recognizes distinct structures that are on 
either microbial and apoptotic cells, or via endogenous PRMs such as 
immunoglobulins and pentraxins (Gaboriaud et al., 2004). 
 
While Ying et al. (1992a) first determined that aggregated SAP could activate 
complement, Hicks et al. (1992) later demonstrated that chemically aggregated SAP 
(and CRP) specifically activates the pathway via multivalent interaction with C1q. 
Interestingly, SAP was found to be able to do so either chemically cross-linked or 
bound to polyvalent ligands at a concentration of 25µg/mL (100 nM) or greater, 
which is an amount lower than the physiological concentration of SAP. This 
activation results from binding of SAP or CRP to an amino-terminal collagen-like 
region of C1q, within residues 14-26 (ibid). This use of the isolated aggregates 
allowed for direct comparison of the pentraxin concentration required for activation, 
without interference of the binding of other ligands that would normally occur under 
physiological conditions (Gewurz et al., 1995). However, this finding raises the 
question of how SAP, given its high concentration in the serum, does not then 
regularly cause complement activation - or at least calls into question the accuracy of 
the ‘normal’ plasma SAP concentrations previously measured. However, it is possible 
that this may be the result of C1q requiring the binding constant to reach a certain 
threshold. This is supported by evidence that C1q binds a single IgG Fc segment with 
very low affinity, with a dissociation constant of approximately Kd ≈ 10−4 M 
(Kinoshita et al., 1989; Srinivasan et al., 1994a). To activate complement via IgG, 
physiological C1q binding thus requires an increase in this binding constant, and this 
can happen in the case of clustering of antigen-driven antibodies which have been 
shown to allow for multivalent C1q binding (Pepys et al., 1994b). 
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Figure 1.3. SAP can activate the complement cascade by binding to C1q. SAP can 
interact with C1q via binding to its collagen-like domain, triggering sequential activation of 
the C1r and C1s proteases associated to the C1q collagen stalks. Activated C1s then cleave 
C4 and C2, which leads to the assembly of the C3 convertase that cleaves C3 for the 
opsonization of targets by C3b. Complement activation generates factors involved in 
inflammation and phagocytosis, and ends in target lysis by the membrane attack complex 
(which includes complement components C5b, C6, C7, C8 and C9).  
 
 
SAP in mice 
 
While SAP is an acute phase protein in the mouse that is induced by IL-6 (Pepys et 
al., 1979), it similarly activates the complement cascade as it does in humans. Also, 
SAP opsonizes targets for phagocytosis via the binding to FcγRs in the same manner 
in both species (Lu et al., 2008; Mold et al., 2001), which are receptors expressed by 
immune effector cells such as monocytes, macrophages, neutrophils, as well as 
dendritic cells (Nimmerjahn and Ravetch, 2008). However, in the mouse, plasma 
levels rise following tissue injury and their concentrations fluctuate in accordance to 
levels of inflammation to induce complement (Bottazzi et al., 2010). (Pilling and 
Gomer, 2012) investigated the physiological role of SAP in mice by knocking down 
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SAP and examining the effects. Interestingly, counter to its role in complement 
activation, they found that SAP promoted the resolution of inflammation induced by 
bleomycin aspiration, as the knockout mice showed significantly higher numbers of 
inflammatory macrophages (CD11b+). These data led to the suggestion that, given the 
inflammatory response was not aberrant in the knockout mice, the lack of endogenous 
SAP likely allows for the persistence of signals that drive inflammation. It has 
therefore been posited that the decrease or absence of SAP allows for the persistence 
of apoptotic cells and debris formed during inflammation that SAP would have 
normally promoted for phagocytosis. Overall, there is a significant degree of overlap 
in the functions of mouse and human SAP, but it is important to note that the above-
described differences exist and need to be taken into account when considering 
experimental results using mice.  
 
SAP in Amyloidosis 
 
SAP was named for its physical association with amyloid deposits present in various 
forms of amyloidosis, a clinical disorder caused by extracellular deposits of insoluble 
amyloid fibrils in the viscera, connective tissue and/or blood vessels. While the 
disease is rare, causing about one per thousand deaths in developed countries, it is 
usually fatal (Pepys, 2006). Organ function progressively becomes impaired as 
amyloid massively infiltrates the parenchyma (ibid). All abnormal amyloid fibrils 
reportedly share a common structure with a cross β core and a polypeptide chains 
running perpendicular to the fibril long axis, whether in the brain or the periphery 
(Sunde et al., 1997). Electron microscopy studies have shown that amyloid fibrils are 
approximately 10 nm in diameter, straight, rigid, non-branching and composed of 
twisted protofibrils (Jaroniec et al., 2004). Common components of amyloid deposits 
are heparan sulfate and dermatan sulfate proteoglycans and glycosaminoglycan 
chains, which are typically tightly bound to the fibrils (Nelson et al., 1991a) and aid in 
fibrillogenesis and stabilization of the structure (Kisilevsky and Fraser, 1996).  
 
It was first claimed that all amyloid deposits also contain SAP by Pepys et al. 
(1994b). This was based on the finding that SAP undergoes avid (Kd ∼1 µmol/l), 
specific, calcium-dependent, reversible binding to apparently all types of amyloid 
fibrils. This study also estimated that the concentration of SAP in amyloid deposits 
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may comprise up to ~15% of their mass (as measured from peripheral deposits). 
Specifically, it is the glycosaminoglycans and protein ligands on amyloid fibrils that 
SAP binds to, and it has ben proposed that this binding, which is highly resistant to 
protease digestion, stabilizes the fibrils and protects them from degradation by 
proteases and phagocytic cells, as it has been shown in vitro (Tennent et al., 1995). 
This was demonstrated via the binding of SAP to amyloid fibrils from the spleens of 
patients with different forms of amyloidosis protecting the fibrils from phagocytosis 
by immune cells and proteolytic enzymes (ibid).  
 
Two studies in 1997 helped to further clarify SAP’s role in amyloidosis, using mice 
with targeted deletion of the SAP gene. Both Botto et al. (1997) and Togashi et al. 
(1997) independently determined that the deletion of SAP led to delayed 
amyloidogenesis in a reactive model of systemic amyloidosis. From these results it 
was hypothesized that SAP likely takes part in amyloidogenesis by accelerating the 
formation of the amyloid deposits. Interestingly, the mice lacking SAP in these 
studies did not show any phenotypic abnormalities, though it could be posited that 
discerning any change would likely require an immune challenge, given mouse SAP 
is an acute phase protein, as previously discussed.  
 
It is important to note however that amyloid formation does not require SAP. This 
was shown using the same casein injection method of amyloidosis induction with 
SAP knockout mice. With a sufficiently powerful stimulus, these mice developed 
amyloid deposits exactly as the WT controls (Botto et al., 1997). An additional point 
of consideration is that human SAP reportedly binds much more avidly to amyloid 
fibrils than mouse SAP does, and is also approximately 30 times more abundant in 
human amyloid deposits than mouse SAP is in mouse amyloid (Hawkins et al., 1988; 
Pepys et al., 1997). In taking this point into account with the results of the studies in 
mice, it could therefore be suggested that human SAP is likely involved more 
significantly in pathogenesis and/or persistence of human amyloid. 
 
While there is substantial evidence for the role of SAP in amyloid fibril stability in the 
case of amyloidosis in the periphery, the obvious question raised is whether it may 
have similar effects with other pathologies involving amyloid deposition. The 
important point to consider with this question however is that other amyloid 
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pathologies are in the brain, rather than the periphery. Results of studies examining 
SAP in the brain have been less clear; assumptions made about the expression of SAP 
by one group of researchers that SAP is expressed exclusively in the liver (Pepys et 
al., 1997) was later challenged by another group that reported human neurons also 
express SAP (Yasojima et al., 2000), thus spurring more questions being raised. It has 
been claimed that SAP binds avidly but reversibly to all amyloid fibrils, which has 
been well characterized in systemic amyloidosis (Pepys, 2006) and also shown to 
occur in cases of sporadic cerebral amyloid angiopathy (CAA)(Charidimou et al., 
2012). CAA is an age related cerebral small vessel disease that is characterized by Aβ 
progressively depositing in the wall of small arteries, arterioles and capillaries of the 
cerebral cortex and overlying leptomeninges. If SAP is present in small damaged 
arteries of the cerebral cortex bound to amyloid, this raises the question of whether it 
could infiltrate the brain and do the same.  
 
In humans, SAP has not been detected in the brain under normal conditions, but it has 
been immunohistologically associated with the pathology that occurs in Parkinson’s, 
Creutzfeldt-Jakob and Lewy body disorders (Akiyama et al., 1991; Kalaria et al., 
1991a), and directly with amyloid deposits in Down’s syndrome and hereditary 
cerebral hemorrhage with amyloidosis (Coria et al., 1988; Iseki et al., 1988; Ogeng'o 
et al., 1996). Moreover, immunohistochemical studies have revealed widespread 
immunoreactivity of SAP in the brains of patients with Alzheimer’s disease (AD) - 
the most prominent form of dementia that afflicts 1 out of every 10 people over the 
age of 65 (Akiyama et al., 1991; Duong et al., 1993; Duong and Gallagher, 1994; 
Duong et al., 1989; Kalaria et al., 1991c; Kalaria and Grahovac, 1990; Kimura et al., 
1994; Perlmutter et al., 1995; Perlmutter et al., 1994).  
 
Alzheimer’s disease 
 
One of the most frequent and devastating health problems currently afflicting the 
elderly is AD, comprising 50-60% of all dementia cases, with no cure or 
fundamentally effective treatment (Ballard et al., 2011). AD is neuropathologically 
characterized by the accumulation of extracellular amyloid-β (Aβ) aggregates in the 
form of plaques and neurofibrillary tau tangles (NFT), as well as significant atrophy 
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of gray matter (Hyman et al., 2012). The underlying molecular mechanisms for 
disease development however are yet to be fully understood (Golde et al., 2011). 
 
Accounting for the vast majority of cases, late-onset sporadic AD likely develops as a 
result of a culmination of multiple factors, including those of aging, environment, and 
lifestyle, and often presents itself in people over the age of 65. Early-onset familial 
AD (eFAD) is a rare autosomal dominant disease affecting people well before the age 
of 65, and sometimes as young as 30, that accounts for approximately 2-3% of all 
cases of AD (Association, 2017). It is important to note however that AD exists in a 
continuum, where there can also be early-onset sporadic and late-onset familial cases, 
and each subtype is not necessarily a pure form unto itself. This is evidenced by 
research showing that about 25% of families with late-onset AD also have a relative 
who develops early-onset AD (Brickell et al., 2006). However, the genetic mutations 
in three genes that can cause eFAD are known: the mutations in the amyloid precursor 
protein (APP), and the enzymes presenilin 1 (PSEN1) and presenilin 2 (PSEN2) result 
in the pathological processing of the normal transmembrane protein APP (Blennow et 
al., 2006). One of the products of the two APP processing pathways (Fig. 1.4), when 
cleaved by the 𝛾-secretase complex, is the 42 amino acid peptide Aβ1-42, most highly 
associated with AD pathology (Rovelet-Lecrux et al., 2006). 
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Figure 1.4. The pathways of APP processing. As a transmembrane protein, APP can be 
processed in a non-amyloidogenic, or ‘normal’ pathway (left) in which it is cleaved by α-
secretase to produce soluble APPα (sAPPα) and C-terminal-83 amino acid fragment (C83), 
then CTFα is hydrolyzed by γ-secretase to generate APP intracellular domain (AICD) and the 
p3 fragment. APP can also be processed via the amyloidogenic pathway (right), where it is 
cleaved by β-secretase resulting in N-terminal soluble APPβ (sAPPβ) leaving the C-terminal 
99 amino acid fragment (CTF99) which is hydrolyzed by γ-secretase to yield Aβ40-42 and 
AICD. Presenilin is an aspartyl protease and a subunit of γ-secretase, and PSEN mutation 
might increase γ-secretase activity to cause plaque formation (Cai et al., 2015). 
 
While the amyloid hypothesis originally proposed Aβ accumulation was the main 
culprit in the disease, it has since become clear that amyloid deposits are not the direct 
cause of AD (Jellinger and Attems, 2013), particularly considering that amyloid 
plaque load is not directly related to cognitive decline (Price et al., 2009). Given the 
lack of correlation of synaptic and neuronal loss to amyloid plaques, soluble amyloid 
oligomers rather than insoluble deposits are considered to be largely responsible for 
the underlying pathology. There is also substantial evidence that increased production 
of Aβ may be the key to initiating AD and trigger tau pathology, supported by 
evidence of the co-occurrence of Aβ and tau pathologies in the AD brain, as well as 
results from genetic, cells and mouse models of AD pathology (Spires-Jones et al., 
2017). Considering our relatively limited understanding of the pathological 
mechanisms all taking place in the lead-up to AD, it is integral that possible 
contributing factors that have been implicated in AD be thoroughly investigated. The 
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aim of the thesis is to therefore explore the role of SAP, a protein that has repeatedly 
been reported in association with key pathological features of AD, particularly given 
that SAP has not been found in the brain under normal physiological conditions.  
 
SAP in the brain in Alzheimer’s disease 
 
It has been proposed that SAP may be a factor in the pathogenesis of AD, given the 
evidence that it is bound to cerebral and cerebrovascular amyloid deposits as well as 
neurofibrillary tangles (Coria et al., 1988; Crawford et al., 2012; Duong et al., 1989; 
Kolstoe et al., 2009). This is also based upon findings that SAP contributes to the 
pathogenesis of systemic amyloidosis (for review see Pepys, 2006), wherein the 
extensive nature of peripheral amyloid deposits may reflect the situation present in the 
AD brain. However, there is also evidence that SAP is located elsewhere in the brain 
aside from only in the vicinity of Aβ plaques and NFTs, suggesting it may be capable 
of exerting other effects in the brain as well, in addition to any interaction that it may 
be having with plaques.  
 
It was first reported by Kalaria and Perry (1993) that SAP was present in the diffuse 
cerebellar amyloid deposits in AD, in contrast to an earlier study that claimed SAP 
staining was restricted to only the plaques of AD patients (Rozemuller et al., 1990). 
However, a key feature that is relied upon for accurate interpretation of these results 
often fails to be thoroughly assessed; in the case of the study by Rozemuller et al. 
(1990), no details of the SAP antibody epitope or specificity are provided, whereas 
the later study by Kalaria et al. (1993) describes the use of two different monoclonal 
SAP antibodies that were and tested for specificity via immunoblotting in their two 
previous studies (Kalaria et al., 1991a; Kalaria and Kroon, 1992). However, although 
the latter study detected bands of the correct size for SAP, they did not report whether 
there was an assessment of the antibodies binding to other pentraxins. This will be a 
key point for consideration in the following sections to be discussed within this thesis.  
 
A point of contention currently exists in the field over whether there is local 
production of SAP in the brain. While it is claimed by some researchers that SAP is 
synthesized and catabolized only by the liver (Al-Shawi et al., 2016), based upon 
human and mouse brain transcriptome studies (Hawrylycz et al., 2012; Zhang et al., 
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2014), and a study that examined mRNA expression in AD patients (Kalaria et al., 
1991c), other studies have shown different results. Points to consider from this 
evidence are that: i) the transcriptome analysis was based upon the expression levels 
under normal physiological conditions, and thus may not reflect the changes in 
expression levels that are likely to occur in a diseased state; and ii) RT-PCR 
techniques have become more sensitive in their detection capabilities since 1991, and 
Kalaria et al. (1991c) neglected to include information on the primers used, which 
may possibly have not been specific or sensitive enough to detect any signal. 
Opposing RT-PCR findings have since been published that show SAP (and CRP) 
mRNAs and proteins are generated by pyramidal neurons and markedly upregulated 
in the brain regions most significantly affected by AD, particularly in the 
hippocampus and mid temporal gyrus, and in the cerebellum as well (Yasojima et al., 
2000). Interestingly, SAP mRNA was also detected in human brain samples that did 
not show AD pathology (ibid). More specifically, Yasojima et al. (2000) report that 
the SAP mRNA level was 2.1-fold in the hippocampus, 2.4-fold higher in the 
midtemporal gyrus, 2.2-fold in both the midfrontal and motor cortices, and 1.7-fold in 
the cerebellum. With no differences reported between liver values of control and AD 
cases, it suggests that the upregulation is specific to the brain in the case of AD. 
Further in situ hybridization experiments found SAP mRNA signals for pyramidal 
neurons in hippocampus CA1 and CA4, dentate granule cells and pyramidal neurons 
of the temporal cortex. Additionally, SAP mRNA was reportedly found in the lung, 
heart, arteries, kidney and spleen, indicating macrophages and neurons may likely 
produce SAP in addition to hepatocytes (ibid). As such findings had not been reported 
previously, possible factors accounting for the detection include the use of tissue after 
a very short post-mortem interval that was not frozen, as well as the use of enhancer 
conditions coupled with higher sensitivity primers.  
 
In examining the evidence for the presence of SAP protein in the brain, extracts from 
the hippocampus of AD patients and controls showed SAP to be at concentrations of 
approximately 1µg/mg protein and 0.6µg/mg protein, respectively (Yasojima et al., 
2000). These results indicated that SAP mRNAs are translated into their protein 
products approximately proportional to their relative mRNA levels. In accordance, 
another more recent study also examined protein levels in AD patients and found SAP 
levels to be elevated in the hippocampus, as well as in the frontal cortex, compared to 
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controls. This study reports a four-fold increase to 110 ng of SAP/mg of protein in 
AD (Crawford et al., 2012), differing from the 1 µg of SAP/mg protein previously 
reported (Yasojima et al., 2000). However, the authors suggest that the difference is 
due to the use of total homogenate rather than protein concentrations of supernatants 
after centrifugation of homogenates. An additional methodological point to consider 
in the difference between the two aforementioned studies would be that each used a 
different commercial SAP antibody for detection of protein levels, but neither 
provides evidence for the specificity of either antibody. Given the significant degree 
of homology between SAP and CRP, as previously discussed, antibody specificity is 
imperative in studies examining pentraxins. In addition, the in situ studies mentioned 
above also demonstrated a high degree of similarity in the distribution of the positive 
signal for both short pentraxins in neurons, and there is immunohistological evidence 
of SAP and CRP both being associated with Aβ plaques in AD (Yasojima et al., 
2000). Therefore, careful interpretation is required with the use of antibodies for these 
pentraxins.  
 
Studies on SAP concentration in the CSF in AD patients have reported multiple 
different findings. It is generally accepted that SAP is normally present in the CSF at 
a concentration of approximately one-thousandth the plasma concentration (Al-Shawi 
et al., 2016; Hawkins et al., 1994; Nelson et al., 1991b). While detection of SAP in 
the CSF of AD patients was found to increase in a study by (Hawkins et al., 1994), 
more recent studies have not been able to confirm this. Mulder et al. (2010), in line 
with Verwey et al. (2008), found that CSF SAP levels remained the same between 
AD patients (or MCI patients who progressed to AD) and controls, but suggested that 
this may be due to high levels of SAP being bound to the significant number of 
plaques existing in the brains of these patients. Specifically, (Verwey et al., 2008) 
found decreases in CSF SAP levels in MCI patients who went on to develop AD, 
proposing SAP as a biomarker. Collectively, these findings pose an important 
question of what SAP might be doing in the brain in the lead-up to AD if, over a 
lifetime, SAP infiltrates the brain across its high concentration gradient and/or 
increases in concentration in the brain. 
 
Initially, the presence of SAP in the brain was thought to indicate a dysfunction or 
‘leakage’ of the BBB in multiple different neurodegenerative conditions (Coria et al., 
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1988; Duong et al., 1989; Kalaria et al., 1991b; Kalaria and Grahovac, 1990; Shi et 
al., 1999). Other known risk factors for dementia, including advanced age, cerebral 
haemorrhage, traumatic brain injury (TBI) and severe or repeated non-penetrating 
head injury (Association, 2017), all, certainly or probably, increase exposure of the 
brain to peripheral proteins, which could then contribute to a disruption of brain 
homeostasis. In old age, it is possible that the increases in SAP that have been 
observed are simply due to the prolonged duration of exposure to normal CSF SAP 
concentrations. However, the compromised cerebral vascular integrity present in other 
pathological conditions may enable plasma, with its 1000-fold higher SAP 
concentration, to enter the cerebral substance to a much greater extent.  
 
Evidence for the ability of SAP to cross the BBB has been shown under an 
experimental condition that has been reasonably well established in the field to cause 
disruption of the BBB and significantly increase its permeability. Administration of 
lipopolysaccharide (LPS) has been shown to induce inflammation and affect 
mediators that regulate the BBB permeability to allow for the infiltration of 
components from the blood (Banks et al., 1998; Minami et al., 1998; Persidsky et al., 
1997; Xaio et al., 2001). A study by Veszelka et al. (2013) utilized the administration 
of LPS to induce a state of inflammation in mice, and first confirmed the migration of 
SAP across the BBB by comparing the influx rates in mice that received peripheral 
injections of human SAP. But, the question first needs to be asked about what the 
BBB is, how it functions and how may it be compromised in neuropathological 
conditions. In the following section, the possibility of BBB leakage in AD will be 
discussed, with evidence for its occurrence (or lack thereof) in humans provided. 
Importantly, as mouse models are often utilized in the examination of 
neurodegenerative disease, the evidence on BBB function will also be examined in 
the appropriate models.  
 
Permeability of the blood-brain barrier in AD 
 
The blood-brain barrier (BBB) is a highly selective semipermeable membrane that 
safeguards the homeostasis of the brain’s microenvironment by regulating tight 
control of the chemical composition crossing from the blood to the CNS (Zlokovic, 
2011). This barrier is comprised of cerebral blood vessels, cerebral endothelial cells, 
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basal lamina, astrocytic foot processes, and pericytes (Iadecola and Nedergaard, 
2007), which all function in restricting fluid and entrained molecules from being 
transported into the brain from the systemic circulation. The initial barrier with the 
blood is formed of tight junction proteins, such as claudin, occludin, and zona 
occludin, while the second barrier of the basal lamina contains type IV collagen, 
fibronectin heparan sulfate, amongst other molecules, which acts as a molecular 
weight filter (Candelario-Jalil et al., 2009).  
 
It has long been hypothesized that compromises in the BBB may be a major 
contributing factor in brain diseases, particularly in the cases of cognitive dysfunction 
associated with aging and AD (Deane et al., 2008). However, it has been difficult to 
definitively demonstrate whether disruptions of the BBB affect brain regions involved 
in cognition due to the lack of suitable methods to assess the integrity of the BBB 
quantitatively and regionally in the human brain in vivo. Until recently, the evidence 
for leakage of the BBB in AD remained unclear; factors that differentiated between 
different types of dementia failed to be taken into account, along with small sample 
sizes of AD patients and less advanced technological means of measurement, thus 
preventing a definitive conclusion from being made. Over the age of approximately 
70, there is increasing evidence of vascular disease intersecting with AD (Rosenberg, 
2014). Cases of mixed dementias are rising as a large number of normal patients show 
amyloid and tau deposits and microinfarcts at autopsy (Sonnen et al., 2011). Changes 
in the vasculature are a normal part of aging, but with increased age there are 
alterations that occur in the BBB that can contribute to the pathological processes in 
different types of dementias (Farrall and Wardlaw, 2009). Because of this overlap, 
careful scrutiny of patients in these studies is crucial, but has not always been 
performed. In the early stages of AD and vascular dementia, it is generally not 
possible to separate the different pathophysiologies, or determine whether there may 
be a mixture of the two (Rosenberg et al., 2014). To best differentiate disease, a 
combination of advanced imaging techniques with CSF analysis is required, but has 
not often been fulfilled in most studies examining BBB leakage.  
 
The interpretations of earlier studies examining BBB breakdown are therefore 
problematic, as more advanced imaging and CSF studies have only recently become 
available to more accurately separate patients carefully into AD, vascular cognitive 
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impairment, and mixed. For measuring BBB leakage, previous studies have relied on 
imaging methods such as positron emission tomography (PET), magnetic resonance 
imaging (MRI) and computed tomography (CT). One such study claiming to find no 
evidence of increased BBB permeability in AD used PET imaging with only 5 AD 
patients and 5 controls (Schlageter et al., 1987) and, along with several other CT and 
MRI studies with very small subject numbers claiming the same results, little 
information was available on controls, and it was not specified whether mixed 
patients were included (Caserta et al., 1998; Starr et al., 2009). 
 
Another method of BBB permeability assessment that is examined either as the sole 
quantification measure or in combination with an imaging technique is the CSF 
albumin ratio. Earlier studies have shown increased concentrations of albumin in the 
CSF with age, indicating that this large protein molecule produced exclusively in the 
liver and restricted to the blood compartment can be abnormally transported across 
the cerebral vessels into the CSF (Farrall and Wardlaw, 2009). Results from this 
method of analysis have been conflicting; while ratios of albumin levels in the CSF to 
those in the blood are high in patients with vascular causes of dementia (Blennow et 
al., 1990), some studies report this ratio to be normal in AD (Frolich et al., 1991). 
These results led to the suggestion that vascular disease was the cause of the increased 
permeability, and not the pathologies present in AD. However, there are drawbacks to 
this method of analysis; albumin is a relatively large protein with a molecular weight 
of 66 kDa, so it cannot be considered as a sensitive measure of permeability. This 
ratio method also fails to pinpoint the site(s) of BBB disruption. Additionally, this 
evidence assumes that the CSF reflects concentrations present in the brain, whereas 
the primary source of protein in the CSF is in fact from the choroid plexus (Wood, 
1980). Therefore, CSF protein composition may only have minimal, if any, 
correlation to the parenchymal changes in the brain (Caserta et al., 1998).  
 
Other studies using protein concentrations to assess permeability of the BBB in aging 
and dementia have relied on autopsy material. For analysis, extravasation of plasma 
proteins, such as albumin, or even fibrinogen (of an even greater molecular weight of 
340 kDa), has been detected qualitatively in selected brain regions by 
immunocytochemistry (Zlokovic, 2008). This approach is perhaps even less ideal, 
given the occurrence of tissue degradation, advanced disease, and coexisting 
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pathologies that exist in post-mortem brains, which further complicate establishing a 
cause-effect relationship.  
 
However, a recent study by Montagne et al. (2015) has helped to clarify the matter of 
BBB leakage in the field of dementia. The aforementioned study has provided the 
most direct evidence to date of BBB disruption with their finding that compromises 
are restricted to the hippocampus in aging and in MCI patients who are at increased 
risk for AD. This examination of 4-times more patients than the previously mentioned 
PET study (Schlageter et al., 1987) used a multimodal approach of an advanced 
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with additional 
analysis of not only CSF biomarkers of BBB breakdown, but also of injury to brain 
vascular cells, markers for inflammatory response and neuronal injury, tau and pTau 
levels, and Aβ levels. Moreover, results of this study were strengthened by their 
capability to perform post-processing analysis with improved spatial and temporal 
resolutions that allowed for quantification of BBB regional permeability (Ktrans 
constant) in the brains of individuals with either no cognitive impairment or MCI. The 
Ktrans brain maps were generated from the arterial input function in patients between 
the ages of 23 to 91, and enabled simultaneous measurement of regional BBB 
permeability in the grey and while matter, as opposed to previous studies that have 
only been able to gather measurements of BBB permeability in the white matter 
(Taheri et al., 2011a; Taheri et al., 2011b; Taheri et al., 2013). 
 
Age-dependent Ktrans increases were found in the CA1 and DG regions of the 
hippocampus, but in subjects with MCI, the Ktrans increases were approximately 60% 
larger than those observed in cognitively intact age matched controls. This measure in 
the MCI patients also correlated with findings of injury to BBB-associated pericytes. 
Interestingly, no changes in hippocampal volume were found in association with 
increased permeability, suggesting BBB dysfunction precedes hippocampal atrophy. 
The significantly increased BBB breakdown has raised the possibility that this 
leakage might therefore contribute to early cognitive impairment, given the 
vulnerability of this region in AD.  
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The BBB of the mouse 
 
In contrast to humans, the case of BBB breakdown in mice is considerably less clear. 
The presence of amyloid has been suggested to be a factor in the opening of the BBB, 
particularly as Aβ has been shown to activate the pro-inflammatory cyclophilin A-
matrix metalloproteinase-9 (MMP-9) pathway in brain pericytes, which in turn results 
in degradation of the BBB tight junctions and basal lamina proteins (Bell et al., 2012). 
This MMP-9 pathway induction has been shown in experimental animals and in cell 
cultures (Deb and Gottschall, 1996), as well as in transgenic mice with APOE4 
which, at the age of 18 months, showed significant levels of the endogenous blood-
derived IgG accumulation in the brain (Bell et al., 2012). Consistent with an increase 
in MMP expression and reduction of BBB tight junctions, increased permeability in 
brain microvessels was also found in nine month old Tg2576 mice which overexpress 
human amyloid precursor protein (Hartz et al., 2012). 
 
Conversely, other studies in different mouse models of AD pathology report different 
findings regarding BBB permeability. It has been reported that 27-month old APP23 
transgenic mice, which overexpress APP751 with the Swedish double- mutation 
under the control of a neuron-specific Thy-1 promoter (Calhoun et al., 1999; 
Sturchler-Pierrat et al., 1997), display no leakage of the BBB (Winkler et al., 2001). 
However, there were significant limitations to this study; assessment of BBB leakage 
was performed using horseradish peroxidase (HRP) and trypan blue, which were 
found to be associated with amyloid-laden vessels, but not at significantly increased 
levels in the neuropil (ibid). These methods of BBB permeability assessment were 
first used as such by (Rossner and Tempel, 1966)trypan blue) and (Brightman and 
Reese, 1969)HRP), but since the late 1960s technology has come a long way in 
developing several other far more accurate methods for BBB assessment. Particularly 
problematic in the case of trypan blue is that its assessment is contingent on it binding 
to the large protein albumin, for which the drawbacks have already been discussed, 
and further it actually lacks specific binding to albumin. HRP can cause degranulation 
of cells and promote the release of neurotransmitters (histamine and serotonin) that 
can interfere with the integrity of the BBB by affecting vascular permeability and so 
can give confounding effects if used in vivo or live tissue (Majno et al., 1961). 
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In relating back to our question of whether SAP might be accessing the brain via 
leakage of the BBB, a study by Shi et al. (1999) directly addressed this question using 
transgenic mice overexpressing β-protein precursor (βPP). Overexpression of βPP in 
transgenic mice (by neuron-specific promoters) has been shown to cause AD-type Aβ 
deposits in the brain (Kalaria, 1996; Nunomura et al., 1999) as Aβ is proteolytically 
produced from β protein precursor (βPP) (Kalaria and Grahovac, 1990). While the 
authors claim to find no disruption in the BBB in this model, the only measure 
examined was immunoreactivity of SAP, which was performed in only three mice, 
between (a rather large range of) ages 13-25 months old, making the results less than 
conclusive.  
 
Recently, a more comprehensive study performed by (Bien-Ly et al., 2015) sought to 
quantitatively measure BBB permeability in multiple different mouse models of AD 
pathology using an antibody-dosing paradigm and a radiotracer assay with molecular 
probes of multiple different sizes (dextran: 3 kDa, albumin: 67 kDa, control IgG: 150 
kDa). The transgenic models examined were the PS2-APP at the ages of 15–16 
months with extensive plaque burden (Grueninger et al., 2010), TauP301L aged 14–18 
months with tau aggregation developed by 8 months (Terwel et al., 2005), and 
TauP301S aged 8– 10 months that exhibit prominent neurodegeneration by 9 months 
(Yoshiyama et al., 2007). No passive entry of any radiotracers were observed for any 
models, and further tests examining endogenous protein showed no differences in 
albumin or claudin-5 for the PS2-APP mice. While the results of this sensitive assay 
suggest a lack of BBB in these mice, the findings should still be taken with caution, 
given the hippocampus (shown to be vulnerable in AD patients, as discussed above) 
was not independently assessed, and looking only at passive entry fails to account for 
increases in permeability that may occur from infection over the lifespan, or in 
advanced age. 
 
Is SAP toxic? 
 
With SAP likely to enter the brain under conditions of compromise and with its 1000-
fold higher concentration gradient in the plasma relative to the CSF, or possibly its 
local production by neurons, the question is raised whether SAP may be exerting 
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effects on the cells present in the brain. Several in vitro studies have investigated the 
effects of SAP application on primary neurons at levels that have been found to be 
physiological in the serum. In rat cerebral neurons, significant levels of cell death 
have been found after 24-hour exposure of SAP at 40 nM concentrations (Urbanyi et 
al., 1994). In agreement with the former study, (Duong et al., 1998) observed 
significantly increased levels of neuronal cell death in cultures exposed to SAP at a 
concentration of ~32 nM for four days, in experiments using postmitotic neurons 
derived from the human-derived NT2 teratocarcinoma cell line, as opposed to rodent 
neurons. Compared to the previous study by Urbanyi et al. (1994), a slightly lower 
concentration of SAP was used; the concentration of only ~32 nM SAP by Duong et 
al. (1998) was chosen based upon the lowest value in the range of the physiological 
serum concentration of SAP, as measured in (Pepys, 1992) for the normal range in 
women (8–55 µg/mL with mean of 24 µg/mL). This demonstrates that even the 
lowest physiological SAP level is toxic for neuronal cells in vitro, however it is 
important to note that SAP would not be expected to reach these levels in the brain 
under normal conditions. Moreover, a later study confirmed SAP toxicity in vitro 
examining a significant increase in cell death in rat neuronal cultures after 2 days of 
incubation with 15 or 30 nM SAP (Pisalyaput and Tenner, 2008). As it has been 
found that SAP localizes to the nucleus (Du Clos et al., 1990) and binds to chromatin 
and to nucleoli (Pepys et al., 1994a), it has been hypothesized that these actions then 
lead to apoptotic cell death (Al-Shawi et al., 2016). 
  
Based upon the results of their previous work, (Urbanyi et al., 2003) went on to 
explore the possible mechanism of SAP-induced cell death using the concentration of 
SAP that they found to cause a plateau of maximal cell death, at 40 nM (with 35–40% 
cell death). Notably, no morphological change or uptake of SAP was observed in 
astrocytes, even after 80 nM SAP exposure, leading them to suggest that the cellular 
uptake mechanism may be specific to neuronal cells (Urbanyi et al., 2003). However, 
only glial fibrillar acidic protein (GFAP), a marker used for astrocytes, was measured, 
thus excluding the consideration of other cells (i.e. microglia) present in the brain 
parenchyma. In neuronal cultures, SAP was found to localize in the cytoplasm of 
neurons that displayed shrunken bodies and dense nuclei, as well as in the membrane-
bordered vacuoles and the nuclei, which showed characteristics of apoptosis such as 
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peripheral chromatin condensation, nuclear fragmentation and reduced cytoplasmic 
volume. The mRNA expression of Bax and Bcl-2 cells after SAP treatment displayed 
an increased Bax/Bcl-2 ratio, which is a measure that predicts cell susceptibility to 
apoptosis (Raisova et al., 2001). In addition, SAP treatment resulted in substantially 
increased levels of Aβ immunoreactivity, providing further evidence for a possible 
role of SAP in AD pathology (ibid).  
 
More recent research has found in vivo evidence in agreement with the previously 
mentioned in vitro studies that also demonstrates SAP eliciting damage to neurons. In 
rats (Urbanyi et al., 2007) performed bilateral intrahippocampal injections of 10 µg 
SAP in both hemispheres to best mimic the physiological hippocampal concentrations 
previously reported in the AD brain (Yasojima et al., 2000). Their evaluation found 
significant increases in apoptosis in the hippocampus and cortex after 4 weeks of SAP 
exposure, where SAP localization in neurons was also confirmed (Urbanyi et al., 
2007). These findings therefore support the relevance of increased SAP levels in the 
brain producing potentially harmful effects.  
 
SAP and amyloid fibrils in the brain 
 
As significant evidence has been shown for the role of SAP in the promotion of 
amyloid fibril stability in the periphery in the case of amyloidosis (Pepys, 2006), the 
question is raised whether it does the same with amyloid deposits associated with AD. 
In vitro experiments using physiological concentrations have shown that the 
aggregation of Aβ1-40 is promoted by SAP, with one study finding an increase in 
aggregation from 7% to 20% in only 16 hours, with 1nM Aβ1-40 in the presence of 
100 nM (25 ug/mL) SAP (Hamazaki et al., 1995). Another similar study took this one 
step further by examining amyloid fibrils that were isolated from spleens of patients 
with amyloidosis and ex vivo Aβ1-40 fibrils from the cerebrovascular amyloid deposits 
of AD, as well as synthetic Aβ fibrils (Tennent et al., 1995). In the presence of three 
different enzymes (pronase, trypsin, and chymotrypsin) that are actually more 
aggressive than those present in vivo (ibid), they found that SAP at concentrations 
ranging from 10-50ug/mL (40-200 nM) dose-dependently inhibited digestion of all 
types of amyloid fibrils by each of these enzymes (ibid). Later findings by (Mold et 
al., 2012) also confirmed the aforementioned findings using under-saturated solutions 
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of Aβ1-42 by again demonstrating the ability of SAP to enhance the stability of 
amyloid fibrils - particularly those that are the principal species deposited in the brain 
in AD, as they are more hydrophobic and fibrillogenic (Selkoe, 2001). Overall, these 
studies demonstrate the importance in considering the effect that SAP may have on 
both the aggregation and persistence of amyloid fibrils in situ. As these data implicate 
that SAP can contribute to the insolubility of plaques.  
 
With the in vitro and in vivo evidence for SAP toxicity previously discussed, the 
question arises whether these effects are relevant and can translate to humans. This 
was partly examined in a study by (Crawford et al., 2012), where SAP levels in the 
brain were compared between AD patients, non-demented patients with AD 
neuropathology (NDAN), and age-matched controls. A key feature of this study was 
the examination of the NDAN group, as their AD pathology of amyloid plaques and 
neurofibrillary tangles were comparable to the AD patients who exhibited cognitive 
impairment. Even though the pathology was similar, the levels of SAP protein and 
staining around plaques and tangles were significantly different in the hippocampus 
and frontal cortex; AD patients reportedly had significantly higher SAP levels than 
both the NDAN and control groups, while no difference in SAP level was detected 
between the latter two groups (ibid). This therefore raised an important question in the 
field whether SAP may be a driving force in AD progression that eventually leads to 
cognitive impairment.  
 
As it has been discussed, SAP is reportedly capable of either entering or possibly 
being produced in the brain and has been implicated in neuronal toxicity (Urbanyi et 
al., 1994) and associated with the pathological features of AD (Crawford et al., 2012; 
Yasojima et al., 2000). However, one critical point that has failed to be taken into 
account in previous studies examining the effects of SAP in the brain is that other, 
very closely related and highly homologous pentraxins are also present in the brain. 
The importance of this consideration is two-fold: i) if prior detection of SAP may 
have been influenced by the presence of other pentraxins, as many commercial 
antibodies are often raised against sequences within the pentraxin domain (to be 
discussed in Chapter 3) and ii) the neuronal pentraxins form complexes with one 
another via their shared pentraxin domain – a particular sequence of amino acids that 
SAP possesses as well (Srinivasan et al., 1994b). For consideration of the latter point, 
	 39	
it is therefore integral to understand the role that the neuronal pentraxins play in the 
brain as well. 
 
The neuronal pentraxins 
 
The pentraxin superfamily includes a subfamily of long pentraxins, which possess the 
C-terminal pentraxin domain with the pentraxin signature and contain a longer N-
terminal domain. A subset of the long pentraxins whose members are particularly 
expressed by neurons are the soluble secreted neuronal pentraxins (NPTXs) NPTX1 
and NPTX2 or NARP, and the transmembrane neuronal pentraxin “receptor” 
(NPTXR), which is a splice variant of the neuronal pentraxin with chromodomain 
(NPCD). It is important to note however that NPTXR does not act as a receptor in the 
classical sense, as it has been found to perform other functions aside from the binding 
of other NPTXs after being cleaved from the membrane (Cho et al., 2008; Lee et al., 
2017). NPTX1, NPTX2 and NPTXR are 50% identical to each other, and the C-
terminal amino acids of the NPTXs, which contain the pentraxin domain, are 20-30% 
identical to SAP and CRP over an approximately 200 amino acid span (Dowton and 
McGrew, 1990; Rassouli et al., 1992; Tsui et al., 1996). 
 
NPTX1 and NPTX2 each possess an N-terminal half that forms coiled copies and a 
C-terminal half that encodes the pentraxin domain, while NPTXR has an amino-
terminal transmembrane domain. The NPTXs form organized heteromeric complexes 
stabilized by disulfide bonds, and they localize at excitatory synapses where their C-
terminal domains interact with the N-terminal extracellular domains of AMPARs 
(Dodds et al., 1997; Kirkpatrick et al., 2000). NPTXs have been implicated in synapse 
formation and remodeling, synaptic plasticity, and clearance of synaptic debris. 
Specifically, using a coculture system of neurons and nonneuronal cells to create 
artificial synapses and reconstitute synaptic transmission, it has been found that 
AMPA receptor subunits GluR2 and GluR4 require the binding of presynaptically-
derived NPTXs for trans-synaptic localization (Sia et al., 2007). At the synapse, the 
presynaptic complex of the linked NPTXs that forms can be cleaved by TACE, 
relocated to the postsynaptic terminal together with their associated pool of AMPARs, 
and enter endosomes, thus increasing efficacy of AMPAR endocytosis (Cho et al., 
2008). A study by Koch and Ullian (2010) examining visual system development 
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used NPTX1 and NPTX2 knockout mice to further confirm the role of NPTXs in the 
establishment of functional synaptic transmission. NPTX1 and NPTX2 knockout 
mice display disrupted AMPA receptor recruitment necessary for synapse formation.  
 
Knockdown of NPTX1 alone has been shown to induce conditions under which 
cerebellar granule cell death is reduced in non-depolarizing culture conditions, 
suggesting its additional role in apoptotic cell death (DeGregorio-Rocasolano et al., 
2001). NPTX1 has therefore been ascribed as having a dual function, given the 
findings of its role in both synapse remodeling and in the gene expression program of 
cell death occurring from potassium deprivation (ibid).  
 
Given this dual role of NPTX1 in excitatory synaptic remodeling and apoptotic cell 
death, Abad et al. (2006) investigated the possible link between NPTX1 and AD 
pathology using Aβ, and found that the treatment of cortical neurons with Aβ (in a 
time- and concentration-dependent manner, with either 10µM or 20µM, after 24 and 
48hrs) resulted in a significant increase in NPTX1, preceding neurotoxicity and 
subsequent apoptosis. It is important to note however that the concentration of Aβ that 
was used represents what would likely be around peak levels that would be found 
endogenously around the synapse or in the vicinity of plaques (though determining 
Aβ concentrations in post-mortem brain is notoriously difficult due to solution 
sensitivity and other factors (Bao et al., 2012), making localization and disease 
progression points to consider for the relevance of this interaction. The knockdown of 
NPTX1 in the same conditions did however allow for synapse survival and reduced 
Aβ-mediated apoptosis. Moreover, the overexpression of NPTX1 in cultured neurons 
without the addition of Aβ appeared to replicate the neurotoxic effects of Aβ. 
 
If NPTX1 is capable of mediating the toxic effects of Aβ, this would then lead to the 
question of whether there is evidence showing this possibility in vivo. Abad et al. 
(2006) addressed this in their study by examining brain samples from 12-month old 
transgenic mice expressing human APP/PS1 and sporadic late-onset AD patients. 
NPTX1 immunoreactivity was seen in the neuritic component of senile plaques, 
particularly in dystrophic neurites in AD and was found to colocalize with tau 
deposits in dystrophic neurites of senile plaques, but not in neurons with 
neurofibrillary tangles. Additionally, increases in NPTX1 protein concentrations were 
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found in AD patient brains, though this was determined by “markedly augmented” 
bands recognized by the antibody in tissue from the AD cases, but levels were not 
quantified. Results of this study therefore suggest that NPTX1 may play an important 
role in the mechanism that mediates the toxic effects of Aβ in AD. In this regard, 
another key finding for consideration is that NPTX1 levels significantly increased in 
primary neurons treated with Aβ at either 10 and 20 µM after 18 hours, which was 
before any morphological or biochemical signs of apoptosis appeared at 24 hours 
exposure (ibid). This raises the question of what effect these increased levels of 
NPTX1 might therefore be having in the buildup to the pathological cascade in AD.  
 
The hippocampus and AD 
 
In looking at the normal distribution of NPTX1 in the brain, high levels have been 
reported in the hippocampus and entorhinal cortex, particularly in the neuropil, and in 
AD it has been reported that these levels rise with Aβ and disease progression (Abad 
et al., 2006; Cho et al., 2008). Concurrently, SAP levels have also been found to be 
upregulated or even produced in this same brain region, with a greater than 2-fold 
increase, in cases of AD (Yasojima et al., 2000). Additionally, as previously 
described, the hippocampus has been shown to have the highest degree of 
permeability in the BBB, particularly in the CA1 and DG regions of aged and MCI 
patients (Montagne et al., 2015). These patterns of possible routes of pathogenesis 
coincide with the hippocampal region of the brain being one of the most significantly 
affected areas in AD (Braak et al., 1993; Mu and Gage, 2011; Whitwell et al., 2012).  
 
The hippocampus is a relatively conserved area of the brain within mammals, 
consisting of a unique neuronal network of various subregions. This structure lies 
deep within the medial temporal lobe of the brain, and includes the hippocampus 
proper (or CA1, CA2 and CA3), EC, DG, subiculum, presubiculum and 
parasubiculum. AD pathology often follows a conserved topographical and 
hierarchical pattern of development and progression that strikes the hippocampus 
first, and most prominently (Braak and Braak, 1991; Scahill et al., 2002). In AD, 
significant levels of neuronal loss occur in this area, particularly in the CA1 (West et 
al., 1994). A reduction in volume occurs from the loss of neurons as well as the 
neuropil and a large number of synapses. The distribution of AD pathology in the 
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form of NFTs and amyloid plaques is reflected in the temporal development of 
cognitive symptoms that are often presented in the course of the disease. One 
prominent symptom is the loss of memory, which attests to the integral role of the 
hippocampus in the consolidation and retrieval of new declarative memory – 
particularly episodic memory, as determined by significant impairment in patients 
with lesions to this area (Scoville and Milner, 1957). 
 
Given the substantial degree of vulnerability exhibited by this region in AD, it is 
therefore imperative to understand the molecular mechanisms driving such 
pathological changes to occur in the lead-up to and progression of the disease. As this 
introduction has thus far established that there may exist a possible role for the two 
pentraxins SAP and NPTX1 in AD, particularly given their presence in the 
hippocampus, it follows to examine what particular features in this structure can be 
affected, and further investigate the possible mechanisms by which such changes may 
be occurring.  
 
Examining hippocampal function 
 
The hippocampus is a unique structure that is particularly accessible to 
electrophysiological study, in that it is comprised of a largely unidirectional circuitry 
and densely packed cell layers. Recording can be measured over a long time from a 
population of cells, which enables such mechanisms as LTP, currently considered the 
best cellular model of learning and memory, to be assessed (Bliss and Gardner-
Medwin, 1973; Bliss and Lomo, 1973). Such recordings are commonly used to test 
the capacity of the circuit for plasticity both in vivo and in vitro, and various studies 
have reported that Aβ oligomers inhibit LTP in mouse models of AD pathology 
(Haass and Selkoe, 2007). Additionally, synaptic transmission can be recorded with 
patch clamp experiments of single neurons within a network, and these more subtle 
changes have been found to be one of the first pathological effects that occur in the 
TASTPM (APP/PSEN1) mouse model of AD pathology (Cummings et al., 2015).  
 
Previous findings from our lab have shown that there is a presynaptic effect of 
NPTX1 and SAP, recorded under chronic conditions in organotypic slices so as to 
more closely reflect those in vivo (Cummings, Benway et al., 2017). As evidence 
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shows increased protein levels of both SAP and NPTX1 in the presence of Aβ, 
paired-pulse ratios were measured in a dose-dependent manner, and significant effects 
were found at concentrations of SAP at 20 nM and NPTX1 at 60 nM (ibid). The 
paired-pulse ratios for each pentraxin decreased, which suggests that their chronic 
application results in an increase in release probability, demonstrating that both SAP 
and NPTX1 are capable of producing potent presynaptic effects at CA3-CA1 
synapses. In addition, and importantly, co-application of both pentraxins produced no 
additional effect on release probability to that of the application of each pentraxin 
alone, thus suggesting that they interact with the same targets when applied together, 
and do not act independently (ibid). The critical implication of these results is that 
SAP, upon entry or with upregulation in the brain, may be able to interact with the 
endogenously released NPTX1, either at the level of NPTX1 or at downstream 
targets. 
 
Ex vivo results from our lab have corroborated those discussed above; patch-clamp 
recordings from acute hippocampal brain slices of 14-month old transgenic mice 
expressing human SAP on the human SAP promoter in the liver (Iwanaga et al., 
1989) also revealed an increase in glutamate release (Cummings, Benway et al., 
2017). Moreover, the magnitude of LTP was found to be significantly decreased in 
SAP mice (ibid), thus demonstrating that both central transmission and synaptic 
plasticity are influenced by tonically raised SAP levels (equal to the physiological 
level in humans) over the course of the life of a mouse, even if only expressed in the 
liver.  
 
In AD, key locations in the brain where detrimental effects are taking place are at 
synapses. As discussed previously, both SAP and NPTX1 are capable of influencing 
synaptic function (Cummings, Benway et al., 2017). The hyperexcitability 
demonstrated by the application of SAP and NPTX1 parallels the effects found to 
occur early in AD, with increased release probability being one of the putative 
physiological effects of released Aβ (Abramov et al., 2009). This type of neuronal 
hyperactivity has been reported in a multitude of studies examining early changes in 
AD (Stargardt et al., 2015).  
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Evidence of increased neuronal hyperactivity have been found in transgenic mice with 
AD pathology at ages as young as 1-2 months old. (Cummings et al., 2015) reported 
increases in release probability in the CA1 region in 2-month old TASTPM mice, in 
accordance with (Busche et al., 2012) who examined 1-2 month old transgenic mice 
overexpressing both APPswe and PS1G384A in neurons and found dramatic increases in 
the fraction of hyperactive neurons in the CA1, which is before the onset of plaque 
pathology at ~3 months of age (Busche et al., 2008). It is also important to note that 
various studies report that this dysregulation continues with age, with Busche et al. 
(2012) having also found the same results as mentioned above in mice at 6-7 months 
of age, and as a recent study found significantly elevated rates and increased 
incidence of action potential bursts in CA1 neurons in APPswe/PS1M146V mice at ages 
between 10-14 months (Siskova et al., 2014). These consistent findings of synaptic 
changes that begin early and persist through the course of the disease in different 
mouse models of AD pathology strongly suggest that synaptic derailment likely 
occurs long before the onset of symptoms and prior to plaque deposition. This 
demonstrates the need for a better understanding of the factors contributing to 
synaptic dysfunction that occur in the lead-up to the manifestation of AD pathology.  
 
Spine loss in AD and the influence of pentraxins 
 
Excessive release of glutamate has been shown to result in injury of dendrites, in a 
state referred to as ‘dendrotoxicity’ (Swann et al., 2000). Consequences of increased 
amounts of released glutamate and synaptic activation would be expected to produce 
morphological changes, which have indeed been found and referred to as part of an 
excitotoxic neurodegenerative process (Isokawa and Levesque, 1991; Scheibel et al., 
1974). One such change that can result from neuronal hyperexcitability is the loss of 
dendritic spines (Swann et al., 2000), which is another key pathological feature of 
AD. Neurons have been found to adjust their number of synapses with adjacent cells 
in accordance with neuronal activity levels via structural changes in dendritic spines 
(Caroni et al., 2012; Holtmaat and Svoboda, 2009). Spine and synapse loss results in 
the altering of neuronal circuits, as spines are the main postsynaptic targets of 
excitatory synapses in the cortex and hippocampus of mammals (DeFelipe and 
Farinas, 1992). The dendritic spines on pyramidal cells are specialized postsynaptic 
structures that are key features of synaptic transmission (ibid), and the loss of spines 
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correlates to a decrease in synaptic strength and disruption in homeostatic modulation 
of the synapse (Matsuzaki et al., 2001). Spines are integral components for the laying 
down and retrieval of memories, (Hasbani et al., 2001; Parsley et al., 2007; Squire, 
1992), and their size changes with plasticity of synaptic transmission (Harris et al., 
2003; Honkura et al., 2008; Matsuzaki et al., 2004; Paulin et al., 2016).  
 
Several transgenic mouse models of AD pathology analyzed for dendritic spine 
anomalies and synaptic loss has provided evidence that these changes occur 
consistently in an age-dependent manner, despite differences in Aβ accumulation in 
the various models analyzed (Knobloch and Mansuy, 2008). In the examination of 
hippocampal spines, decreases in spine density in the outer molecular layer of the DG 
were found at 4 months of age in the Tg2576 mouse model (Jacobsen et al., 2006), 
with supporting evidence found by (Wu et al., 2004) in 3-month old PDAPP 
transgenic mice with significant reductions in the granule cells of the posterior region 
of the DG (Wu et al., 2004). In accordance, (Lanz et al., 2003) evaluated spine density 
of both models in the CA1 and found significant reductions in the Tg2576 and 
PDAPP models at 4.5 months and 2 months, respectively. Collectively these results 
suggest that spine density is reduced prior to Aβ plaque deposition.  
 
There are also consistent reports of synapse and spine loss found in tissue samples 
from patients with AD, specifically in the hippocampus and throughout the cortex, the 
areas most significantly affected in the disease (DeKosky and Scheff, 1990; Selkoe, 
2002; Walsh and Selkoe, 2004). A greater extent of spine loss has been found to be 
associated with low mental status (DeKosky and Scheff, 1990; Selkoe, 1989), with 
MCI patients less affected AD patients, but still higher than in controls (Arendt, 
2009). These findings from humans and mouse studies suggest that synapse and spine 
loss occur early in the development of AD (particularly in relation to diagnosis) and 
increase as the disease advances, thus providing good indication of disease 
progression. However, the question remains whether there are other factors, alongside 
the likely candidate of soluble amyloid, that may be contributing these changes.  
 
Recently, a study by (Figueiro-Silva et al., 2015) presented evidence for NPTX1 
being a negative regulator of excitatory synapse density, which was in line with 
previous research that found NPTX1 in dystrophic neurites in the brains of AD 
	 46	
patients (Abad et al., 2006). Specifically, they found that knockdown of NPTX1 
increased the number of dendritic protrusions and excitatory synapses, along with 
neuronal excitability, in cultured rat cortical neurons. This was further supported by in 
vivo evidence that showed an enhancement in excitatory drive and long-term 
potentiation in the hippocampus of behaving mice with NPTX1 knockdown 
(Figueiro-Silva et al., 2015). These results therefore pose the question whether 
increased concentrations of NPTX1, as reported to occur in AD patients, produce a 
decrease in spine density. Additionally, as SAP colocalizes in similar regions 
surrounding plaques, it should be considered whether the two pentraxins may be 
capable of producing an augmented effect on the synapses during the progression of 
AD in areas of the brain either already burdened with, or prior to the deposition of, 
Aβ.  
 
Role of the immune system in AD and possible effects of pentraxins 
 
Recent evidence has shown that the resident microglia of the brain can play a vital 
role in the pathological progression of AD, particularly involving the mediation of 
synapse loss (Hong et al., 2016). In a normal state, the CNS modulates its own 
immune system comprised primarily of astrocytes and microglia to protect against 
pathogens and ensure homeostasis. It has been reported that microglia make up to 5-
20% of all cells in the CNS (Li et al., 2014). Microglia remain in a state of quiescence 
under normal conditions of health, with ramified projections scanning the local 
environment (Town et al., 2005) so as to maintain tissue homeostasis or quickly react 
to pathogen invasion or injury (Davalos et al., 2005; Nimmerjahn et al., 2005).  
 
Upon microglial activation, such as during times of infection, their phagocytic 
potential greatly enhances (Blander and Medzhitov, 2004), and they display an 
increase in soma size and rescinded projections back toward the cell body. Activated 
microglia display increased motility, increased proliferative abilities and upregulation 
of the production of inflammatory cytokines and chemokines involved in the rapid 
acute immune response (Frank-Cannon et al., 2009; Mosher and Wyss-Coray, 2014). 
Importantly, this microglial response is usually self-limiting and discontinues once the 
insult has been resolved. However, chronic states of neuroinflammation have been 
associated with neurodegenerative diseases including AD, in which it is proposed that 
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inflammation crosses a tipping point from being beneficial to harmful and likely aid 
in disease progression (Streit, 2006). 
  
There is substantial evidence for neuroinflammation being a key feature of the 
pathology of AD, with post-mortem tissue from AD patients showing markers of 
inflammation enriched in the hippocampus and frontal cortex with AD pathology, in 
positron emission tomography studies showing an inverse correlation between 
microglia and cognitive status (Edison et al., 2008), and genome-wide microarray 
studies of gene expression finding significant correlations between microglia gene 
expression changes and Aβ plaque development (Matarin et al., 2015). However, in 
the past few years the role that inflammation plays in the progression of AD has come 
into question. The branding of microglia as ‘dangerous’ immune effector cells was 
derived from cell culture studies that found endotoxic-treated microglia producing 
potential neurotoxins that led to neuronal death in vitro, dismissing the integral 
protective functions of microglia with assumptions made based upon a limited 
experimental scope (Giulian, 1987). While many researchers in the field had 
supported the initial hypothesis that inflammatory cytokines may be the forces driving 
pathology (Akiyama et al., 2000; Rubio-Perez and Morillas-Ruiz, 2012), which early 
studies with non-steroidal anti-inflammatory drugs (NSAIDs) in AD patients 
supported (Breitner et al., 1994), subsequent large randomized trials failed to produce 
any beneficial effect on the etiology of AD (Aisen et al., 2003; Soininen et al., 2007). 
Surprisingly, NSAIDs were even found to lead to increased incidence of AD in 
patients with MCI (Thal et al., 2005), clearly necessitating the need for a reassessment 
of the hypothesis.  
 
A common hypothesis from more recent research is that neuroinflammation is 
beneficial, and that it is when other factors impede the inflammatory process that the 
neuroprotective capabilities of microglia diminish. One major factor is age, which is 
also the top risk factor for neurodegenerative diseases. Under normal physiological 
conditions, it has been shown that the microglia population maintains itself 
throughout adult life through mitosis of resident microglia (Graeber et al., 1988). 
While there is evidence that microglia progenitors from the bloodstream can infiltrate 
the CNS to contribute to immune defense, it is likely that this only occurs at times of 
dysfunction in the BBB with injury or inflammation (Ajami et al., 2007). Therefore, 
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the endogenous microglia must show resilience to a multitude of insults over the 
course of a lifespan, enduring repeated cycles of cell division, thus prompting the 
question of what their limit might be before they start to experience telomere 
shortening and eventually a state of senescence. 
 
Morphological and behavioral changes in microglia that occur with age have been 
implicated in the pathological process of neurodegenerative disease  (see review by 
Conde & Streit, 2006). With age, it has been found microglia take on more ‘reactive’ 
morphology via an upregulation of proinflammatory cytokines (Koenigsknecht-
Talboo et al., 2008; Perry et al., 1993; Sierra et al., 2007), and also have been found to 
display reduced motility (Orre et al., 2014). A study by Hefendehl et al. (2014) 
confirmed these findings with their analysis of the morphology and behavior of 
microglia in vivo in three difference age groups of mice, with young (3-month old), 
adult (11-12-month old) and aged (26-27-month old) using 2-photon microscopy. 
Additionally, this study found that microglia displayed an increased soma volume, a 
shortening of process length, and a disruption of homogenous tissue distribution with 
the advancement of age (ibid). This evidence, taken together with findings that aged 
microglia demonstrate an extended and enhanced pro-inflammatory activation state 
(Njie et al., 2012; Sierra et al., 2007), strongly suggest that there is likely to be a 
dyregulation in the microglial response with age. The implication of such dysfunction 
is that the brain is therefore more susceptible to the pathologies of AD, given that, 
with the onset of microglia senescence, healthy microglia become exhausted and the 
remaining dysfunctional aged cells cannot offer the level of protection required. It is 
therefore possible that in the case of AD, microglia activate and clear the toxic species 
that are being produced, but can only do so up until a ‘tipping point’ is reached, where 
the aged microglia can no longer maintain homeostasis, and the inflammation 
produced from higher levels of activation switches from being beneficial to 
detrimental.  
 
Aside from being incapable of sufficient clearance of toxic species in AD, microglia 
have also been found to play an active role in neurodegeneration via the re-initiation 
of one of the processes that they are involved in during development, involving 
synaptic pruning via the classical complement pathway. During development, a great 
excess of synapses are generated in the brain, and so to prevent metabolic waste, 
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microglia take on the role of mediating synaptic pruning, as has been confirmed in 
studies that have disrupted microglial detection capabilities and found excesses of 
immature synapses (Paolicelli et al., 2011; Paolicelli and Gross, 2011). While 
normally this function ceases after development, recent studies suggest that this 
process becomes re-activated in AD (Hong et al., 2016; Vasek et al., 2016), 
particularly involving the pattern recognition molecule C1q, which is the initiator of 
the complement cascade. This pathway normally plays a key role in the inflammatory 
response with the elimination of foreign intruders, debris and apoptotic cells (Ricklin 
et al., 2010), but can also play a detrimental role at the synapse with exposure to 
soluble Aβ oligomers in AD, as reported by Hong et al. (2016). In the aforementioned 
study, use of the J20 mouse model of AD pathology (overexpressing human APP) 
revealed elevation of C1q particularly in the hippocampus and frontal cortex, which 
has also been reported in the APP/PS1 mouse model (Jankowsky et al., 2004). 
Importantly, elevated levels were reported as early as 1-month of age, prior to synapse 
loss, and coincided with punctate Aβ deposition in the hippocampus. During 
development, C1q promotes the activation of C3, a downstream factor that opsonizes 
synapses for elimination via phagocytic microglia engulfment (Stevens et al., 2007). 
Using a series of KO experiments, Hong et al. (2016) found this mechanism to be 
induced by oligomeric Aβ, in a region-specific manner that resulted in significant 
synaptic loss.  
 
While microglia have been shown to bind and clear amyloid in several models of AD 
pathology (Koenigsknecht et al., 2004; Koenigsknecht-Talboo et al., 2005; Mandrekar 
et al., 2009; Bamberger et al., 2003), from the evidence discussed above it is highly 
likely that this protective mechanism becomes impaired with the progression of AD. 
With the findings from these aforementioned studies taken together, the re-expression 
of complement receptors that microglia exhibit with exposure to Aβ that lead to 
synapse engulfment may in large part be due to dysfunction as a result of aging. If it 
is indeed a delicate homeostatic balance that gets tipped during AD to produce such 
detrimental effects, then it is imperative to determine the contributing factors that may 
be pushing cells towards the direction of a tipping point.  
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Pentraxins and microglia 
 
Both SAP and NPTX1 have been found at higher concentrations in the AD brain, and 
associated with Aβ plaques and neurofibrillary tangles (Abad et al., 2006; Duong et 
al., 1997). Moreover, both pentraxins have also been show to bind to C1q (Stevens et 
al., 2007; Ying et al., 1992b). SAP, aggregated or attached to most of its ligands, was 
first found to bind to the collagen-like domain of C1q and cause activation of the 
complement cascade by (Ying et al., 1992b). This result was confirmed by (Hicks et 
al., 1992) who additionally found that chemically aggregated SAP was able to 
activate the complement system at a concentration of 100 nM and over. However, this 
result should be considered with caution, as 100 nM is nearly half the concentration of 
physiological levels reported Pepys et al. (1978), and the authors report that 
complement was activated by cross-linked SAP, which consisted of dimers and 
insoluble aggregates, whereas native SAP protein did not cause activation at the same 
concentration (Hicks et al., 1992). Veerhuis et al. (2003) later observed the co-
localization of SAP and C1q in fibrillar Aβ plaques, which were associated with the 
accumulation of activated microglia in the temporal cortex of post-mortem AD brain 
tissue. Also, using human microglia isolated from post-mortem brain specimens, they 
found that co-application of SAP at a physiological concentration of 85 nM, Aβ at 10 
µM and C1q at 5 nM significantly increase the Aβ1–42-induced secretion of the pro-
inflammatory cytokines IL-6 and TNF-α  by microglia in vitro, indicating that SAP 
may be capable of attracting and activating microglia synergistically with Aβ and C1q 
(ibid).  
 
The possible interaction of NPTX1 and microglia has been explored very little. While 
Stevens et al. (2007) raise the possibility of NPTX1 being involved in synapse 
elimination based on the evidence of NPTX1 binding to C1q, no studies have 
confirmed this, or any interaction of NPTX1 with microglia. However, when NPTX1 
is not in a complex with other pentraxins, studies have found that it is capable of 
exerting very different effects involving cell death and mediating the effect of Aβ 
(Abad et al., 2006; DeGregorio-Rocasolano et al., 2001), raising the question of 
whether it may be involved in the immune response during AD as well.  
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SAP and behavior 
 
With the evidence discussed thus far of the vulnerability of the hippocampus in AD, 
coupled with the findings that SAP is either generated in neurons or crosses the BBB 
and co-localizes with Aβ plaques in this same region, our next aim was to determine 
whether high expression of this normally peripheral protein might produce detectable 
cognitive impairment in mice with AD pathology. With the evidence from Crawford 
et al. (2012) of higher levels of SAP in the hippocampus and the localization of SAP 
around plaques in AD, but not in NDAN patients, the question is raised whether SAP 
may be playing a role in the advancement of AD pathology that leads to cognitive 
impairment. Recent research has shed light onto what may be one of the earliest 
detectable signs of cognitive impairment in patients who are at risk for developing 
AD later in life. Ritchie et al. (2017) used a battery of computerized cognitive tests 
with over 200 middle age adults with a family history of dementia and were 
reportedly able to detect changes in visuospatial functions, which was associated with 
lower brain hippocampal volume. In contrast to previous cognitive testing that has 
detected alterations in function at much later stages (Salmon, 2012; Twamley et al., 
2006), this study aimed to detect the underlying neuropathological changes that might 
be occurring in the preclinical stage of dementia, rather than in the prodromal period. 
These results indicate that tests in spatial navigation and spatial memory that are 
specifically reliant on hippocampal function are more sensitive measures of the 
cognitive changes occurring in AD, prior to the onset of symptoms (Ritchie et al., 
2017).  
 
Mouse models and behavior assessment  
 
For analysis of hippocampal function in rodents, various tests have been developed to 
assess spatial memory. These tests often rely on the use of different mazes in which 
the animal is trained on and requires them to remember a particular location (i.e. the 
location of a platform in the Morris water maze), or the location it has previously 
visited to alter its response accordingly, such as in the T-maze or Y-maze (Stewart et 
al., 2011). The T-maze forced alternation task has previously been shown as one of 
the most sensitive tests to detect hippocampal dysfunction (Dudchenko, 2001), and 
corresponds to the type of cognitive test that was found to be a more sensitive 
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preclinical measure of impairment in humans, as discussed above. This task has been 
reported to show high sensitivity to the phenotype of the Tg2576 mouse model of AD 
(Stewart et al., 2011) despite its relative simplicity. Previous work from our lab has 
used the T-maze to assess cognitive impairment in the TASTPM mouse model of AD, 
and has shown no detectable changes in spatial memory in mice up to the age of 9 
months, though higher anxiety levels were found (Benway MSc, 2011).  
 
Given the evidence discussed previously, the question is raised whether SAP could 
possibly be contributing to cognitive dysfunction in the case of AD, and if such 
changes can be detected through the use of hippocampal-dependent tasks and mouse 
models of AD pathology. In order to examine the effects of SAP in relation to AD 
pathology, a mouse model was recently generated using TASTPM mice that express 
physiological levels of human SAP in the liver (Al-Shawi et al., 2016), but no 
behavioral tests on these mice have been performed. TASTPM mice are double 
transgenic models carrying two mutations associated with early onset AD: the 
Swedish mutation in APP and the M146V mutation in PSEN1. Amyloid-β deposits 
can be seen as early as 3 months of age, and extracellular, fibrillar Aβ plaques are 
observed around six months (Howlett et al., 2004). As discussed previously, our lab 
has also reported increases in release probability in the CA1 region in 2-month old 
TASTPM mice (Cummings et al., 2015).  
 
While the characterization of mouse models such as the TASTPM mice has provided 
advantages in the investigation of AD pathology, it is important that the limitations of 
these models also be considered when relating back to diseases that affect humans. 
The ability to genetically modify mice with relative ease has greatly enhanced our 
understanding of the etiology and mechanisms of many disorders. However, to make 
such transgenic models often requires the use of ‘artifical’ promoters that do not 
reflect complete endogenous expression of a protein, such as with the overexpression 
of APP using the Thy-1 promoter that gives expression only in neurons (Andra et al., 
1996). Additionally, a major criticism with the use of transgenic models is that they 
are based on genetic mutations that are associated with rare familial AD genes, and do 
not reflect the changes that occur in humans over the course of decades. With mice, 
only a 2-2.5 year window exists in which the disease can be replicated, meaning that 
the slow initiation of the disease process cannot be fully examined. Even with such 
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limitations, mouse models currently provide one of the most useful tools for 
examining different features of disease development and progression, particularly as 
mice possess sufficient genetic and neuroanatomical similarity to humans. 
 
Summary 
 
Much is yet to be determined in the field of AD research as to what factors contribute 
to the buildup and progression of the disease pathology. While possible roles of the 
pentraxins, specifically NPTX1 and SAP, have begun to be established, further 
elucidation of the other effects they may be influencing in the brain in relation to AD 
are required.  Herein I consider the effects of SAP and NPTX1 and their interplay, 
given the ability of the pentraxin family members to interact with one another, and 
use multiple techniques to explore what this may affect, in relation to AD.  
 
Using and histological molecular biology techniques, I provide evidence confirming 
the presence of SAP protein in the brain of AD patients and also demonstrate its 
ability to cross the BBB in the mouse models used. I also show that NPTX1 and SAP 
colocalize around Aβ plaques in both humans and mice.  
 
Considerable evidence has so far been directed towards the synapse being the site of 
the initial dysfunction occurring in AD (Oddo et al., 2003; Scheff et al., 2006). 
Therefore, to address what increased concentrations of both these proteins may be 
having on synapses in the brain, cell culture work was performed to assess spine 
density with the application of SAP and NPTX1, alone and together, at concentrations 
reported to first cause changes in synaptic transmission (Cummings, Benway et al., 
2017).  
 
Given the significant role of the immune system in AD, I also broaden the 
experimental scope and examine the effect of SAP and NPTX1 on microglia in 
organotypic cultures so as to more closely mimic physiological conditions. 
Additionally, with the evidence confirming the presence of SAP in the brain, and 
evidence suggesting it may play a role in cognitive decline (Crawford et al., 2012), it 
follows that behavioral tests be performed in order to examine whether human SAP 
may be capable of enhancing the pathological features present in the TASTPM mouse 
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model in a way that produces cognitive effects. Overall, new insight with be provided 
into the effects that both SAP and NPTX1 can have in the brain, importantly focusing 
on their possible interaction with each other, and in relation to the progression of AD.  
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Chapter 2 
 
Materials and Methods 
 
Molecular biology 
 
Mouse brain dissections 
 
All experiments were conducted according to UK Home Office regulations under the 
Animals (Scientific Procedures) Act 1986 and in agreement with the 
GlaxoSmithKline statement on the use of animals, as well as UCL local ethical 
guidelines.  
 
For obtaining brain samples, mice were decapitated and brains were swiftly removed 
and dissected on ice. Following the isolation of cortex or hippocampus, tissue for 
protein and RNA analysis was immediately snap frozen on dry ice and stored at -80oC 
until required. 
 
Brain tissue homogenization for protein and gene expression analysis 
 
Mouse cortex or hippocampus were sonicated (Branson sonifier, 450) for 30s at 9W 
in ice cold RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
0.15M NaCl, 20mM Tris.HCl (pH 7.4), 2mM EDTA (pH 8.0), 50mM sodium 
fluoride, 40mM β-glycerophosphate, 1mM EGTA (pH 8.0), 2mM sodium 
orthovanadate, 1mM PMSF, protease inhibitor tablet (Roche), 0.055 units aprotinin 
(Gunter et al.), 1% phosphatase inhibitor cocktail (Gunter et al.)). Samples were 
centrifuged at 13,000RPM for 10 minutes twice, with supernatants kept each time and 
insoluble pellets disposed of. Half the volume of the resulting homogenate was 
separated and diluted with half the volume of 3X Laemmli buffer (188 mM Tris-Cl 
[pH 6.8], 3% SDS, 30% glycerol, 0.01% bromophenol blue, 15% β-mercaptoethanol) 
and boiled for 3 minutes before being stored at -20oC until required. Non-laemmli 
diluted homogenate was used for protein concentration quantification for each 
homogenate using the Bio-Rad Bradford protein assay by comparison to a standard 
curve generated from serial dilutions of bovine serum albumin. 
 
	 56	
For gene expression analysis, mouse cortex and hippocampus samples were 
homogenized using a homogenizer for 30 seconds on ice using RNA lysis buffer 
(QIAGEN). Following homogenization samples were aliquoted and stored at -80oC. 
 
Quantitative real-time PCR 
 
Quantitative real-time PCR (qRT-PCR) primers were designed to span exon 
boundaries to distinguish between the PCR amplification from cDNA versus 
contaminating genomic DNA. Primer3-BLAST software (NCBI) was used to help 
determine primer specificity against all transcripts from the genome. Apcs (SAP) 
primer sequences (Eurofins MWG Operon):  
 
Forward: 5' GTTCCACACCCAAGTAACAGC 3'; 
Reverse: 5' TTCAGATTCTCTGGGGAACAC 3'. 
 
Specificity of the Apcs primers was tested using cDNA from the liver of 4 months old 
WT mice C57BL/6. Forward and reverse primers were incubated with cDNA 
samples, 0.25 µM of each primer and KAPA2G PCR ReadyMix (Anachem) and 
resolved using a 3% agarose gel with ethidium bromide and visualised using Bio-Rad 
Chemi-Doc MP imaging system. Cycling conditions: 95°C for 5 min, (95°C for 15 s, 
58°C for 15 s, 72°C for 20 s)x30 cycles, then 72°C for 5 min. A single band of the 
predicted product size (155 bp) was observed for the Apcs primer pair, with no band 
observed in the control lanes (cDNA synthesis reaction lacking reverse transcriptase), 
or in the cDNA from the cortex. To independently assess the specificity of these 
primers, a melt curve analysis was performed following PCR of liver cDNA on a 
CFX96 system (Bio-Rad) and by incubating PCR products containing SYBR green 
PCR mix (Bio-Rad) from 60°C to 95°C in 0.5°C increments every 5 s. A single peak 
corresponding to one product size was observed for the Apcs primers. To assess the 
efficiency of the primers a dilution series of the liver cDNA was tested by PCR using 
the SYBR green PCR mix in triplicate and the data was plotted for DNA dilution 
versus Cq with a line of best fit. The efficiency value for the primer pair was 0.976 
with an r2 value of 0.99, demonstrating the primer pair efficiency was close to 100% 
with low technical variation.  
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Molecular cloning: Generation of pentraxin overexpression constructs 
 
Total RNA was extracted from hippocampal tissue of 4-month old male C57BL/6 
mice using the miRNeasy protocol (Qiagen). The synthesis of cDNA was performed 
using 2 µg total RNA with the high-capacity cDNA reverse transcription kit 
(Thermofisher). The entire cDNA sequence for Apcs, Nptx1, Nptx2 and Nptxr was 
amplified by high-fidelity PCR (Platinum Pfx, Invitrogen) using the primers listed in 
Table 1 and then subcloned into the pEGFP-N1 expression vector (Clontech) using 
the EcoR1 and BamH1 restriction sites upstream of GFP to create a pentraxin-GFP 
fusion. 
 
 
Table 2.1. Primer sequences to clone the cDNA of the pentraxin family 
  Upstream   Forward Primer  Downstream  Reverse Primer  
Gene Restriction  Sequence Restriction Sequence 
  Enzyme (5'->3')  Enzyme (5'->3')  
	 	
CGGAATTCAGCATGG 
 
CGCGGATCCCGATCC 
Apcs EcoR1  ACAAGCTACTGCTTT BamH1 CAGACACGGGGCCT 
 (SAP) 
 
GGATGTTTGTC 
 
GATGACTAC 
  
CGGAATTCGCCATGC 
 
CGCGGATCCCGGTTG 
Nptx1 EcoR1  TGGCCGGCCGCGCCG BamH1 ATCTGGCGACAAGCC 
  
CACGCACC 
 
TCGAATGTCC 
  
CGGAATTCGAGATGC 
 
CGCGGATCCCGCAA 
Nptx2 EcoR1  TGGCGCTGCTGACCG BamH1 GTCCAGGAGCCGCTC 
  
TCGGC 
 
TTCACAGG 
  
CGGAATTCAGCATGC 
 
CGCGGATCCCGTGCC 
Nptxr EcoR1  TGGCGTTCCTCGGTGC BamH1 TTTGCCCTCCCCTTG 
    CGTCATCTG   CACACATC 
 
 
HEK293T cell transfection 
 
Human embryonic kidney (Stewart et al.) cells were cultured in DMEM high-glucose 
supplemented with 10% fetal bovine serum (Gibco), 1% 
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penicillin/streptomycin/glutamine (Invitrogen) at 37°C in 5% CO2 and 95% humidity. 
Cells were cultured in 35 mm dishes (300,000 cells per dish). After 24 hrs, at 
approximately 30% confluence, each plate of cells was transfected using the calcium 
phosphate method with 20µg of pEGFP-NPTX1, -NPTX2, -NPTXR, -SAP or empty 
pEGFP. For the calcium phosphate transfection, to plasmid DNA, 125 mM CaCl and 
2x HBS (274 mM NaCl, 42 mM HEPES, 15 mM D-glucose, 10 mM KCl, 1.4 mM 
Na2HPO4; pH 7.05) were added. After 5 min this mixture was administered dropwise 
to the cells. The cells were incubated for 4 hr, then the transfection media was rinsed 
off and replaced with fresh fetal bovine serum media. The cells were incubated for 48 
hr prior to collection. 
 
Pentraxin antibody specificity 
 
In the current study, it was imperative to determine antibody specificity given the 
significant degree of homology between the pentraxins. To achieve this, the protein 
sequences for mouse SAP, NPTX1, NPTX2 and NPTXR were aligned in order to find 
regions that were not conserved amongst the pentraxin family (Fig. 1.1). Commercial 
antibodies were chosen if they were against these regions. However, it is important to 
note that most did not fit this criterion, which made extensive specificity testing 
critical.  
 
Antibody specificity was tested by Western immunoblotting using lysates from 
HEK293T cells overexpressing each of the pentraxin family members individually 
(Fig. 3.1 A, B). Antibodies demonstrated to be specific were: NPTX1 monoclonal 
antibody (raised against rat NPTX1, 137- 312 aa); NPTX2 polyclonal antibody 
(against recombinant human NPTX2, N-term-350 aa); NPTXR antibody (against 
recombinant human full length NPTXR, 1-489 aa); and SAP polyclonal antibody 
(against recombinant mouse SAP, 21-224 aa). The antibodies in Table 2.2 were 
demonstrated to be specific for the pentraxin each was raised against.  
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Table 2.2. Specific pentraxin antibodies 
  
Antibody         Species  Company 
Catalog    
Number  
    RRID 
Anti-SAP  Sheep; polyclonal  R&D AF2558 AB_2236171 
Anti-
NPTX1 
Mouse; monoclonal BD Biosciences 610369 AB_397755 
Anti-
NPTX2 
Rabbit; polyclonal Proteintech 10889-1-AP AB_2153875 
Anti-
NPTXR 
Mouse; polyclonal Abcam AB168254 AB_2572281 
Anti-GFP Chicken; polyclonal Abcam AB13970 AB_300798 
 
 
Western immunoblotting 
 
Protein samples were Bradford assay-corrected and resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% polyacrylamide 
gels, and transferred to nitrocellulose membranes (0.45 µm Bio Rad). A molecular 
weight standard (BioRad, #161-0374) was used to verify protein molecular weights. 
Proteins were transferred via electrophoresis (30V, overnight), washed in Tris-
buffered saline with 0.1% Tween-20 (TBST) and blocked to prevent non-specific 
antibody binding in 5% milk/TBST for 1 hour at room temperature. Membranes were 
incubated in the appropriate concentration of primary antibody (see Table 2) in 5% 
milk/TBST overnight at 4°C. Following overnight incubation, membranes were 
washed in TBST for 5 changes of 7 minutes each at room temperature and again 
blocked for 10 minutes in 5% milk/TSBT. Incubation with the appropriate 
horseradish peroxidase-conjugated secondary antibody specific to the species of the 
primary antibody (1:10,000; Jackson ImmunoResearch) was performed in 5% 
milk/TBST for 1 hour at room temperature, then again washed as before, with a final 
wash of TBS. An enhanced chemiluminescence detection kit (ECL, Amersham) was 
used to reveal peroxidase activity. ImageLab software (v4.1, BioRad) was used for 
image acquisition and densitometric analysis, as described (Taylor et al., 2013). 
Image acquisition and densitometric analysis was performed using ImageLab (v5.2, 
BioRad) and statistical analyses were performed using Prism6 (GraphPad Software). 
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Co-immunoprecipitation 
 
HEK293T cell lines were transfected as previously described, with 20 µg of pEGFP-
NPTX1, -NPTX2, -NPTXR, -SAP or empty pEGFP, or a combination of two. After a 
48 hr incubation, cells were washed and scraped into 400 µl immunoprecipitation (IP) 
buffer (10 mM NaH2PO4, 100 mM NaCl, 10 mM Na4P2O7, 1 mM Na3V04, 1 mM 
PMSF (phenylmethane sulfonyl fluoride) and 1% Triton X-100). The co-
immunoprecipitation procedure was adapted from that of (O'Brien et al., 1999). 
Briefly, Protein-G and L agarose beads (Gunter et al.) were washed in IP buffer three 
times. The beads (50 µl/sample) were then coupled to 6 µg of the appropriate 
antibody (see Table 2) in 60 µl PBS solution and the mixture was incubated at 4°C for 
2 hr. Following incubation, the beads were washed again in IP buffer. The collected 
cells were sonicated for 10 s, then centrifuged at 5,000 rpm for 20 min at 4°C. The 
supernatant was added to the coupled beads and incubated overnight at 4°C with 
rotation. Following incubation, the mixture was spun at 13,000 rpm for 2 min at 4°C, 
and supernatant was collected and frozen. The coupled beads were then washed with 
1 ml IP buffer three times, IP buffer without Triton-X 100 three times, IP buffer with 
500 mM NaCl and then PBS alone (twice), all at 4°C. Protein samples were collected 
by boiling in 3x Laemmli buffer before being frozen for storage. They were 
subsequently diluted to 1x Laemmli for loading. Image acquisition was performed 
using ImageLab (v5.2, BioRad). 
 
Purified Native and Recombinant Pentraxin proteins 
 
Recombinant human neuronal pentraxin 1 was obtained from R&D Systems: 
rhNPTX1 (-NP), and human native purified SAP from Abcam (#ab96056). Pentraxin 
concentrations were calculated and re-suspended according to the molecular weight of 
the monomeric structure for each type of pentraxin used. Stock vials of pentraxins 
were maintained at -80ºC for long-term storage, or -20ºC for short-term use. Serial 
dilutions were made to obtain working concentrations in culture medium, which was 
stored at +4ºC for a maximum of 7 days. All solutions were made under sterile 
conditions. As the human purified SAP contained sodium azide and EDTA, in order 
to avoid any off-target effects, the SAP was desalted by buffer exchange as described 
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by (Pilling and Gomer, 2012). Briefly, an Amicon Ultra 0.5 ml centrifugal filter unit 
with an Ultracel 10 kDa membrane cut-off (Merck Millipore) was used to reduce the 
buffer in which the SAP was re-suspended. The SAP solution was then diluted with 
20 mM sodium phosphate buffer (pH 7.4) four times sequentially with 80% of the 
original volume of the SAP solution, and centrifuged after each dilution step. The 
final concentrated SAP solution was recovered and diluted to 80% of the original 
starting volume with 20 mM sodium phosphate buffer (pH 7.4). The SAP solution 
was sterilized using a 0.22 µm Millex GV filter (Merck Millipore). The integrity, 
purity and concentration of the desalted SAP and neuronal pentraxins were confirmed 
using non-denaturing and denaturing PAGE (Fig. 3.1 Ci, Cii) alongside a BSA 
standard. Given the pentraxins normally form pentamers containing one or more type 
of pentraxin, the presence of pentamers was verified using non-denaturing PAGE. 
Image acquisition was performed using ImageLab (v5.2, BioRad) 
 
Non-denaturing and denaturing PAGE  
 
Non-denatured samples were mixed 1:1 with 2x Tris/glycerol sample buffer: 125 mM 
Tris-HCl (pH 6.8), 20% glycerol and bromophenol blue (10 µg/ml) as described in 
Cummings, Benway et al. (2017). Samples were resolved on a 10% acrylamide gel, 
with 375 mM Tris-HCl (pH 8.8), 0.06% TEMED and 0.05% APS, and 
electrophoresed in buffer with: 25 mM Tris base and 192 mM glycine. Samples to be 
denatured were mixed with 3x Laemmli buffer and boiled for 2 min. Denatured 
samples were resolved using 10% SDS-PAGE, with 375 mM Tris-HCl (pH 8.8), 
0.1% SDS, 0.06% TEMED and 0.05% APS. The electrophoresis buffer contained: 25 
mM Tris base, 192 mM glycine, and 0.1% SDS. Image acquisition was performed 
using ImageLab (v5.2, BioRad). 
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Experimental animals 
 
For analysis, four lines of transgenic mice were used in our study: 
 
• TASTPM mice were transgenic for APPswe+PSEN1M146V on the Thy-1 
promotor and generated as previously described (Cummings et al., 2015, 
Matarin et al., 2015). 
• TgSAP mice were transgenic for the human APCS (SAP) gene, including 5′ 
and 3′ flanking sequences, with a steady state SAP plasma concentrations 
within the human range (Iwanaga et al., 1989). 
• TgSAPLine38 (TgSAPL38) mice were transgenic for the human APCS (SAP) 
gene and had >2-fold higher human SAP expression than TgSAP mice and 
developed by UCL (Al-Shawi et al., 2016). 
• 3xTg mice were transgenic for APPswe+PSEN1M146V on the Thy-1 promoter, 
and crossed with TgSAPL38 mice. 
The TASTPM mouse model was chosen as the model of AD pathology for the present 
study for a multitude of reasons. Previous studies have revealed that TASTPM mice 
develop amyloid plaques as early as 3 months of age, and extracellular, fibrillar Aβ 
plaques have been observed at approximately six months (Howlett et al., 2004) and, 
given the previous research showing the association of SAP and NPTX1 with Aβ, this 
feature was integral to have for our investigation of the pentraxins. As discussed 
previously, our lab has also reported increases in release probability in the CA1 
region in 2-month old TASTPM mice, and has characterized the first 
electrophysiological changes that occur in this mouse model (Cummings et al., 2015). 
Moreover, our lab has generated microarray data that show the expression levels of 
genes in this mouse model and the changes in expression with age, and have found 
correlations in this data with human AD data, particularly in immune genes. The 
TASTPM model was therefore chosen based upon the substantial amount of 
characterization already performed by our lab and others in order to provide a basis 
from which to compare other pathological features. 
 
WT animals used for the experiments were from C57BL/6J colonies. All other strains 
were on a C57BL/6J background. Male mice were bred in UCL Biological Services 
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Unit or the Royal Free Hospital, and generated as previously described (Pardon et al., 
2009). Mice were housed in groups of 2-5 from weaning and, for behavioral testing, 
singly housed for only a brief 1-2 hour period daily during testing to allow for 
individual feeding. Mice were otherwise kept under standard housing condition in 12-
hour light dark cycles, and allowed ad libitum access to food and water. All mice used 
were male. 
 
LPS and SAP treatment in vivo  
 
To test the ability of SAP to cross a compromised blood-brain barrier a protocol 
modified from Veszelka et al. (2013) and Bien-Ly et al. (2015) was used. Briefly, 4- 
to 6- month-old male C57BL/6 mice were given two intraperitoneal injections of 
lipopolysaccharide (LPS, from Escherichia coli 0111:B4; Sigma-Aldrich; 100 µg per 
injection per mouse dissolved in phosphate-buffered saline) or vehicle at 0 and 6 
hours. Mice then received a further injection of either 250 µg purified native human 
SAP (Abcam) in 20 mM phosphate buffer or vehicle at 22 hours. Mice were perfused 
with phosphate-buffered saline at 24 hours and the brain dissected and snap frozen for 
Western blot analysis. Image acquisition and densitometric analysis was performed 
using ImageLab (v5.2, BioRad) and statistical analyses were performed using Prism6 
(GraphPad Software). 
 
Spine density analysis 
 
Primary cultures of hippocampal neurons were prepared with a modified protocol 
(Beaudoin et al., 2012; Salih et al., 2012) from P0 to P1 mice expressing green 
fluorescent protein (GFP) on the Thy1 promoter, line S (Feng et al., 2000), resulting 
in a subset of their glutamatergic neurons being fluorescent. Following decapitation, 
the brains were quickly removed and placed in ice-cold dissection media (160mM 
NaCl, 5mM KCl, 1mM MgSO4, 4mM CaCl2, 5mM, HEPES, 5.5 mM glucose, 5µM 
phenol red, pH 7.4). The cortices and hippocampi were then dissected under a light 
microscope in dissection media, and kept on ice in fresh dissection media. When all 
brains had been dissected, cortices and hippocampi were removed from dissection 
media, diced, and incubated at 37ºC for 30 minutes in enzymatic digestion media 
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(dissection media, 1.5mM L-cysteine, 0.5mM EDTA, 5mM CaCl2, 30mM NaOH, 
100V papain, 1% DNaseI), with occasional agitation. Digested tissue was allowed to 
settle, digestion media removed, and inactivation media added (serum media: MEM 
w/Earle’s w/o l-glutamine, 5% FBS, 0.4g/l glucose, 0.25%w/v BSA), for 2 minutes 
before removal, and then serum media was added. Cells were liberated from digested 
tissue via trituration, with the resulting cell suspension pipetted off from settled 
debris, pelleted at 1,000RPM for 5 minutes at room temperature, and then the pellet 
re-suspended, and plated at a density of 130,000 cells/cm2 in poly-d-lysine coated 24 
well plates, in neuron media (Neurobasal Media, 4% B27 with vitamin A, 1% 
Glutamax-I). 
 
One-half the media volume was replaced with Neurobasal/B27 media 24-hrs after 
plating, and then once a week after that. After 4 days, 10µM FUDR was added to the 
media to inhibit non-neuronal cell growth. Neurons were maintained for 14 days, and 
for neurons treated with pentraxins, purified native human SAP or recombinant 
human NPTX1 was dissolved in the culture medium at the specified concentration 
and applied for 7 days starting at 7 DIV. Neurons were fixed at day 14 in 2% (w/v) 
PFA in in PBS for 10 minutes, then washed once in PBS for 10 minutes. Coverslips 
were then washed 3 times in 0.125% Trition X/PBS solution and blocked in 8% horse 
serum in 0.125% Trition X/PBS for 40 minutes at room temperature. Neurons were 
then incubated with primary antibody anti-GFP (1:300) in 8% horse serum in 0.125% 
Trition X/PBS solution at 4°C overnight. On the following day neurons were washed 
3 times for 10 minutes each in PBS, then incubated in 8% horse serum in 0.125% 
Trition X/PBS with the secondary antibody: Alexa Fluor 488 goat anti-chicken IgG 
(H+L) (Abcam) at 1:600 dilution. Neurons were then washed as before in PBS and 
also stained with DAPI (1:10,000 in PBS) for 5 minutes to identify cell nuclei, then 
washed again, as before. Coverslips were mounted onto SuperFrost® Plus glass slides 
(VWX International) with Fluoromount G (SoutherBiotech) mounting media and 
sealed with nail varnish.  
 
Spine imaging and analysis 
 
To image dendritic spines, dendrites were chosen at random and scanned (confocal 
microscope: Olympus Fluoview 300; Olympus 60x oil immersion objective, with 3x 
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zoom. Images taken were in a z-stack formation at 0.2µm steps through the neuron 
over a depth of 2.4 µm, with 12 z-stack images were taken per image. Spine density 
was quantified by counting the number of spines in approximately 100um-long 
sections of either primary, secondary or tertiary dendrites, for 2 dendrites per neurons, 
5 neurons per coverslip, and 12-18 coverslips per prep, in a blinded manner. Counts 
were taken from 3 independent preparations, with 2-3 mice used per preparation. All 
sample sizes for spine density analysis are expressed as number of coverslips. ImageJ 
was used to trace and determine the length of dendrites and to count spines, using 
NeuronJ add-on. Spines were counted manually by scrolling through image stacks, 
and the density was calculated by dividing by the dendrite length.  
 
In order to assess the impact of treatment on spine density, two-way ANOVAs with 
multiple comparisons were conducted. As experiments were designed such that 
control experiments were interleaved between the different pentraxin treatments, the 
control group is common to all experiments. Where appropriate, post-hoc 
comparisons were conducted, adjusted with the Sidak correction for multiple 
comparisons. All statistical analyses were performed using Microsoft Excel and 
Prism6 (GraphPad Software).  
 
Organotypic hippocampal slices 
 
Organotypic slices were prepared under sterile conditions from 5-7 day old C57BL/6J 
mouse pups of either sex using standard methods (De Simoni and Yu, 2006; Stoppini 
et al., 1991; Paulin et al., 2016). Briefly, mice were killed by decapitation and the 
brain rapidly removed and placed immediately in ice-cold dissection artificial 
cerebrospinal fluid (artificial CSF, containing (in mM): 125 NaCl, 2.4 KCl, 26 
NaHCO3, 1.4 NaH2PO4, 20 D-glucose, 3 MgCl, 0.5 CaCl, pH 7.4, ~315 mOsm/l). The 
forebrain was hemisected and a segment cut away from the dorsal aspect of each 
hemisphere, at an angle of approximately 15° off parasagittal. Slices were cut at 300 
μM using this angled cut as it is optimal for maintaining the viability of CA1 
neurons. Slices were incubated at 37ºC at the interface between a 5% CO2/air and 1 
ml culture medium (50% Modified Eagle Medium plus Glutamax, 25% horse serum, 
23% Earl’s balanced salt solution, 36.1 mM glucose, 50 units/ml 
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penicillin/streptomycin, 6.25 units/ml nystatin, pH 7.25, ~315 mOsm/l). Hippocampal 
slices were placed on small hydrophilic membrane discs (confetti; Millipore, cat. no. 
FHLC01300) on the bottom of the insert rather than directly onto the insert. Plating 
the slice on the confetti membrane piece enabled the slice to develop normally in 
culture by providing a surface for adherence and growth. The medium was replaced 3 
times a week. For slices treated with pentraxins, purified native human SAP or 
recombinant human NPTX1 was dissolved in the culture medium at the specified 
concentration and applied for 7 days starting at 13–15 DIV. Both control and treated 
sliced were taken for experimentation at 20–22 DIV, at the same time point that was 
used for our previous electrophysiological studies, after providing optimal time for 
the slices to recover and receive exposure to treatment conditions.  
 
Organotypic slices were fixed and stained using a modified protocol from (Gogolla et 
al., 2006). Briefly, slices were treated with 2% PFA in PBS for 30 minutes, then 
washed once in PBS for 10 minutes. Permeabilization of the slices was performed 
overnight, in 0.5% Trition X/PBS solution, at 4°C. The following day, slices were 
blocked in 20% BSA in 0.5% Trition X/PBS solution, for 4 hours at room 
temperature. Slices were then incubated with primary antibodies anti-IBA1 (Rabbit, 
Wako Pure Chemical Industries, LTD 019-19741, 1:250) and anti-CD68 (Rat, AbD 
Serotec, MCA 1957T, 1:250) in 5% BSA in 0.5% Trition X/PBS solution at 4°C 
overnight. Slices were then washed 3 times for 10 minutes each in 0.5% Trition 
X/PBS, then incubated in 5% BSA in 0.5% Trition X/PBS with the appropriate 
secondary antibody: Alexa Fluor 488 donkey anti-rabbit IgG (H+L) (Invitrogen), at 
1:500, and Alexa Fluor 594 donkey anti-rat IgG (H+L) (Jackson ImmunoResearch 
Laboratories) at 1:500. Incubation was for 4 hours at room temperature in dim light, 
then slices were washed 3 times for 10 minutes in PBS. Slices were treated with 4’,6-
diamindino-2-phenylindole (Pereira et al.) (1:10,000) to identify cell nuclei for 5 
minutes, then washed again with PBS. Slices were mounted onto SuperFrost® Plus 
glass slides (VWR International) and Fluoromount-G (SouthernBiotech) mounting 
media was added before applying the coverslip and sealing with nail varnish. Slices 
were mounted with the membrane because the slices become firmly attached to the 
membrane substrates over time in the culture, making it difficult to separate the slice 
from the membrane without causing damage.  
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Organotypic slice imaging and analysis  
 
Slices were imaged for quantification using an Olympus Fluoview confocal 
microscope using excitation wavelengths at 568 and 488. For microglia counts, 3 
areas of 62,500 µm2 from the CA1 and DG were imaged from each slice using a 40x 
water objective. Images taken were in a z-stack formation at 1.0µm steps through the 
organotypic slice, with 10 z-stack images taken per image within the region of interest 
covering a 10µm depth of the slice. Quantification was performed using ImageJ to 
make compositions of the 2 channels, and the manual count function was used to 
determine number of microglia within the defined area, with cells identified by their 
morphology. Microglia were counted as IBA1-positive cells, and only counted if their 
cell body was present. Activated microglia were classified based upon morphology 
and high-intensity CD68 staining. In order to avoid imaging through the glial scar of 
hypertrophic astrocytes that forms on the top layer (approximately the top 3-5µm) of 
the hippocampal organotypic slice (del Rio et al., 1991), all images were obtained 
from below this depth of the cell surface. 
 
For analysis of cell counts, each slice is considered as independent, despite 
originating from the same pup and, therefore, sample sizes represent the number of 
slices from which counts were taken. However, data for each group were obtained 
from a maximum of three slices prepared from any single animal. A minimum of 
three independent organotypic preparations was used to calculate the means for each 
treatment.  
 
In order to assess the impact of treatment on microglia numbers and activation levels, 
two-way ANOVAs with multiple comparisons were conducted. As experiments were 
designed such that control experiments were interleaved between the different 
pentraxin treatments, the control group is common to all experiments. Where 
appropriate, post-hoc comparisons were conducted, adjusted with the Sidak correction 
for multiple comparisons. All statistical analyses were performed using Microsoft 
Excel and Prism6 (GraphPad Software).  
 
 
 
	 68	
Immunohistochemistry for human samples 
 
Human AD samples were processed and then obtained by collaborators at the Queen 
Square Brain Bank. Tissue sections (7 µm thick) were cut from wax embedded 
hippocampi of four sporadic Alzheimer’s disease cases (Table 3.1) donated to the 
Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, 
University College London. Ethical approval for the study was obtained from the 
National Hospital for Neurology and Neurosurgery Local Research Ethics 
Committee. Sections were deparaffinised in xylene and rehydrated using graded 
alcohols. Immunohistochemistry against NPTX1 and SAP required antigen retrieval 
with a pressure cooker for 10 min in citrate buffer (pH 6.0). Endogenous peroxidase 
activity was blocked (0.3% H202 in methanol, 10 min) and non-specific binding with 
10% dried milk solution for 1 hour. Tissue sections were incubated with the primary 
antibodies (1:100 anti-NPTX1 and 1:100 anti-SAP, Table 2.2) overnight at 4°C, 
followed by biotinylated anti-mouse IgG and biotinylated anti-goat respectively 
(1:200, 30 min; DAKO) and ABC complex (30 min; DAKO). Color was developed 
with diaminobenzidine/H202 (Lashley et al., 2011) and counterstained with 
haematoxylin. For mouse brains, immunoperoxidase histochemistry was performed 
on a Ventana Discovery XT staining platform using the Ventana DAB Map Kit. Wax 
sections of formalin fixed tissue were pretreated with Ventana Protease 3 (for SAP 
staining) or sCC1 (for NPTX1) and blocked for 8 min using Superblock (Medite). 
The primary antibodies used were: an in-house monospecific polyclonal rabbit 
antiserum was used to detect human SAP (1:200 for 4 hrs), anti-NPTX1 (Table 2.2; 
1:200, 1 hr), and Amyloid beta 6F3D Dako (Invitrogen, 1:50, 1 hr). Sections were 
counterstained with haematoxylin. 
 
Behavioral Assessments 
 
Mice were food deprived to 90% free feeding weight from 2 days before the start 
(habituation) of the T-maze experiment. Ad libitum access to water was provided. The 
holding room was maintained on a reversed 12 hr. light and 12 hr. dark cycle with 
lights off at 7 am, and temperature was controlled at 21 ± 2C. All mouse cages 
consisted of sawdust, nesting material, and play tubes from the age of weaning. All 
procedures were carried out in accordance with the UK animals Scientific Procedures 
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Act. 
 
T-maze spatial alternation task 
 
Mice were handled at the start of food deprivation and throughout T-maze habituation 
period for 15 minutes per animal per weekday. Mice were tested in 4 batches, with 
n=16-18/batch. Hippocampal function was assessed using a standard forced choice T-
maze paradigm (Dudchenko, 2001; Stewart et al., 2011).  
 
The room within which the T-maze was performed contained visible landmark cues 
on each of the 4 walls. This was done to aid the mice in making the correct choice 
using non-egocentric cues outside of the maze (Dudchenko, 2001). The T-maze was 
constructed from three arms, each arm measuring 50 x 8 x 10 cm. The maze was 
placed on a table in a room with numerous distal visual cues, such as black and white 
posters on the walls. The maze had clear Perspex walls and a grey floor. Black 
wooden blocks were used to block the start and goal arms. Mice ran for a drop of 
reward (Nestlé Carnation Condensed Milk) that was placed in a food cup at the end of 
each goal arm.  
 
All mice received 4 days of habituation to the maze, during which mice were placed 
in the maze for 5 minutes with all arms open and allowed to explore. Drops of reward 
were scattered in day 1 and 2 of habituation along the floor and in food wells to 
encourage exploratory behavior, then restricted to only the food wells at the ends of 
the goal arms in days 3 and 4. The behavioral regime consisted of 3 weeks, with 5 
days of training per week (from Monday-Friday). Each day animals received 6 trials, 
and each trial consisted of a sample and choice run. In the sample run, the mouse was 
placed at the starting point at the base of the T, a block was raised and the mouse was 
allowed to go to the available arm and eat a drop of reward from the food well 
(entrance to the other arm was blocked by a barrier) (Fig. 6.1 A). On the second run 
(choice run), the mouse was returned to the starting point, and the barrier in the 
previously blocked arm was removed. The starting block was then raised and the 
animal was allowed to choose between the two arms, but only rewarded if it chose the 
previously unvisited arm (Fig. 6.1 B). Thus, a correct choice was made when the 
mouse selected the arm not visited in the sample run. After the choice run mouse was 
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removed to its holding box from the maze. The location of the sample arm (left or 
right) was varied pseudorandomly across the session. Mice received three left and 
three right presentations, with no more than two consecutive trials with the same 
sample location. Response time was measured as the time from when the mouse was 
placed in the maze and start block removed until all four feet were over a specified 
line at the entry point to each goal arm. Because prolonged response times for choice 
runs effectively introduce a delay to the trial by increasing the amount of time the 
mouse must remember its previous choice, a time limit was placed. Mice were 
allowed five minutes to make a choice to enter a goal arm in both runs before a trial 
was aborted and 20 seconds to consume the reward after entering a goal arm. If the 
incorrect arm was chosen during the choice run the mouse was confined in the arm for 
20 s and then removed from the maze. Arms were cleaned with 70% ethanol between 
runs and animals. During the first 2 weeks of training the choice run followed 
immediately after the sample run (there was a delay of approximately 15 s between 
runs). To prevent the mice from determining the arm with reward using scent cues, 
the reward station at the end of each arm contained a cap filled with approximately 
2mL reward, on top of which was a paper barrier where the drop of reward was 
placed.  
 
In the 3rd week, four days of test delays were introduced between the sample and 
choice run. During the specified interval, each animal was placed in a separate 
holding box. Each mouse received 2 of each of the delay lengths per day varied 
pseudorandomly across days. Delay times were 2.5, 5 and 10 minutes.  
 
Data presented from the training are means blocked across 2 days for each animal.  
Response time and performance were analyzed by repeated measures ANOVA with 
effect of training block measured within-subjects and the effect of genotype and 
treatment between groups. Data was analyzed using Microsoft Excel and Prism6 
(GraphPad Software).  
 
Elevated plus maze (1 trial only test) 
 
The plus-maze was constructed from 2 enclosed arms (30 cm x 5 cm x 20 cm) and 2 
open arms (30 cm x 5 cm x 0.8 cm) connected by a small central platform (5 x 6 cm). 
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The maze was elevated 30 cm above a table. Mice were placed in the center of the 
plus maze facing an open arm and allowed to freely explore the maze for a 6 minute 
trial. The time spent on each arm (open vs. closed) was recorded, as well as the 
number of entries into the arms (an entry into an arm was defined as all 4 paws resting 
on a given arm). Data was analyzed using Microsoft Excel and Prism6 (GraphPad 
Software).  
 
Open field (1 trial only test) 
 
The open field consisted of a white plastic cylinder (diameter: 47.5 cm, height 36 cm) 
with a white plastic floor. Mice were put into the open field periphery and allowed to 
explore freely for 15 min. The path of each mouse was recorded using an hp 1080p 
Autofocus f2.0 camera. The open field was divided into a central circle and a 
peripheral ring with the area of center equal to area of periphery. Mice were tracked 
within a defined area of interest (optical division of equal areas consisting of the 
central circle vs. peripheral ring) using Image Pro (v7.0). Analysis of data was 
completed using custom functions created using R statistical programming (v2.14.1). 
Statistical analyses were performed using Microsoft Excel and Prism6 (GraphPad 
Software).  
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Chapter 3 
 
NPTX1 and SAP colocalize in the brains of mouse models of AD pathology and 
human AD patients 
 
 
Introduction 
 
SAP and NPTX1 localization in the brain 
 
A four-fold increase in SAP levels has been reported in the hippocampus and cortex 
of AD patients compared to controls, to an average of 110ng SAP/mg protein when 
total homogenate is examined (Crawford et al., 2012). However, additional members 
of the pentraxin family are expressed by neurons, share a significant degree of 
homology to SAP (Fig. 1.1), and have been shown to localize to amyloid deposits in 
the brain as well (Abad et al., 2006). It is therefore important to note that studies 
investigating SAP levels in the brain have failed to simultaneously evaluate those of 
the other neuronal pentraxins, and that the specificity of the antibodies used in some 
studies has not been definitively demonstrated. Therefore, the first goal of this chapter 
is to thoroughly verify antibody specificity, along with their affinity to intended 
targets. Considering that both NPTX1 and SAP have been reported to be associated 
with neuritic plaques in post-mortem brain tissue of people with AD (Abad et al., 
2006; Duong et al., 1989; Kalaria et al., 1991a), I went on to compare the localization 
of these pentraxins in post-mortem brains from AD patients using the antibodies that I 
had determined to be specific for each pentraxin. Determining the specific 
localization of SAP in the brains of AD patients can help to determine whether it may 
be capable of interacting with NPTX1 or of enhancing plaque stability as it does in 
the periphery (Pepys, 2006).  
 
While in humans SAP remains at a relatively stable circulating plasma concentration 
of ~10–100 µg/mL (~0.4–4 µM, based on 25 kDa monomer; Pepys et al., 1978), in 
mice, SAP acts as an acute-phase response protein (Pepys and Hirschfield, 2003). 
While there has been no published evidence for SAP production or infiltration into the 
brains of mice either under normal conditions or with transgenes for AD pathology, is 
it important to consider whether this may be possible, particularly given the 
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widespread use of mouse models in the field of AD. I therefore sought to determine, 
with the independently validated primers and antibodies, whether SAP could be 
detected in mouse models of AD pathology. Moreover, I also asked the question of 
whether higher levels of SAP in the periphery can results in infiltration into the brain, 
using mouse models transgenic for human SAP, with and without human transgenes 
for AD. To best address these questions, two different transgenic lines that express 
human SAP on the human SAP promoter in the liver were used in our study: TgSAP 
mice that have a steady state SAP plasma concentrations within the human range 
(Iwanaga et al. 1989), and TgSAPL38 mice that have a human SAP concentration in 
sera of over twice the amount that is within the human range (with a mean 
concentration of 216.9±154.9 mg/L), as determined by Al-Shawi et al. (2016). To 
address this question in terms of AD, this study then examined the effect of crossing 
the high-SAP expressing mice with the TASTPM mouse model, as it possesses AD 
transgenes that encode pathogenic variants of human APP and human presenilin-1. 
The TASTPM mice were transgenic for APPswe+PSEN1M146V on the Thy-1 promotor 
(Cummings et al., 2015, Matarin et al., 2015). 
 
How might SAP get into the brain? What effect could this have? 
 
In humans, under normal physiological conditions, penetration of SAP through the 
BBB is poor, as only low nanomolar concentrations of SAP have been found in the 
brain, with previous findings of concentrations in older adults averaging 
approximately 28ng SAP/mg protein in the hippocampus (Crawford et al., 2012) and 
8.5ng/mL in the CSF (Hawkins et al., 1994). However, SAP has consistently been 
found at higher concentrations in the brains of AD patients (Crawford et al., 2012; 
Yasojima et al., 2000) and bound to Aβ plaques (Duong et al., 1989; Kalaria et al., 
1991a). It has therefore been proposed that SAP likely crosses into the brain due to 
dysfunction of the BBB (Kalaria et al., 1991b), albeit there is also evidence for its 
upregulation by neurons in brains from AD patients (Yasojima et al., 2000). It is 
important also to consider the substantial concentration gradient that is likely to allow 
for such penetrance (Pepys et al., 1978), along with the considerable amount of 
evidence for BBB breakdown occurring in many cases of AD (Blennow et al., 1990; 
Montagne et al., 2015).  
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With the findings stated above that the peripheral pentraxin SAP is present in the 
brain at increased levels in AD, it is thus important to consider what possible effects it 
may therefore be capable of invoking, and how it may be doing so. NPTX1, NPTX2, 
and NPTXR can all form heteropentamers via the pentraxin domain, and function in 
developmental and activity-dependent synaptic plasticity (Kirkpatrick et al., 2000; Xu 
et al., 2003). Given the structural similarity of SAP to the NPTXs, particularly in the 
pentraxin domain, the question arises whether infiltrating SAP could mimic or 
otherwise directly interact with the NPTXs, possibly modulating synaptic 
transmission in the CNS. This study therefore explored whether this could be the case 
in a series of coimmunoprecipitation experiments with our specificity-tested 
antibodies.  
 
In the following results section, the RT-PCR, antibody specificity, 
coimmunoprecipitation, western blot and lps experiments were performed by myself, 
and the staining of human and mouse tissue was performed by our collaborators at the 
Queen Square Brain Bank and by the lab of Professor Sebastian Brandner, 
respectively. All necessary controls were carried out and were all negative and 
validated by pathologists at the Queen Square Brain Bank or the UCL Institute of 
Neurology.   
 
 
Aims 
 
The aim of this chapter is to first determine whether the peripheral pentraxin SAP can 
be detected in a mouse model of AD pathology and in patients with AD using 
independently validated and specific antibodies. Secondly, we test whether SAP can 
permeate the BBB under a condition of BBB breakdown and lastly to investigate 
whether SAP can interact with its similarly structured family members of the brain - 
the neuronal pentraxins.  
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Results 
 
 
Determination of antibody specificity  
 
Reliable detection of the different members of the pentraxin family was integral to our 
experiments. The significant levels of homology between each pentraxin could easily 
allow for misidentification and, generally, commercial antibodies for SAP were raised 
against the conserved pentraxin region of SAP. This was also the case for many 
antibodies available for NPTX1. Therefore, given the significant overlap of this 
region among pentraxin family members, it was necessary to determine antibody 
specificity using molecular biology cloning techniques.  
 
 
In order to ensure antibody specificity, the protein sequences for mouse SAP, CRP, 
NPTX1, NPTX2 and NPTXR were aligned, and we attempted to choose commercial 
antibodies that were against the regions of SAP and the neuronal pentraxins that were 
not conserved amongst the pentraxin family. However, most antibodies commercially 
available did not generally fit this approach, and thus extensive practical specificity 
testing was required.  
 
Specificity of each pentraxin antibody used in this study was tested by overexpressing 
each individual pentraxin in HEK293T cells and subsequently running Western 
immunoblots (Fig. 3.1 A, B) to test that signal would not be detected for the incorrect, 
or for multiple, pentraxin proteins. I thus identified a highly specific antibody for 
SAP, NPTX1, NPTX2 and NPTXR after testing ten commercial antibodies. 
Moreover, serial dilutions of purified/recombinant pentraxin proteins were used, with 
concentrations of all the purified/recombinant pentraxins independently verified to 
determine the relative affinity of each of these specific pentraxin antibodies to its 
respective target (Fig. 3.1 D). The formation of pentamers, size and integrity 
verification of proteins was also verified. Here, our results show that the SAP 
antibody showed higher affinity than the NPTX1 antibody (Fig. 3.1 D), which is an 
important point to consider for the experiments that followed. 
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Figure 3.1. Pentraxin antibodies used are highly specific. A) HEK293T cells were 
transfected with constructs expressing each murine pentraxin fused to GFP individually to 
confirm their expression. After 48 hours, lysates were collected and 25µg protein was 
resolved using a 10% SDS-PAGE gel. Western blotting was performed using a GFP antibody 
to confirm the expression and molecular weight of each NPTX-GFP protein. All bands 
corresponded to the predicted molecular weight of each GFP-fused pentraxin, with 
GFP:27kDa, SAP:25kDa, NPTX1:47kDa, NPTX2:47kDa, NPTXR:65kDa. NT: Non-
transfected. B) We identified antibodies that were specific for each pentraxin. HEK293T cells 
overexpressing each pentraxin were probed with the specified pentraxin antibody. Only 
specific bands for each antibody were detected on each blot, with lysates loaded from 
HEK293T cells overexpressing each of the pentraxins loaded (labeled above each lane). Note, 
the specific antibodies are also specific over the pentraxin C-reactive protein (CRP). C) 
Recombinant human neuronal pentraxins and native purified human SAP proteins form 
homopentamers. Ci) Pentameric structure verification of each non-denatured pentraxin 
protein, 2µg protein resolved per well on a non-denaturing PAGE gel. Bands correspond to 
pentameric forms of the proteins at their expected high molecular masses. Cii) Denatured 
human pentraxin protein resolved in duplicate lanes for verifying concentration, size and 
integrity. D) Affinity test of the specific pentraxin antibodies. A dilution series of each 
recombinant pentraxin protein in a set of 100-fold decreasing concentrations shows NPTX2 
has higher affinity than other pentraxin antibodies, with band detection capable at a 
concentration of 10ng protein loaded. Faint bands for NPTXR and SAP at 10ng indicate 
higher affinity than the NPTX1 antibody. Figure adapted from Cummings, Benway et al. 
(2017). 
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Can SAP be detected in the brains of mouse models of AD pathology? 
 
 
We next sought to independently determine whether SAP could be detected in the 
brains of the TASTPM (homozygous) mouse model of AD pathology. As these mice 
develop fibrillar Aβ plaque deposits by four months of age, we examined whether the 
expression of SAP in the brain could be detected or possibly upregulated in mice with 
the pathology associated with such changes in expression in human patients with AD	
(Crawford et al., 2012; Duong et al., 1989). To best detect any evidence for 
upregulation, we tested for SAP mRNA expression at the ages of 4 and 18 months 
with APCS (SAP) primers we developed and verified to be specific (Chapter 2). 
 
Using our primers, we detected no expression of SAP at the mRNA level in the cortex 
of 4, or 18-month old WT, or 18-month old homozygous TASTPM mice using RT-
qPCR (Fig. 3.2 A, B). In accordance, no expression of SAP was detected using 
microarray analysis of hippocampus, cortex or cerebellum of WT mice or mice 
transgenic for genes for familial AD at 2, 4, 8 and 18 months of age 
(www.mouseac.org; see Matarin et al., 2015). With SAP being an acute-phase protein 
in mice, its expression levels in the brain were not expected to be high, but it would 
be possible for levels to rise in these mice given that inflammation is increased in 
TASTPM mice (ibid). Given the discrepancies in the evidence for SAP expression in 
the brain (Al-Shawi et al., 2016; Hawrylycz et al., 2012; Yasojima et al., 2000), it was 
necessary to confirm whether this could have been the case by using our specific tools 
and models. However, we detected no SAP in whole-brain lysates from 20-month old 
TASTPM and WT mice, suggesting that SAP does not cross the BBB in this mouse 
model of AD pathology. 
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Figure 3.2. SAP RNA is not detected in the cortex of WT or TASTPM mice. A) Apcs 
(SAP) transcription was detected by RT-PCR in liver but not the cortex of 4-month old WT 
mice or in B) 18-month old WT or TASTPM mice. During the cDNA synthesis, RNA 
samples lacking the reverse transcriptase (-RT) enzyme served as a negative control to test for 
contamination. C) No SAP detected in whole-brain lysates from 20 month-old TASTPM or 
WT mice. 
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We next sought to determine if the higher concentrations of NPTX1 protein 
reportedly found in the brains of AD patients (Abad et al., 2006) corresponds to 
mRNA levels in the TASTPM mice. Using the same transgenic mouse database at 
www.mouseac.org, along with independently verified data from RT-qPCR 
experiments performed in our lab (Dr. Dervis Salih) we found that NPTX1 mRNA 
expression levels are dysregulated and actually decreased in the TASTPM mouse 
model of AD pathology, with expression significantly lower in the homozygous 
TASTPM mice at 4 and a trend toward a significant decrease (p=0.07) at 18 months 
of age (Fig. 3.3). This finding was unexpected, given the increase in NPTX1 
immunoreactivity that is associated with dystrophic neurites in the brain tissue of the 
APP/PS1 mouse model of AD pathology previously reported (Abad et al., 2006).  
Figure 3.3. NPTX1 expression is dysregulated in the hippocampus of TASTPM mice. 
Gene expression changes (compared to WT) of NPTX1 in the hippocampus of WT and 
TASTPM homozygous mouse models from (www.Mouseac.org; Matarin et al., 2015). Two-
way ANOVA revealed a main effect of genotype. Sidak post hoc multiple comparison of 
control to normalized NPTX1 levels are indicated *p<0.05. Data presented as mean ± SEM. 
 
Different mouse strains have been found to have endogenous serum SAP levels that 
range from 20 µg/ml to 150 µg/ml, and to be classified as high and low SAP-
responder strains after stimulation (Le et al., 1982). Given these variations, it was 
important to establish whether any SAP detection was possible with the consideration 
that compromises in the BBB of these mice may have occurred over the course of 
their lifespan. To investigate SAP and NPTX1 at the protein level in this mouse 
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model, western blots were run for 18-month old WT and homozygous TASTPM 
mice. No SAP could be detected in these mice at this advanced age, corresponding to 
the lack of any mRNA expression found and suggesting very low levels not detectable 
by our specific antibody, thus indicating that SAP is unlikely to cross the BBB in 
mice.  
 
 
 
 
 
 
 
 
Figure. 3.4. NPTX1 protein concentration is not significantly different between the 
brains of old WT or TASTPM mice. (A) Western blot showing NPTX1 levels in 18-month 
old WT and homozygous TASTPM mice. (B) NPTX1 levels were normalized to prominent 
band protein levels using Ponceau-S. Data presented as mean ± SEM from WT (n=3) and 
TASTPM (n=4). Unpaired t-test revealed no significant difference. 
 
 
 
Interestingly, NPTX1 protein levels in the 18-month old homozygous TASTPM mice 
were not found to be significantly different from those in the WT mice, despite the 
expression levels showing a trend for decreased NPTX1 expression at this age, (Fig. 
3.4 A, B). Two-way ANOVA on the expression data revealed a significant effect of 
genotype [F(1,54) = 10.78, p=0.0018], and post hoc tests found a significant decrease 
in NPTX1 at 4 months (p=0.0369) and a trend toward a significant decrease at 18 
months (p=0.0708). Although we find a difference between NPTX1 expression and 
protein levels in this mouse model, it is important to note that cellular homeostasis is 
likely taking place in this instance, as elevated protein concentrations (possibly due to 
accumulation around amyloid plaques) may be causing downregulation in mRNA 
synthesis. Also, it is generally accepted within the field that it is the concentration and 
interactions of proteins that dictate the causative forces in the cell (Greenbaum et al., 
2003). 
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SAP and NPTX1 accumulate around plaques in hippocampus and cortex of AD 
patients 
 
Table	3.1.	Post-mortem	sporadic	Alzheimer’s	disease	cases	
Case	number	 Age	at		 Age	at		 Duration		 Gender	
		 onset	 death	 (years)	 		
1	 80	 85	 5	 M	
2	 46	 52	 6	 F	
3	 58	 68	 10	 M	
4	 54	 64	 9	 M	
 
As both NPTX1 and SAP have been reported to be associated with neuritic plaques in 
post-mortem brain tissue of AD patients (Crawford et al., 2012; Yasojima et al., 
2000), we next compared the localization of these two pentraxins in post-mortem 
brains from AD patients (Table 3.1; Fig. 3.5 A, B). As the antibodies tested above 
detect both mouse and human NPTX1 and SAP, the same antibodies were used for 
the staining of the AD patient tissue.  
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.5. Comparison of the distribution of NPTX1 and SAP in hippocampus and on 
amyloid plaques in AD patients. A) Post-mortem AD hippocampus stained for NPTX1 
(brown diaminobenzidine staining). Ai) NPTX1 is evident in the hippocampus, particularly 
within the polymorphic layer of the dentate gyrus, stratum lucidum of CA3 and stratum 
radiatum of CA1. 4x objective. Aii) A neurofibrillary tangle (white arrowhead) distal to 
neuritic plaques (black arrowheads) in the hippocampus. Both are heavily stained for NPTX1. 
20x objective. Aiii) A higher magnification (40x objective) image showing NPTX1 
associated with a neuritic plaque in the temporal cortex. B) Post-mortem AD hippocampus 
stained for SAP. Bi) Note the lower level of staining compared to NPTX1. 4x objective. Bii) 
Cortical plaques stained for SAP. Biii) Higher magnification image (40x objective) of plaques 
stained for SAP. Panels A-B: Brown staining is SAP or NPTX1, as labeled.  
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NPTX1 showed a high level of staining in dystrophic neurites around the periphery of 
plaques and general diffuse staining between the neurons with only faint staining in 
the core of the plaque. In addition, there was a general staining of NPTX1 in the 
polymorphic layer of the dentate gyrus in the tissue in human (Fig. 3.5 Ai). NPTX1 
staining was also seen filling dystrophic neurons remote from plaques in the human 
AD brain samples, possibly representing neurons with tau pathology (Figure 3.5 Aii).  
 
SAP staining was also seen in association with plaques in post-mortem brains from 
AD patients (Figure 3.5 Bi, Bii, Biii). Although very faint, this staining was present 
diffusely around the plaques but was not evident elsewhere in the tissue. As the SAP 
antibody showed higher affinity than the NPTX1 antibody for their respective targets 
(Figure 3.1 D), the relative strength of antibody staining suggests that only a small 
amount of SAP is present on the plaque compared to NPTX1. This is perhaps not 
surprising as the NPTX1 is reportedly produced in glutamatergic nerve terminals and 
so this staining likely represents locally released NPTX1, possibly from the 
dystrophic neurites themselves. Therefore, with the possible exception of structural 
changes of the proteins occurring when bound around amyloid plaques resulting in a 
differential change in the binding of the antibodies, the pentraxin binding to plaques 
appears to be strongly dominated by NPTX1 when compared to SAP.  
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Figure 3.6. Distribution of SAP in WT, TgSAP and in TASTPM mice at 12 months of 
age. A) No SAP can be detected in the brain of WT mice. B) SAP staining can be seen in 
TgSAP mice. Bi) SAP is evident in the fiber tracts of the cerebellum, pons, medulla and 
inferior colliculus, and diffuse staining is present throughout the thalamus, hippocampus and 
cortex. Bii) Faint, diffuse staining of SAP in the hippocampus. Area of interest indicated by 
box on Bi. Biii) Higher magnification image of CA1, with very faint SAP staining. Area of 
interest indicated by box on Bii. C) No SAP can be detected in the brain of TASTPM mice. 
D) In 3xTg mice, a similar SAP staining pattern is seen to the TgSAP mice (B), with faint 
staining that can be seen in the hippocampus (Dii, Diii) as well as around plaques (Div, area 
of interest indicated in Diii). E) Confirmation of Aβ plaques in the 3xTg model with amyloid 
beta 6F3D Dake, showing a high number of dense-core plaques in the hippocampus (Eii, 
Eiii). Panels A-E: Brown staining is SAP or Aβ, as labeled.  
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SAP can enter the brain and is present on plaques in 3xTg (APP/PS1/SAP) mice 
 
 
For the human SAP staining in the mice, an in-house monospecific polyclonal rabbit 
antiserum was used to detect SAP. This SAP antibody was independently validated 
for specificity by the lab’s collaborators as described in Bodin et al. (2010).  No SAP 
staining could be detected in the WT or TASTPM mice at 12 months of age (Fig. 3.6 
A, C), demonstrating that mouse SAP is not likely being produced or leaking into the 
brain in this model of AD pathology, at least not at significant enough levels to be 
detected at this age. In the case of the TgSAP mice, diffuse staining was present in the 
hippocampus, with slightly stronger staining present in the regions of the 
fornix/fimbria (Fig. 3.6 Bi, Bii). 
 
 
To determine the extent to which human SAP can enter the brain of a mouse model 
with both AD pathology and a high steady-state plasma SAP concentration we 
examined staining in our 3xTg model, which express approximately (at least) twice as 
much human SAP in the liver at the TgSAP mice (Al-Shawi et al., 2016). It can 
clearly be seen that SAP staining is present throughout several regions of the brain in 
the 3xTg mouse, with higher levels in the cerebellum, pons, medulla and some in the 
thalamus. There is also diffuse staining present throughout the hippocampus and 
cortex (Fig. 3.6 Di). In examining the hippocampus, the level of staining is very 
similar to the lower-expressing TgSAP model (Fig. 3.6 Bi), restricted to mostly 
diffuse staining associated with the amyloid plaques (Fig. 3.6 Dii, Diii, Div).  
Amyloid-β plaque staining was also performed in these models to confirm this 
attribute of the TASTPM phenotype (Fig. 3.6 E).  
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Figure 3.7. Distribution of NPTX1 in WT, TgSAP and in TASTPM mice at 12 months of 
age. A) NPTX1 staining in the hippocampus of an adult WT mouse. Note the similar pattern 
of staining to human (Fig. 3.5 A; i.e. polymorphic layer of dentate gyrus, particularly heavy 
staining in stratum lucidum of CA3 and lighter staining in stratum radiatum of CA1; but in 
the case of the mouse, also in all layers of CA3 and in stratum oriens in CA1). Aii) Higher 
magnification image of the CA1. The area of interest is indicated in Ai). Note the presence of 
NPTX1, particularly in stratum radiatum (SR) and stratum oriens but a near-absence in 
stratum pyramidale (SP) and stratum lacunosum moleculare (SLM). B) NPTX1 staining in 
the hippocampus of a TASTPM mouse. A similar pattern of staining to WT, with dense 
staining around the periphery of the plaque and only faint staining in the center (Biii, with 
area of interest in Bii). C) NPTX1 staining in the hippocampus of a 3xTg mouse. A similar 
pattern of staining to the WT and TASTPM mice, with staining around the outside of plaques 
that can be seen in Cii, but less intense than the staining around plaques in the TASTPM 
mice. Panels A-C: Brown staining is NPTX1, as labeled. 
 
 
In examining NPTX1 staining in these mouse models (Fig. 3.7), a similar pattern of 
staining to humans is observed (from Fig. 3.5), particularly in the hippocampus. All 
three genotypes showed high levels present in the polymorphic layer of DG with 
heavy staining in stratum lucidum of CA3 and slightly less amount in stratum 
radiatum of CA1 and all layers of CA3 (Fig. 3.7 Aii, Bii, Cii). The level of staining of 
NPTX1 was again relatively higher around plaques found in the hippocampus, as 
compared to SAP, even in the higher-expressing TgSAP models (Fig. 3.7 Cii). A high 
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degree of staining can also be seen around plaques in the TASTPM mouse model, 
(Fig. 3.7 Biii) particularly with a greater extent of staining around the outside of 
plaques than in the TgSAP mouse (Fig. 3.7 Cii).  
 
 
SAP can enter the brain under conditions of BBB breakdown 
 
 
Under physiologically normal conditions, SAP is not expected to cross the BBB, but 
evidence from (Veszelka et al., 2013) has demonstrated that SAP can permeate an 
LPS-challenged BBB into the brain. Moreover, both Yasojima et al. (2000), and later 
Crawford et al. (2012), have shown significantly higher SAP levels in the brains of 
AD patients. We therefore hypothesize that it may cross the BBB under conditions of 
breakdown, as has been reported to occur in AD (Montagne et al., 2015), as well as in 
other conditions of inflammation or diseased states (Reinhold and Rittner, 2017).  
 
 
 
 
 
 
 
Figure 3.8. SAP crosses the compromised BBB. Mice were administered LPS to 
compromise the BBB and injected with native human SAP or PBS, then each hippocampus 
was probed for SAP. A) Western blot showing SAP levels in the four groups of mice. Liver 
from an animal injected with SAP is shown in the last lane as a positive control. B) SAP 
levels were normalized to total protein levels (Ponceau-S). Data presented as mean ± SEM 
from 2 animals per group. Two-way ANOVA confirmed a significant effect of LPS (p= 0.01) 
and no significant effect of SAP injection and no interaction. Figure adapted from Cummings, 
Benway et al. (2017). 
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We thus tested for levels of mouse and/or human SAP in the brain using Western blot 
in WT mice after injection of human SAP with or without compromising the BBB by 
treatment with LPS (Fig. 3.6 A). In the absence of LPS, we could detect only very 
low levels of SAP in the brain of untreated mice or mice injected with human SAP 
(250 µg). However, 22 hours after the first of two LPS administrations, injection of 
human SAP resulted in a strong SAP signal in both hippocampus and cerebellum. 
Furthermore, even without injection of human SAP, endogenous mouse SAP levels 
were increased in the brain, albeit at rather variable levels (Fig. 3.6 B). Two-way 
ANOVA confirmed a significant effect of LPS (p=0.01) and no significant effect of 
SAP injection and no interaction. 
 
SAP binds to NPTX1 in HEK cells overexpressing pentraxins  
 
Given the evidence that SAP can cross a compromised BBB and its presence in the 
brain of AD patients, we next sought to investigate whether SAP can interaction with 
the neuronal pentraxins. The coimmunoprecipitation procedure used was adapted 
from that of (O'Brien et al., 1999), using HEK293T cells transfected with the 
constructs that I made expressing each murine pentraxin fused to GFP and the 
appropriate antibodies that were verified. Here, we confirmed the results previously 
reported (Kirkpatrick et al., 2000; Xu et al., 2003) and showed that NPTX1, NPTX2 
and NPTXR form heteropentamers when they are overexpressed together in 293T 
HEK cells (Fig. 3.7).  Interestingly, we found that the peripheral pentraxin SAP can 
form a complex with NPTX1, NPTX2, and NPTXR (Fig. 3.7). This finding further 
supports the hypothesis that SAP can interact with the neuronal pentraxins, and 
potentially their downstream targets.  
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Figure 3.9. SAP forms complexes with each of the neuronal pentraxins. HEK293T cells 
were transfected with constructs expressing the combinations of pentraxins indicated, each 
fused to GFP. After 48 hours, lysates were collected and tested by immunoprecipitation (IP) 
followed by Western blotting with antibodies specific to each pentraxin. The bands 
correspond to the molecular weight predicted for each full-length pentraxin fused to GFP, 
with molecular weights for GFP ~27 kDa, SAP ~25 kDa, NPTX1/2 ~47 kDa and NPTXR 
~53 kDa (Fig. 3.1 A). Note: the NPTX1 and NPTXR antibodies were not effective at 
immunoprecipitation, even for NPTX1 and NPXTR themselves, in part due to lower affinity 
(Fig. 3.1 D). Experiment undertaken by Benway, T.; Figure adapted from Cummings, 
Benway et al. (2017). 
 
 
Summary 
 
Previous studies have reported both SAP and NPTX1 to be associated with features of 
AD pathology (Abad et al., 2006; Yasojima et al., 2000), though none have examined 
either pentraxin in relation to the other in this context. After performing a multitude of 
experiments testing for the specificity and affinity of different antibodies, we were 
able to successfully identify ones for SAP and NPTX1 that could be used for 
examining the location of both pentraxins in the brains of AD patients and mouse 
models of AD pathology. In the post-mortem human AD tissue, these experiments 
revealed the presence of both pentraxins around plaques, confirming previous 
findings (ibid). Additionally, the results suggest that only a relatively small amount of 
SAP is present around plaques compared to NPTX1, considering the different levels 
that we found for the affinity of the antibodies used.  
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In mice, heavy staining for NPTX1 was found throughout the regions of the 
hippocampus, as previously reported (Cho et al., 2008). Interestingly, SAP staining 
was present, albeit diffuse and at low levels, in the hippocampus of transgenic mice 
expressing human SAP in the liver with plasma concentrations within the human 
range  (Iwanaga et al. 1989). This suggests that SAP is capable of crossing the BBB 
in mice when at higher levels in the serum.  
 
In the TASTPM mouse models of AD pathology, we found no evidence for SAP 
mRNA expression up to the age of 18 months, in line with previous results (Shi et al., 
1999). Interestingly, a dysregulation of NPTX1 mRNA was found between the ages 
of 2 and 18 months, but the examination of protein levels revealed no differences 
between TASTPM and WT mice at 18 months of age, suggestive of a feedback 
mechanism that may be occurring due to high levels of NPTX1 deposition around 
plaques.  
 
In TASTPM mice crossed with high-expressing SAP mice (3xTg), we show further 
evidence of SAP penetrance into the brain, with evidence of both SAP and NPTX1 
staining around the plaques in these mice. The ability of SAP to cross the BBB was 
confirmed using an LPS-mediated experimental condition to cause a disruption of the 
BBB, in line with the findings from (Veszelka et al., 2013). 
 
With the high degree of structural similarity between SAP and NPTX1, and the 
evidence for their co-localization in the brain, we hypothesized that the two 
pentraxins may be capable of interacting with one another. This was confirmed in our 
co-immunoprecipitation experiments. SAP was found to bind to not only NPTX1, but 
to NPTX2 and NPTXR as well. This finding raises the question of what other effects 
SAP may therefore be capable of eliciting in the brain via its interaction with the 
NPTXs, particularly with NPTX1, given that it ahs also been implicated in AD.  
 
Overall, we can confirm previous reports that SAP is present in the brains of patients 
with AD and is particularly associated with plaques. Our novel finding that SAP can 
form a complex with NPTX1, NPTX2, or NPTXR (Fig. 3.7), together with the 
evidence that SAP can enter the brain if there is a breakdown of the BBB, suggest that 
this peripheral pentraxin may be capable of influencing other effects in the brain, 
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beyond its proposed role in possibly stabilizing plaques, as previously reported 
(Tennent et al., 1995). In fact we have recently reported that SAP causes direct 
regulation of synaptic function, interacting with the neuronal pentraxin family 
members in this context (Cummings, Benway et al., 2017). In considering the role of 
SAP in the brain, it is therefore crucial that the effects of SAP are examined in respect 
to other neuronal pentraxins as well.  
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Chapter 4 
 
Chronic application of NPTX1 decreases spine density in primary cultured 
neurons 
 
 
Introduction  
 
As the main postsynaptic targets of excitatory synapses on pyramidal cells in the 
cortex and hippocampus of mammals, dendritic spines are key features of synaptic 
transmission (DeFelipe and Farinas, 1992). The strength of the synapse is directly 
related to different features of dendritic spines and is highly plastic, making spines 
important homeostatic modulators (Matsuzaki et al., 2001). Structural changes in the 
number and shape of dendritic spine are the key features mediating synaptic plasticity 
in the brain (Fu and Zuo, 2011), although following adolescence spines become more 
stable and last for the majority of a lifetime (Zuo et al., 2005). However, with 
advanced age, is it not uncommon for spine loss to occur. Synapse density in old 
monkeys was found to be 30-60% reduced from that of adults (Peters et al., 1998), 
while in mice the use of chronic, in vivo two-photon imaging has revealed that the 
density of the dendritic spines of apical dendrites in cortical pyramidal neurons is 
stable in mice from 8–15 months of age, but the long-term retention of spines is 
significantly lower in old mice, with spines that are smaller in size with age (Mostany 
et al., 2013). 
 
There are several pathophysiological factors that can contribute to dendritic spine 
loss, including excitotoxicity induced by glutamate overspill, reduced presynaptic 
neurotransmitter release, interaction of protein oligomers with synaptic molecules, 
inflammation, altered Ca2+ release from stores, and disruptions in mitochondria 
function (Herms and Dorostkar, 2016). Neuropathological lines of evidence 
supporting synaptic pathology for AD have been well characterized in AD patients 
(Penzes et al., 2011) and in some mouse models of AD pathology (Herms and 
Dorostkar, 2016). Synaptic loss is consistently reported in studies analyzing post-
mortem tissue samples from patients diagnosed with AD (DeKosky and Scheff, 1990; 
Selkoe, 2002). In these patients, loss of dendritic spines has been shown in both the 
hippocampus and cortex, which are the areas most significantly affected by AD 
pathology (DeKosky and Scheff, 1990; Walsh and Selkoe, 2004). While there is 
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substantial synapse loss in AD, there is also notable loss in patients with MCI, 
indicating that this loss progresses as the pathology advances (Arendt, 2009). 
 
Figure 4.1. Putative lifetime trajectory of dendritic spine number in the in a normal 
subject and in AD. Bar across the top indicates the emergence period of symptoms and 
diagnosis. In normal subjects (black line), spine numbers increase before and after birth, then 
spines are selectively eliminated during childhood and adolescence to adult levels. In AD (red 
line), spines are rapidly lost in late adulthood, suggesting perturbed spine maintenance 
mechanisms that may underlie cognitive decline. Figure modified from Penzes et al. (2011). 
 
Some mouse models of AD pathology also display dendritic and synaptic 
perturbations, similar to findings in human studies. In the Tg2576 mouse model that 
overexpresses a mutant form of APP (isoform 695) with the Swedish mutation 
(KM670/671NL), significant decreases in spine density are found in the outer 
molecular layer of the DG beginning as early as 4 months of age, far before the first 
detection of plaque deposition at 18 months of age (Jacobsen et al., 2006). Wu et al. 
(2004) found similar results in 90-day-old PDAPP mice that possess the APP V717F 
mutation, as they had significant decreases in spine densities of superficial granule 
cells in the posterior region of the DG. Additionally, examining both of the 
aforementioned models, (Lanz et al., 2003) found decreases in spine density in the 
CA1 region of the hippocampus for the Tg2576 and PDAPP mouse lines, at 4.5 and 2 
months of age, respectively. Importantly, these reductions have been found to precede 
overt AD pathology in these models. Given that changes in spine density can occur 
before significant AD pathology in humans and some mouse models of AD 
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pathology, the question arises as to what other factors may be contributing to this 
effect.  
 
NPTX1 and SAP are both present at higher concentrations in the brains of AD 
patients (Abad et al., 2006; Yasojima et al., 2000) and we have confirmed the 
distribution of both pentraxins in the hippocampus of such patients. We have also 
shown that SAP is capable of entering the brain under conditions of BBB breakdown 
and of interacting with the neuronal pentraxins. Given the results that both SAP and 
NPTX1 have presynaptic effects on glutamate release in the hippocampus (Benway, 
Cummings et al., 2017), with the application of either each separately or both together 
producing an increase in glutamate release probability, the question arises as to 
whether there are corresponding effects of these pentraxins at the postsynaptic 
terminal as well.  
 
In parallel to our work, a recent study by Figueiro-Silva et al. (2015) looked at spine 
numbers in primary cultures of cortical neurons after NPTX1 knockdown and found a 
significant increase in dendritic protrusions, as well as an increase in the number of 
excitatory synapses. This finding led to our hypothesis that NPTX1 negatively 
regulates excitatory synapse formation. Therefore, it is the purpose of our study to 
determine whether increased levels of NPTX1 and/or SAP will correspondingly 
decrease synaptic density of hippocampal neurons, and investigate whether the effect, 
if any, is modulated by SAP, given the evidence provided for their interaction. 
 
 
In the following results section, all immunohistochemistry and imaging experiments 
were performed by myself. 
 
 
 
Aims 
 
The aim of the following chapter is to investigate whether chronic exposure of 
NPTX1 and/or SAP elicits changes in the number of spines in primary neurons. This 
will help to provide a clearer understanding of synaptic alterations that may be 
occurring over the course of AD, when the concentrations of these proteins are at 
higher levels in the brain.  
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Results 
 
 
Determining influence of SAP and NPTX1 on spine density in primary neurons 
 
To determine the effects of exogenously applied SAP, NPTX1, or both pentraxins 
together, recombinant human NPTX1 protein and/or purified native SAP protein was 
added to the medium of hippocampal neurons at concentrations that first evoked 
significant changes in synaptic transmission (Cummings, Benway et al., 2017). In 
these experiments, exogenous application was our chosen paradigm in order to avoid 
any potentially confounding neomorphic effects of overexpression, and to best reflect 
a potential physiological condition. The following concentrations were added to the 
media of hipppcampal neurons from P0 GFP-mice at 7 DIV for 7 days: NPTX1 at 60 
nM and SAP at 20 nM. Untreated neurons were used as the controls, and the data 
from 3 independent neuronal preparations for each type of treatment was pooled. 
 
A section of approximately 100µm in length was sampled per dendrite, for two 
dendrites per neuron. An average of 5-6 neurons was sampled per coverslip, and the 
average spine density per coverslip (n) was then analyzed. Sample areas were taken 
from primary, secondary and tertiary dendrites of clearly immunolabeled GFP 
neurons (Fig. 4.3). Even sampling was performed as much as possible, where dendrite 
location and image quality allowed. Numbers generated for “all dendrites” are the 
mean spine densities of each dendrite in a coverslip sampled, regardless of the order. 
 
In order to determine whether NPTX1, SAP or co-application of SAP and NPTX1 can 
exert postsynaptic effects, spine density of hippocampal neurons was measured after 7 
days of treatment, at DIV 14. Importantly, we first established that there were no 
differences in spine density between dendrites of different orders. Our results 
confirmed those of previous studies (Duan et al., 2003) showing no difference 
between primary (emerging from the cell soma), secondary (first branches from a 
primary), or tertiary (first branches from a secondary) dendrites (Fig. 4.2), and so we 
initially examined the effects of the pentraxins on overall spine density for all types of 
dendrites examined.  
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Figure 4.2. No differences in spine density were observed between different order 
dendrites of hippocampal neurons. One-way ANOVA revealed no difference in the average 
spine densities between primary (n=5), secondary (n=14) and tertiary (n=10) dendrites. Data 
presented as mean ± SEM. 
 
 
In analyzing all hippocampal dendrites, two-way ANOVA revealed a main effect of 
NPTX1 [F(1,40)=6.162, p=0.0174], and post hoc tests showed that exogenously 
applied NPTX1 significantly decreased the overall spine density of GFP neurons after 
chronic exposure from a mean of 0.67 ± 0.05 spines/µm in the controls to 0.47 ± 0.04 
spines/µm in the NPTX1-treated neurons (Figure 4.4 p=0.0488).  
 
In examining the effects of SAP treatment alone and the effects of the co-application 
of SAP and NPTX1 on neurons, no significant changes were found in spine density 
(Fig. 4.4 The maintenance of dendritic spines with SAP treatment would therefore 
suggest that, while SAP has similar effects to NPTX1 at the presynaptic terminal on 
glutamate release probability, it differs from NPTX1 in its influence on spine density 
and interestingly counteracts the effect of NPTX1.  
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Figure 4.3. Dendrites of hippocampal neurons chronically treated with NPTX1 show a 
decrease in spine density, but co-application of SAP attenuates this effect. A) 
Immunolabeling with GFP in representative control GFP-immunolabeled hippocampal 
neuron from mice expressing GFP. Scale bar 50µm. B) Control tertiary dendrite from insert in 
A). C) 20 nM SAP-treated tertiary dendrite. D) 60 nM NPTX1-treated tertiary dendrite. E) 20 
nM SAP+60 nM NPTX1-treated tertiary dendrite. Scale bar, 10µm. 
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Figure 4.4. Application of NPTX1 at 60nM decreases spine density in hippocampal 
neurons, while application of SAP at 20nM blocks the effect of NPTX1. Two-way 
ANOVA with presence/absence of NPTX1 as one factor, and the presence/absence of SAP as 
the other factor, revealed a significant main effect of NPTX1, with a decrease in spine density 
for NPTX1-treated neurons (n=9) compared to controls (n=13). SAP treatment alone (n=15) 
produced no effect, but for neurons treated with SAP+NPTX1 (n=7), the effect of NPTX1 
was blocked by SAP. Sidak post hoc multiple comparison of control to NPTX1-treated are 
indicated *p<0.05. Data presented as mean ± SEM. 
 
 
Interestingly, these results show that SAP blocks the effect of NPTX1 on overall 
hippocampal spine density, rather than adding to its effect. This lack of an additive 
effect is reminiscent of the paired-pulse ratio data from Cummings, Benway et al. 
(2017), providing further evidence that SAP and NPTX1 interact at the synapse and 
likely act on similar targets. In this case a higher concentration of NPTX1 was used 
(60 nM) than the sub-maximal concentration (6 nM) used in the aforementioned 
study, and yet the effect of the addition of SAP not only failed to be additive, but was 
instead blocked by the same concentration of SAP (20 nM) used in both experiments.   
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In looking separately at the different types of dendritic projections, two-way ANOVA 
revealed a significant main effect of NPTX1 [Fig. 4.5 A; F(1,17)=9.468, p=0.0068] 
on primary hippocampal dendrites and a significant interaction between NPTX1 and 
SAP in secondary dendrites [Fig. 4.5 B; F(1,38)=5.265, p=0.0274]. While the 
blocking effect of SAP does not appear to be evident in primary dendrites, we still 
find that there is a lack of any additive effect of the SAP application. In considering 
why only the primary dendrites are significantly affected by NPTX1, it is important to 
consider that different order dendrites have different diameters, with primary 
dendrites being thicker than secondary or tertiary (Lu et al., 2015).  It was predicted 
that tertiary dendrites may be more susceptible to changes in the milieu of the culture 
system given their tendency to form varicosities and show spine loss (relative to 
primary and secondary dendrites) under conditions of ischemia (Meller et al., 2008). 
However, we found the opposite; primary dendrites showed a higher susceptibility to 
spine loss, which is likely to be explained by the cytonuclear signaling being more 
efficient in primary dendrites due to their proximity to the cell soma (Li et al., 
2015). 
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Figure 4.5. Application of NPTX1 at 60nM decreases spines of primary hippocampal 
dendrites. A) Two-way ANOVA revealed a significant main effect of NPTX1 on primary 
dendrites (p=0.007) with a decrease in spine density for neurons treated with NPTX1; with 
control (n=5), NPTX1-treated (n=6), SAP-treated (n=5), and NPTX1+SAP-treated (n=5). B) 
Two-way ANOVA revealed a significant interaction of SAP and NPTX1 on secondary 
dendrites (p=0.027), with control (n=14), NPTX1-treated (n=7), SAP-treated (n=13), and 
NPTX1+SAP-treated (n=8). C) No significant effects on spine density were found for tertiary 
dendrites, with control (n=10), NPTX1-treated (n=5), SAP-treated (n=5), and NPTX1+SAP-
treated (n=6). Two-way ANOVA performed with presence/absence of NPTX1 as one factor, 
and the presence/absence of SAP as the other factor. Data presented as mean ± SEM.  
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Summary 
 
 
Excitatory synaptic contacts are formed on dendritic spines, and the loss of spines is 
highly correlated to the loss of synaptic function. Changes in number and shape of 
dendritic spines are key modulators of synaptic plasticity (Fu and Zuo, 2011). There is 
substantial evidence that dendritic spine dysfunction is an important factor in the 
pathogenesis of AD (see review by (Herms and Dorostkar, 2016).  
 
Determining the factors that play a role in the pathological lead-up to AD, and 
precede the rise in amyloid and tau pathology, are of the utmost importance in further 
deciphering the mechanisms that produce the devastating effects that occur. Here, we 
sought to determine whether two proteins found to be upregulated in AD, SAP and 
NPTX1 (Abad et al., 2006; Yasojima et al., 2000), are capable of exerting an effect on 
primary hippocampal neurons, independent of the influence of Aβ. This was 
important in establishing whether these pentraxins are capable of exerting effects that 
may occur before the onset of Aβ deposition, when it may be possible that the levels 
of these proteins are rising in the brain. 
 
Previously it has been shown that treatment with both SAP and NPTX1 can elicit 
presynaptic changes in glutamate release (Cummings, Benway et al., 2017). 
Interestingly, no additive effect of SAP was found in these experiments when co-
applied with NPTX1, suggesting that these two pentraxins do not act independently of 
each other. Here, our results further support this hypothesis; while there was a 
significant decrease in spine density in NPTX1-treated hippocampal neurons, the co-
application of SAP and NPTX1 similarly did not produce an additive effect. 
 
Taken together, the observations that SAP alone does not influence spine density, but 
can interfere with the effects of NPTX1 on spine density when co-applied, support the 
hypothesis that these two pentraxins have different effects at the synapse, but can 
interact or affect the same targets. It is important to note, however, that previous 
results in our lab have found that LTP is impaired in SAP transgenic mice (Cummings 
et al., 2017). Concordantly, Figueiro-Silva et al. (2015) also report enhanced LTP 
after NPTX1 knockdown. These results therefore suggest that both pentraxins could 
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be capable of influencing synaptic plasticity, but to different degrees of severity that 
may depend on length of exposure and concentration.  
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Chapter 5 
 
The effect of NPTX1 and SAP on microglia in organotypic cultures 
 
 
Introduction 
 
A major risk factor for the development of neurodegenerative disease is age. Age-
dependent changes in microglia morphology are likely to be a key factor in the 
pathological process (Conde and Streit, 2006). This hypothesis is based upon the 
evidence that microglia populations in the brain are maintained over a lifetime with 
the findings that the CNS microglial population is maintained without peripheral, 
bone marrow-derived influences (Ajami et al., 2007) and that microglial cells have a 
low proliferative rate (Saijo & Glass, 2011). It therefore follows that this long-lived 
microglial cell population would be susceptible to the aging effects that occur over the 
lifespan. 
 
In healthy aged brains, microglia numbers show a significant increase with age, with 
higher numbers likely accounting for the decrease of the surveillance volume as 
shown by shorter process lengths, as assessed by comparing mice at different ages 
(Hefendehl et al., 2014). Aged microglia respond with more severe and longer-lasting 
pro-inflammatory activation that is associated with neuronal death and lack of 
functional recovery (Njie et al., 2012; Sierra et al., 2007). 
 
It can therefore been hypothesized that ageing microglia can contribute to the brain’s 
susceptibility of neurodegeneration, whereby they are neuroprotective in healthy 
brains, but subsequently undergo morphological changes that result in a buildup to the 
homeostatic tipping point upon which they lose their neuroprotective capacity and 
instead contribute to pathology. In the case of AD, the progressive buildup of Aβ 
poses added stress to the ageing microglia (Streit et al., 2009). Although microglia are 
able to respond to Aβ early in progression (Bamberger et al., 2003; Koenigsknecht 
and Landreth, 2004; Koenigsknecht-Talboo and Landreth, 2005; Mandrekar et al., 
2009), it is likely that the battling of this toxic species over such a prolonged period of 
time promotes accelerated senescence and, in turn, inhibits Aβ phagocytosis.   
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The complement cascade is a line of defense that plays a major role in phagocytosis 
by microglia (Frank and Fries, 1991), as well as immune complex removal and 
synaptic maturation (Sunyer et al., 1998), and it is known to be activated by the 
versatile pattern recognition molecule C1q (Gaboriaud et al., 2004). C1q is localized 
to the synapse and signals phagocytic microglia to facilitate beneficial synapse 
elimination in early development (Bialas and Stevens, 2013; Schafer et al., 2012; 
Stevens et al., 2007). However, C1q levels have been found to rise and accumulate at 
the synapse early in AD, with the synaptic deposition being induced by prefibrillar 
oligomeric Aβ. C1q expression is upregulated in microglia in pre-plaque brains and is 
shown to be required for oligomeric Aβ synaptic loss in vivo, determined using C1qa 
KO mice and looking at downstream effects of activation (Hong et al., 2016).  
 
SAP can directly interact with C1q by forming a complex with its collagen-like 
domain to cause activation (Roumenina et al., 2006). NPTX1 has been found to bind 
to C1q through a region in the C-terminal (Stevens et al., 2007), but the effects of this 
binding, if any, have yet to be studied. Given the results that SAP and NPTX1 are 
associated with amyloid plaques and NFTs in AD brains (Duong et al., 1989; Tennent 
et al., 1995)Cummings, Benway et al., 2017), and that levels of both pentraxins are at 
higher concentrations in the AD brain (Duong et al., 1997) (Abad et al., 2006), the 
question is raised whether this may correspondingly lead to higher levels of 
microglial activation, as both can interact with C1q. It is therefore important to 
consider whether such activation may be part of the process leading up to the tipping 
point for microglia in AD.  
 
While the role of the peripheral pentraxins in the immune response has been well 
established, it is unclear whether the neuronal pentraxins play such a significant role 
in this response as well. Neuronal pentraxins are known to be involved in synaptic 
plasticity, synapse formation and synaptic clearance, which are all influenced by 
microglia (Osera et al., 2012). (Miskimon et al., 2014) recently provided some 
evidence for NPTX2 in immune function using NPTX2 KO mice by examining the 
microglial response to sciatic nerve transection, an injury known to result in increased 
glial activation (He et al., 1997). In this case, NPTX2 deletion resulted in a significant 
increase in microglial activation. From this result it would suggest that NPTX2 
somehow regulates the immune response, though how it is able to do so requires 
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further investigation. Therefore, it may be the case that the other neuronal pentraxins 
are capable of influencing the immune response as well. In particular, given its high 
degree of structural similarity to NPTX2, NPTX1 may also be capable of somehow 
influencing the immune response. This becomes an important point to consider 
provided the evidence that NPTX1 co-localizes with the pathological amyloid and tau 
proteins in AD (Abad et al., 2006), and the role of the immune system in the disease 
progression.  
 
To test whether chronic exposure of SAP and NPTX1 can influence the regulation of 
microglia numbers or activation at levels observed to cause pre- and postsynaptic 
effects, organotypic cultures were used to provide a model that preserves the neuronal 
circuits and cellular architecture seen in vivo including astrocytes and microglia - an 
important consideration in the examination of proteins initially studied with respect to 
synapses, such as the pentraxins. 
 
In the following results section, all immunohistochemistry and imaging experiments 
were performed by myself. 
 
 
Aims 
 
This chapter investigates the effects of SAP and NPTX1 in the brain in relation to 
conditions present in AD using a 3D ex vivo model that preserves both 
cytoarchitecture and cell interactions that form the mouse hippocampus. Specifically, 
microglia numbers and rates of activation were measured to determine whether 
exposure to levels of pentraxins that are known to affect synaptic transmission will 
also elicit a response from the immune system.  
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Results 
 
Hippocampal organotypic slices show a high proportion of activated microglia  
 
 
The age at which to observe microglial activity in organotypic slices was chosen to be 
at DIV 20-22, as this allowed for an appropriate amount of time for slices to recover 
(based on previous observations from our lab) and allowed for an appropriate amount 
of time for chronic treatment with the pentraxins. Electrophysiological recordings 
previously discussed (Benway, Cummings et al., 2017) were also performed at this 
age, which us to compare and characterize these slices at the same timepoint.   
 
The proportion of activated microglia in the untreated control slices was 57.5 ± 0.02% 
(mean ± SEM). This result is consistent with findings from (Gerlach et al., 2016), 
who also examined microglia activation using double-immunolabeling of Iba1 and 
CD68 in hippocampal organotypic slices. Their findings revealed rapid and long-
lasting activation microglial activation through to DIV 7 using CD68 
immunoreactivity, but also confirmed this extended activation state by examining 
gene expression profiles of two markers of microglial activation MHCIIAB and IL-
1B (Graeber et al., 2011; Kettenmann et al., 2011) up through DIV 15. Gerlach et al. 
(2016) also provide profiles of microgliosis in organotypic slices over the course of 
15 DIV, where spikes in activation are reported in the first 3 days, followed by a 
plateau and then steady but gradual increase in activation levels over time. 
Additionally, previous results from our lab show no significant changes in number of 
microglia or in activation levels between DIV 7 and DIV 21, confirming the minimal, 
if any, increase in activation levels or numbers of microglia that occur following the 
first week of adjustment in culture (Nair MSci Dissertation, 2015).  
 
Effects of SAP, NPTX1 and SAP+NPTX1 application on microglia in organotypic 
slice cultures 
 
 
In order to determine whether SAP and NPTX1 have effects either separately or 
together on microglia in the hippocampus, organotypic hippocampal slices were 
exposed to human pentraxin protein levels that first evoked changes in release 
probability as found in Cummings, Benway et al. (2017). Given these concentrations 
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produced both presynaptic and postsynaptic changes, the question is then raised about 
other effects the pentraxins may be having on other cell types that influence neural 
function.  
 
 
 
 
Figure 5.1. Representative image of microglia in the hippocampus of an organotypic 
slice. A) Microglia stained with Iba1 (green) and CD68 (red) in the CA1 of WT mouse 
organotypic slices (DIV 21) showing representative images of resting microglia (blue arrows) 
and activated microglia (purple arrows). B) Higher power image of representative resting 
microglia (blue arrows) and active microglia (purple arrows), where characteristics are clearly 
shown. Scale bars, 20µm. 
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Microglia were characterized based upon both their morphology and immunolabeling 
with Iba1 and CD68 (Fig. 5.1). Inactivated microglia were defined as Iba1-positive 
cells with a resting phenotype of highly ramified processes and a small somata, and 
each microglia occupying a small distinct area (Boche et al., 2013). Microglia were 
defined as “resting” even with exhibiting some CD68-positive staining, based upon 
the criteria that CD68 staining was restricted to the periphery of the cell body, the cell 
body was not increased in size, and the microglia still possessing normal projections 
from its cell body. Activated microglia were defined as Iba1- and CD68-positive cells 
with an amoeboid phenotype of a larger, swollen cell body of approximately 2-3 
times larger than resting microglia, with clearly rescinded projections from the soma. 
Morphological features based upon a physiological review of microglia morphology, 
as described in Kettenmann et al. (2011).  
 
 
As performed previously to investigate the chronic effects of pentraxins at the 
synapse, native purified human SAP 20 nM and/or recombinant human NPTX1 60 
nM was applied to the media of organotypic slices for a period of 7 days, beginning at 
DIV 13-15. Untreated organotypic slices of the same age were used as the controls, 
and the data from 3 independent experiments for each type of treatment were pooled. 
The CA1 and the DG were the two regions of the hippocampus examined, as they 
show high levels of vulnerability to pathology in human AD patients as well as in 
mouse models of AD. 
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Figure 5.2. Application of NPTX1 decreases number of microglia and co-application of 
SAP and NPTX1 suppresses activation of microglia in DIV 20-22 organotypic slices. 
Immunolabeling with Iba1 (green) and CD68 (red) in: A) Control CA1; B) 60 nM NPTX1-
treated CA1; C) 20 nM SAP-treated CA1; and D) 60 nM NPTX1+ 20 nM SAP-treated DG. 
Scale bar, 20µm. 
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Effect of SAP and NPTX1 on microglia numbers  
 
 
In organotypic cultures treated with NPTX1 (60nM; Fig. 5.2 B), SAP (20nM; Fig. 5.2 
C) or both pentraxins (Fig. 5.2 D), two-way ANOVA revealed a significant 
interaction between SAP and NPTX1 treatment [Fig. 5.3 A; F(1,70)=16.24, 
p=0.0001], and significant main effects of both SAP [F(1,70)=16.92, p=0.0001] and 
NPTX1 [F(1,70)=18.10, p=0.0001]. Post hoc tests found that microglia numbers in 
the hippocampus significantly decreased after the chronic 7-day treatment of NPTX1 
(p<0.0001). However, this effect of NPTX1 was blocked by SAP, as hippocampal 
slices treated with both pentraxins showed no change compared to those of the 
control, and the co-treated slices showed a significantly higher number of microglia 
than the NPTX1-treated slices (p<0.0001).  
 
In the CA1 (Fig. 5.3 B), two-way ANOVA showed a strong trend toward significance 
of the interaction between SAP and NPTX1 (p=0.0585), and main effects of SAP 
treatment [F(1,59)=10.89, p=0.0016] and NPTX1 treatment [F(1,59)=13.39, 
p=0.0005]. Post hoc tests again revealed NPTX1 treatment significantly decreased the 
number of microglia (p=0.0002), which SAP again blocked (p=0.0041).  
 
In the DG (Fig. 5.3 C), two-way ANOVA revealed a significant interaction between 
SAP and NPTX1 [F(1,62)=22.53, p<0.0001], and main effects of SAP treatment 
[F(1,62)=20.58, p<0.0001] and NPTX1 treatment [F(1,62)=13.22, p=0.0006]. Post 
hoc tests again revealed NPTX1 treatment significantly decreased the number of 
microglia (p<0.0001), which SAP again blocked (p<0.0001). 
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Figure 5.3. Application of NPTX1 at 60nM decreases number of microglia in 
hippocampal organotypic slices, while application of SAP at 20nM has no effect alone 
but blocks the effect of NPTX1. A) Two-way ANOVA revealed an interaction between SAP 
and NPTX1 treatment (p=0.0001), with total (CA1 + DG) microglia numbers in the 
hippocampus decreased for NPTX1-treated slices (n=10) compared to controls (n=39), but 
increased in SAP+NPTX1 (n=16) compared to only NPTX1-treated. SAP treatment alone 
(n=9) produced no effect. B) In the CA1, two-way ANOVA revealed a strong trend for 
interaction between SAP and NPTX1 treatment (p=0.0585), with microglia numbers 
decreased for NPTX1-treated slices (n=10) compared to controls (n=32), but increased in 
SAP+NPTX1 (n=13) compared to only NPTX1-treated. SAP treatment alone (n=8) produced 
no effect. C) In the DG, Two-way ANOVA revealed an interaction between SAP and NPTX1 
treatment (p<0.0001), with microglia numbers decreased for NPTX1-treated slices (n=10) 
compared to controls (n=35), but increased in SAP+NPTX1 (n=14) compared to only 
NPTX1-treated. SAP treatment alone (n=7) produced no effect. Sidak post hoc comparison to 
control and to NPTX1-treated are indicated **p<0.01; ***p<0.001;  **** p<0.0001. Data 
presented as mean ± SEM. 
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Effect of SAP and NPTX1 on microglia activation 
  
 
In looking at microglial activation levels in organotypic cultures treated with NPTX1 
and SAP (Fig. 5.4 A), two-way ANOVA revealed a significant interaction between 
SAP and NPTX1 treatment [F(1,70)=4.799, p=0.0318], and a significant main effect 
of NPTX1 [F(1,70)=24.79, p<0.0001]. Post hoc tests found that the proportion of 
activated microglia numbers in the hippocampus significantly decreased after the 
chronic 7-day treatment of both SAP and NPTX1 (p<0.0001), though no effects found 
with the application of either pentraxin on its own.  
 
In the CA1 (Fig. 5.4 B), two-way ANOVA revealed a significant interaction between 
SAP and NPTX1 [F(1,59)=7.832, p=0.0069], and a main effect of NPTX1 treatment 
[F(1,59)=8.979, p=0.0040]. Post hoc tests again revealed a decrease in the proportion 
of activated microglia numbers after the treatment of both SAP and NPTX1 
(p=0.0020), and no effect of either pentraxin on its own. 
 
In the DG (Fig. 5.4 C), two-way ANOVA revealed a significant interaction between 
SAP and NPTX1 [F(1,63)=4.557, p=0.0367], and a main effect of NPTX1 treatment 
[F(1,63)=6.950, p=0.0105]. Post hoc tests showed a significant decrease in the 
proportion of activated microglia with co-application of both pentraxins compared to 
only SAP-treated slices (p=0.0221). 
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Figure 5.4. Co-application of NPTX1 at 60nM and SAP at 20nM decreases the 
proportion of activated microglia. A) Two-way ANOVA revealed an interaction between 
SAP and NPTX1 treatment (p=0.0318), with co-application of SAP+NPTX1 (n=17) 
decreasing the proportion of total (CA1+DG) activated microglia in the hippocampus 
compared to controls (n=38) and SAP-treated (n=9). NPTX1-treatment alone (n=10) 
produced no effect. B) In the CA1, two-way ANOVA revealed an interaction between SAP 
and NPTX1 treatment (p=0.0069), with co-application of SAP+NPTX1 (n=13) decreasing the 
proportion of activated microglia compared to controls (n=32) and SAP-treated (n=8). 
NPTX1-treatment alone (n=10) produced no effect. C) In the DG, two-way ANOVA revealed 
an interaction between SAP and NPTX1 treatment (p=0.0367), with co-application of 
SAP+NPTX1 (n=14) decreasing the proportion of activated microglia compared to SAP-
treatment alone (n=7), but not controls (n=36). NPTX1-treatment alone (n=10) produced no 
effect. Sidak post hoc comparison to control and to NPTX1-treated are indicated *p<0.05; 
**p<0.01; ***p<0.001;  **** p<0.0001. Data presented as mean ± SEM. 
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Summary 
 
 
The overall aim of the current study is to investigate the effects of the peripheral 
pentraxin SAP and the neuronal pentraxin NPTX1 in the brain at higher levels, 
considering the evidence for increased concentrations of both proteins found in AD 
brains (Abad et al., 2006; Yasojima et al., 2000). We have used organotypic cultures 
in our study to examine the effect of SAP and NPTX1 on microglia in a region of the 
brain where both pentraxins have been shown to localize around amyloid plaques in 
brains of AD patients. The results of this chapter show that these pentraxins are 
capable of affecting microglia number and activation, and demonstrate that there is an 
interaction between both that influences the immune response.  
 
In the CA1 and DG regions of the hippocampus where, earlier in this thesis, we 
confirmed both pentraxins are distributed (Fig. 3.5), NPTX1 has a significant effect in 
decreasing the number of microglia (Fig. 5.3). Interestingly, this effect is completely 
blocked by SAP, with co-application of both pentraxins bringing microglia numbers 
back to those in the controls. However, SAP treatment alone has no effect on total 
numbers of microglia. Increases in NPTX1 protein levels and expression have been 
shown to lead to apoptotic neuronal death (Abad et al., 2006; DeGregorio-Rocasolano 
et al., 2001), and these results now indicate that NPTX1 may also be involved in the 
process of cell death in microglia. This blocking effect of SAP on NPTX1 toxicity can 
be supported by previous findings from Cummings, Benway et al. (2017), where co-
application of the two pentraxins in organotypic slices produced no additive effect in 
paired-pulse ratios, suggesting that they are competing for the same target with SAP 
blocking the effect.  
 
While activation levels of microglia were unaffected by treatment of either pentraxin 
alone, the co-application of SAP and NPTX1 produced a significant decrease in the 
proportion of activated microglia in both regions of the hippocampus (Fig. 5.4). This 
further confirms the conclusion from Cummings, Benway et al. (2017) that the two 
pentraxins are not acting independently, but instead interacting either together or on 
the same targets when applied together. 
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Overall, these results suggest that SAP, upon entry into the brain, can interact with 
endogenous NPTX1 to alter the role that NPTX1 plays in affecting microglia number 
and activation. While we hypothesized that chronic SAP and NPTX1 treatment would 
cause increased microglial activation levels, this was not the case. Treatment with 
SAP or NPTX1 alone did not cause an increase in activation of microglia, but, 
interestingly, their co-application caused a decrease in activation levels.  
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Chapter 6 
 
Mice expressing human SAP demonstrate no spatial working memory 
impairment  
 
Introduction 
 
 
In AD, it is widely accepted that the degree of synaptic loss provides a much stronger 
indication of cognitive decline than does the extent of Aβ plaque burden (Scheff et al., 
2006; Terry et al., 1991). When considering the data from Cummings, Benway et al. 
(2017), it is clear that chronic exposure to SAP modulates synaptic transmission, as 
electrophysiological recordings from both organotypic brain slices with exogenous 
application of SAP and acute brain slices of TgSAP mice demonstrated increases in 
glutamate release probability. Further, the latter result also revealed that sufficient 
SAP can enter the brain of the mouse to cause this effect, even when only expressed 
at normal human levels in the liver (Cummings et al., 2017; Iwanaga et al., 1989). 
With these results clearly demonstrating that SAP can influence central transmission 
and synaptic plasticity, the question arises whether the effects that SAP produces at 
the synapses will translate to cognitive effects.  
 
To examine this question in relation to AD, we used the TASTPM mouse model. 
Alterations in hippocampal synaptic paired pulse facilitations have been found in this 
model at very young ages (2 months), before detectable deposition of amyloid plaques 
(Cummings et al., 2015). However, in previous behavioral tests, cognitive 
performance of TASTPM mice up to the age of 9 months showed no impairment in 
hippocampus-specific memory tasks, using the same measures employed in the 
current study (Benway MSc Dissertation, 2011). However, an age of 9 months may 
have been too young for any cognitive changes to occur, given the brain’s resilience 
and capability of sustaining normal cognitive functioning even in the presence of 
pathology up to, in many cases, well advanced ages (Negash et al., 2013). Therefore, 
an older age of 13-14 months with increased pathology was chosen as the time point 
at which to compare any difference in cognitive performance between genotypes.  
 
It has been shown that human SAP promotes the aggregation of amyloid in vitro at 
physiological concentrations of SAP at 0.01 µM and Aβ1-40 at a concentration of 1 nM 
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(Hamazaki, 1995). Given Aβ1-40 is found in human plasma and cerebrospinal fluid at 
concentrations around 0.6 nM (Seubert et al., 1992), the observation of the effects 
with using 1 nM Aβ1-40 with SAP are of physiological relevance. Further, it has been 
shown that this binding of SAP to Aβ fibrils prevents their digestion, with in vitro 
experiments showing two aggressive proteinases (human neutrophil cathepsin G and 
extent elastase) and phagocytic cells to be inhibited in their degradation of fibrils by 
bound SAP blocking their actions (Tennent et al., 1995). 
 
In humans, SAP in the periphery binds to and stabilizes amyloid fibrils (Kolstoe et al., 
2009). The dissociation of SAP from these peripheral fibrils has been show to result 
in their partial clearance from the plasma, and may aid in the symptoms of 
amyloidosis (Pepys et al., 2002). Given the role SAP in stabilizing amyloid deposits 
in the periphery, it led to the suggestion that it may do the same with amyloid plaques 
in the brains of AD patients, particularly with the significantly higher levels of SAP 
reported in the hippocampus and cortex of AD patients compared to controls 
(Crawford et al., 2012). Additionally, SAP knockout mice with casein-induced 
amyloidosis showed a significantly decreased and delayed amyloid deposit load in the 
body as compared to WT mice with induced amyloidosis, but it is important to note 
that this study reflects amyloid deposits in the body, and not in the brain (Botto et al., 
1997). 
 
The aim of the present study is to focus on the peripheral pentraxin SAP after having 
established in Chapter 3 that it can enter the brain, deposit on plaques, and likely 
interact with the neuronal pentraxins at the synapse. To accomplish this, we will 
examine the effect of human SAP in the TgSAPL38 and 3xTg (TgSAPL38/TASTPM) 
mouse models in an attempt to determine whether there are any behavioral effects of 
SAP or the amyloid mutations and, if so, whether these changes are additive or 
interact. With the finding that human SAP expressed in the liver can enter the brains 
of mice (Fig. 3.6), it was hypothesized that human SAP could bind to the plaques in 
the brains of the TASTPM mouse and thus result in enhanced plaque pathology that 
may then contribute to cognitive impairment. This was also proposed in light of the 
finding by Cacucci et al., (2008) of a correlation between plaque load and cognitive 
impairment; while many studies find no such correlation, it is important to note that 
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this study examined the hippocampal plaque load and neocortex plaque load 
separately, and only found this correlation only with plaques in the hippocampus.  
 
T-maze forced alternation task 
 
Our present investigation has thus far concentrated on examining the effects of SAP 
and NPTX1 in the hippocampus, in light of findings that these proteins are localized 
in this area and at elevated levels in patients with AD (Abad et al., 2006; Crawford et 
al., 2012). Therefore, the behavioral task chosen for testing was one that shows high 
sensitivity to hippocampal dysfunction (Deacon and Rawlins, 2006; Dudchenko, 
2001). 
 
The T-maze forced alternation task tests the spatial working memory of the mouse, as 
it must remember what arm of the maze it has previously visited and alter its choice 
on the second run in order to receive a food reward. Mice employ the use of distal 
cues to determine which arm to next visit, and this type of short-term memory is 
utilized within the one trial, and once used, is typically forgotten (Dudchenko, 2004). 
Rodents tend to naturally alter their choice of goal arm, which is an instinctive 
behavior that is necessary for location of food, water, shelter and mates within their 
natural habitat. As this tendency is encouraged during the habituation period using the 
food reward, it is often found that even prior to training, WT mice will show a ~75% 
correct response rate in the task, with this increasing to >90% correct following the 
training period (Cacucci et al., 2008; Deacon and Rawlins, 2006). 
 
The cognitive demand of the T-maze can be increased by adding delays between the 
sample and choice runs. To test for subtle memory deficits, we used delays of 2.5, 5 
and 10 minutes for the test phase of the task. Also, to prevent demotivation, trials 
using longer delays were always interspersed pseudorandomly with trials of the 
shortest delay period. 
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  A                                                               B 
 
Figure 6.1. Schematic of forced-choice alternation T-maze task. Mice first ran the A) 
sample run with one blocked arm followed by the B) choice run with both arms open and 
reward in arm not previously visited. One drop of reward was placed on top of a barrier 
covering a small cup full of reward, designed to prevent the use of olfactory cues. Maze was 
cleaned with 70% EtOH between trials. 
 
 
Locomotor and Anxiety testing 
 
 
To further investigate cognitive function in our novel TgSAPL38 mouse models, mice 
were also evaluated in terms of locomotor activity and anxiety levels. To accomplish 
this, mice were tested in the open field and the elevated plus maze (EPM). Both tests 
are based on the approach-avoidance conflict, which is established by the 
contradiction of the innate exploratory behavior of a mouse, with the aversive 
properties of a large open space or brightly lit environment (Ohl, 2005). 
 
Open field 
 
The open field test consists simply of an inescapable open arena, and has been shown 
to be successful for use on mice (Prut and Belzung, 2003). With its ability to quickly 
measure many clearly defined behaviors, it is one of most common tests for 
locomotor activity, exploration and anxiety-related behaviors (ibid). For the purposes 
of our study, the open field was used to test two main parameters:  1) the proportion 
of time spent in center as an indicator of anxiety, and 2) total distance travelled as a 
measure of overall exploratory/locomotor activity.  
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Elevated plus maze (1 trial only test) 
 
The EPM is another simple method for assessing anxiety responses of rodents (Pellow 
et al., 1985). The task consists of a platform that includes an elevated open alley that 
produces a strong approach–avoidance conflict, and a dark enclosed alley, which does 
not. Assessment of anxiety behavior of rodents is evaluated by using the ratio of time 
spent on the open arms to the time spent on the closed arms. The benefit to using this 
assay over ones that present noxious stimuli (i.e. foot shock), is that it relies on the 
preference of the rodents for dark, enclosed spaces (approach) and their fear of open 
spaces and heights (avoidance), without eliciting a conditioned response (ibid). 
 
 
In the following results section, all behavioral experiments were performed by myself. 
 
 
Aims 
 
 
Here we aim to evaluate the cognitive performance of mice with the transgene for 
human SAP and determine whether SAP can influence the phenotype of mice with 
AD pathology to produce effects on memory. 
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Results 
 
Hippocampal-dependent memory 
 
No deficit in either TASTPM or TgSAP L38 mice at 13-14 months of age 
 
 
In the current study, mice between the ages of 13-14 months were tested in the 
forced-choice T-maze. The following four genotypes of mice were tested over three 
mixed cohorts: WT, TgSAPL38, TASTPM and 3xTg (TgSAPL38+TASTPM). 
Additionally, tests of motor function and anxiety were conducted in order to assess 
for confounding factors. Given the higher levels of anxiety reported in AD patients 
(Horning et al., 2014), these control measures were particularly relevant here. 
 
The protocol used within the present study for testing within the T-maze was adapted 
from that previously published for use on mice (Cacucci et al., 2008). However, 
because previous results showed no memory impairment with advanced plaque 
deposition in the TASTPM mice (Benway MSc Dissertation 2011), the current study 
modified the protocol from Cacucci et al. (2008) by increasing the delay time between 
sample and choice runs in order to increase cognitive demand in an attempt to best 
discern any memory impairment.   
 
For the T-maze task, correct responses were pooled into 2-day blocks for analysis. 
Two-way ANOVA of choice response over the 5 training blocks revealed no 
significant effect of interaction but main effects of block [F(4,156)=5.68, p=0.0003], 
genotype [F(3,39)=3.383, p=0.028], and subjects (matching) [F(39,156)=5.749, 
p<0.0001]. Post hoc analysis revealed that the TgSAPL38 and TASTPM mice fail to 
show a significant improvement across the blocks as compared to the WT and 3xTg 
(Fig. 6.2), as they unexpectedly began training with a high percentage (>80%) of 
correct choices, which therefore left little room for improvement. 
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Figure 6.2. TASTPM and TgSAPL38 mice fail to show improvement in T-maze task. 
Percent correct for choice runs of each genotype during the blocked training period for WT 
(n=15), TgSAPL38 (n=12), TASTPM (n=8) and 3xTg (n=8). Each block is 2 pooled days of 
training, with 6 trials per mouse per day. Two-way ANOVA revealed main effects of block 
and genotype. Sidak’s post hoc multiple comparison of control to TASTPM genotype are 
indicated **p<0.01, ***p<0.001. Data presented as mean ± SEM. 
 
 
In the analysis of response times (Fig. 6.3), two-way ANOVA did not reveal a 
significant interaction, but there were main effects of block [F(4,156)=22.17, 
p<0.0001], genotype [F(3,39)=3.344, p=0.029] and subjects (matching) 
[F(39,156)=7.149, p<0.0001]. Post hoc tests found that all genotypes were able to 
improve their performance time over the course of the five blocks (WT: p<0.0001; 
TgSAPL38: p<0.001; TASTPM: p<0.001; 3xTg: p<0.0001). These tests also showed 
that the 3xTg mice took a significantly longer time to respond at the beginning of 
training, during block 2 (p=0.0045). The increased amount of time required for the 
3xTg mice to make a choice may possibly indicate a higher level of anxiety in this 
mouse model. To determine whether higher levels of anxiety might account for this 
difference, subsequent anxiety tests were performed.  
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Figure 6.3. 3xTg mice require more time to make choice response in T-maze. Response 
times for choice runs during blocked training period for WT (n=15), TgSAPL38 (n=12), 
TASTPM (n=8) and 3xTg (n=8). Two-way ANOVA revealed main effects of block, 
genotype, and subjects (matching). Sidak’s post hoc multiple comparison of control to 3xTg 
genotype are indicated **p<0.01. Data presented as mean ± SEM. 
 
 
 
To further increase cognitive demand, “long” delay tests of 2.5, 5 and 10 minutes 
were introduced between sample and choice runs in the T-maze task. In looking at the 
performance in this long delay version, two-way ANOVA revealed significant main 
effects of genotype [F(3,117)=4.256, p=0.0068] and delay [F(2,117)=5.094, 
p=0.0076], though no significant effect of interaction was found. 
 
Post hoc tests revealed that the 3xTg mice performed significantly better than the WT 
mice with the 2.5 min delay test (p=0.0191). Interestingly, no differences were found 
between genotypes at either the 5 or 10-minute delays (Fig. 6.4). Overall, these delay 
results demonstrate that mice with the TASTPM AD transgenes, a human SAP 
transgene, or both, do not exhibit spatial working deficits at 13-14 months of age.  
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Figure 6.4. Mice with TASTPM transgenes make more correct choices with a 2.5-minute 
delay. Percentage of correct arm choices for WT (n=15), TgSAPL38 (n=12), TASTPM (n=8) 
and 3xTg (n=8). Two-way ANOVA revealed significant effects of genotype and delay. 
Sidak’s post hoc multiple comparison of control to 3xTg genotype are indicated *p<0.05. 
Data presented as mean ± SEM. 
 
 
 
To further elucidate cognitive performance, an additional probe trial was included in 
the training on days 5 and 10, in which the orientation of the maze was reversed to 
provide a greater spatial memory challenge. This test allows for the assessment of the 
animals’ use of external visuospatial cues (place response) versus an egocentric 
strategy utilizing only intramaze cues in order to make a correct choice (O'Keefe and 
Nadel, 1978). Results from these probe trials (Fig. 6.5 A,B) showed that genotype did 
not influence place or response choice at either time point during the training period.  
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Figure 6.5. No difference between genotypes for probe trials. Probe trial place response 
scores for A) day 5 and B) day 10, with WT (n=15), TgSAPL38 (n=12), TASTPM (n=8), and 
3xTg (n=8). Data represented as mean +/- S.E.M. 
 
 
 
Locomotor and anxiety testing 
 
In order to further characterize the phenotype of the novel TgSAPL38 transgenic mice, 
two additional tests of anxiety were performed. The open field and EPM tests 
represent standard measures of mouse anxiety commonly employed in behavioral 
studies (Pugh et al., 2007b; Scullion et al., 2011). 
 
 
 
Open field test 
 
The open field test allows for free exploration in a circular enclosure, and exploits a 
rodents’ natural tendency to display thigmotaxis - their preference to explore the 
periphery of a novel environment and remain closer to the walls. The open field is 
used to measure anxiety by quantifying the time spent in the inner, more anxiogenic 
area, versus the periphery.  
 
First, in order to assess overall locomotor activity in the different genotypes compared 
to WT mice, total distance travelled within the open field arena was measured. Two-
way ANOVA revealed a significant effect of the TASTPM genotype on the total 
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distance accumulated [F(1,37)=34.65, p<0.001] over the course of 15 minutes in the 
open field test (Fig. 6.6 A). Post hoc tests performed again revealed the anxiogenic 
effect of the TASTPM genotype, with both the TASTPM and 3xTg mice exploring 
the arena significantly less than the WT (p<0.0001 and p<0.01, respectively). 
 		 
 
 
 
 
Figure 6.6. Mice with TASTPM transgenes have lower exploratory drive and spend less 
time in center of open field. A) Total accumulated distance in the open field, and B) 
percentage of time spent in the center of the open field arena for the 15-min test, for WT 
(n=14), TgSAPL38 (n=11), TASTPM (n=8), and 3xTg (n=8). Two-way ANOVA revealed 
significant effects of TASTPM in A), and of TASTPM and SAP in B). Sidak’s post hoc 
multiple comparison to control are indicated **p<0.01, ****p<0.0001. Data presented as 
mean ± SEM. 
 
 
 
In examining the percentage of time mice spent in the center of the open field task 
(Fig. 6.6 B), two-way ANOVA again revealed a significant main effect of the 
TASTPM genotype [F(1,36)=48.59, p<0.0001], and of SAP [F(1,36)=5.48, 
p=0.0249]. Post hoc Sidak tests revealed that mice with the TASTPM AD transgenes, 
both with and without high SAP levels, demonstrated significantly greater levels of 
anxiety than the WT mice (p<0.0001 and p<0.01, respectively). These results are in 
line from those of Benway MSc Dissertation (2011), which found that TASTPM mice 
at the ages of 7-9 months of age displayed significantly higher levels of anxiety than 
WT mice. It can be seen from these results however that mice only expressing higher 
levels of human SAP do not demonstrate higher levels of anxiety. 
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Elevated Plus Maze 
 
 
Figure 6.7. No difference between genotypes for time spent in the open arm of the EPM. 
Relative dwell times in open arm for WT (n=15), TgSAPL38 (n=12), TASTPM (n=8), and 
3xTg (n=8). Data represented as mean +/- S.E.M. 
 
 
In the EPM, anxiety is measured by the preference of rodents for the closed arms over 
the open, more ‘anxiogenic’ ones (McDermott and Kelly, 2008). The interpretation is 
that the more time spent in the open arms of the maze, the less anxious the animal. 
However, with this measure, two-way ANOVA revealed no differences between 
genotypes (Fig. 6.7).  
 
Summary  
 
 
In order to assess possible deficits in hippocampal-dependent spatial working memory 
in our TgSAPL38 and 3xTg models, the T-maze forced alternation task was chosen, 
due to its high sensitivity to dysfunction within the hippocampus (O'Keefe and Nadel, 
1978). The T-maze task used was adapted from the protocol in Cacucci et al. (2008) 
in order to provide a greater cognitive challenge to elucidate any impairment in spatial 
working memory.  
 
In our examination of T-maze training performance, we found that the WT and the 
3xTg mice were able to learn the task and show an improvement in performance over 
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the 10-day training period. Unexpectedly, the TASTPM and the TgSAPL38 mice 
began training at levels that left little room for improvement (Fig. 6.2). This failure to 
‘improve’ could therefore be interpreted as an inability to forget the training that they 
experienced during habituation. However, the high percentages in correct choices 
made suggest that these mice do not necessarily display spatial memory impairments 
at this age tested. As TASTPM mice already possess a significant plaque load at this 
age of 13-14 months (Howlett et al., 2004; Matarin et al., 2015), our results further 
support the view that the plaques are not the cause of memory impairment. These 
results are also in line with previous work from our lab examining the spatial memory 
performance in younger TASTPM compared to WT mice in the same task at 4 and 8 
months of age, where TASTPM mice start at the same levels as the WT and end 
training at levels comparable to WT, with no significant differences found between 
the genotypes (Benway, MSc Dissertation, 2011; Fig. 6.8). 
 
 
 
 
Figure 6.8. TASTPM mice at 4 and 8 months of age show no difference in performance 
to WT in T-maze training. Percent correct for choice runs of each genotype during the 
blocked training period for WT 4 months (n=13), WT 8 months (n=13), TASTPM 4 months 
(n=11) and TASTPM 8 months (n=10). Two-way ANOVA revealed main effects of block 
[F(2.94, 172) = 9.30, p<.001], indicating again that all groups were able to learn and improve 
their performance in the 15-sec delay version of the task, and a main effect of genotype [F(1, 
43) = 7.14, p=.011]. Data presented as mean ± SEM, adapted from Benway, MSc 
Dissertation, 2011. 
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Unimpaired spatial memory function in these transgenic mice, with or without SAP, 
is further demonstrated in the analysis of the trials with long delays, in which all 
transgenic mice show comparable (if not better, in the case of the 3xTg) performance 
to WT mice. These results therefore suggest that cognitive function remains intact in 
mice expressing higher levels of human SAP, with and without the AD transgenes, at 
least in measures of this test. These results are again in line with previous work shown 
in Fig. 6.9 with younger TASTPM mice compared to WT that found no significant 
differences between genotypes in performance of the task with longer delays 
(Benway, MSc Dissertation, 2011).  
 
 
Figure 6.9. TASTPM mice at 4 and 8 months of age show no difference in performance 
to WT in longer delay. Percentage of correct arm choices for WT 4 months (n=13), WT 8 
months (n=13), TASTPM 4 months (n=11) and TASTPM 8 months (n=10). Two-way 
ANOVA revealed a significant effect of delay [F(1.86, 78.10) = 7.09, p=.002]. Data presented 
as mean ± SEM. 
 
The additional test of the probe trial similarly revealed no differences in performance 
when mice were required to utilize only external visuospatial cues instead of a mix of 
external and egocentric cues in the choice response phase of the task. When 
examining other factors of the task, we find that with response time, 3xTg mice took a 
significantly longer amount of time to make a choice in the earlier trials of training, 
which likely indicates higher levels of anxiety in this mouse model. This was also 
demonstrated in the open field test in which mice with the AD transgenes spent 
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significantly less time exploring than the WT or the TgSAPL38 mice, as measured by 
less distance travelled in the field. This anxiogenic effect of the TASTPM transgenes 
was further confirmed with these mice spending less time in the center of the open 
field than the WT and TgSAPL38 mice. However, no differences were found between 
genotypes in the EPM anxiety test, indicating that the anxiogenic effects of the AD 
transgenes may only be mild at the age of 13-14 months. 
 
Overall, these results suggest that mice expressing human SAP alone or with the 
human genes APPSWE/PSEN1M146V for AD have normal spatial working memory. 
While there was an effect of the AD transgenes on the open field measures of anxiety, 
the high levels of human SAP in these mice did not augment this effect. However, in 
looking at the data from the T-maze and anxiety tests together, it appears that there 
may be changes in cognitive flexibility in mice with the TASTPM transgenes, but that 
overexpression of human SAP alone does not result in this effect at the ages tested.  
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Chapter 7 
 
Discussion 
 
In this thesis I have investigated the influences of the two pentraxins SAP and NPTX1 
in the brain in relation to AD, and to one another, using a range of different 
techniques. In order to best determine prevention or treatment strategies for AD, it is 
imperative that we gain a better understanding of the factors potentially contributing 
to the progression of the disease. As both SAP and NPTX1 had previously been 
associated with pathological features of AD, the novel findings reported herein 
contribute to the field of neurodegenerative disease by building upon and clarifying 
the effects of both pentraxins at elevated concentrations in the brain. 
 
Molecular and histological investigation: SAP and NPTX1 in the hippocampus 
 
Due to the particular vulnerability to pathology and high levels of neuronal loss 
displayed by the hippocampus in AD (Braak and Braak, 1991; Scahill et al., 2002), 
the features and functions of this region were chosen as the focus for the experiments 
of this thesis. Using the tools that we generated or independently verified we were 
able to confirm previous reports that a sufficient level of SAP crossed the BBB into 
the brain, or was possibly also expressed at low levels, to allow for it to be detected in 
the brains of patients with AD (Kalaria et al., 1991a; Perlmutter et al., 1995). This 
peripheral pentraxin was found to localize around plaques in these patients, where 
NPTX1 presence was also confirmed. Additionally, we have been able to approximate 
the relative amounts of both pentraxins on plaques and find that there is substantially 
more NPTX1 than SAP in these regions. However, the presence of SAP around the 
plaques, at least qualitatively, in the same location as NPTX1 suggests it still may be 
able to influence Aβ deposition, possibly via an interaction with the neuronal 
pentraxin.  
 
An observation of interest in the experiments in AD patient brains was that strong 
NPTX1 staining was also found in the dystrophic neurites around plaques. It is likely 
that these neurites in the plaques are axonal boutons, rather than dendrites, as we 
found no evidence of NPTX1 being taken up by dendrites. Previous studies from our 
lab have found an increase in glutamate release probability to be both the first effect 
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of rising Aβ to occur in the TASTPM mouse model of AD pathology (Cummings et 
al., 2015), and also to occur after chronic exposure to NPTX1 (Cummings, Benway et 
al., 2017). Together these findings are in line with the effects produced from Aβ 
release in response to specific stimulus paradigms in normal rats (Abramov et al., 
2009), which is consistent with the evidence that increasing NPTX1 levels can 
mediate the effects of Aβ (Abad et al., 2006). 
 
In considering what factors may be influencing the dysregulation of the role of 
NPTX1 at the synapse in mediating the synaptic clustering of AMPA glutamate 
receptors to mediating the effects of Aβ, recent research has revealed possible routes 
by which this change may take place. Lee et al. (2017) investigated the role of 
NPTXR at the synapse using overexpression and knockdown of the ‘receptor’ in 
cultured neurons, and interestingly found that NPTXR knockdown resulted in a 
decrease in NPTX2, but had no effect on levels of secreted NPTX1. Overall, they 
found that NPTXR was a rate-limiting factor in synapse organization, where it 
recruits and stabilizes the other two neuronal pentraxins in a complex on the 
presynaptic membrane. Interestingly, this condition parallels what may be occurring 
in AD; microarray data from Matarin et al. (2015) shows the expression levels of 
NPTXR in TASTPM homozygous mice decreasing with age (Fig. 7.1). While this 
evidence might suggest that a decrease in the amount of NPTXR at the synapse could 
lead to an excess amount of unbound NPTX1, the decrease shown in the TASTPM 
data is only modest, and would require further investigation to determine whether 
NPTXR levels decrease in AD patient brains. However, as unbound NPTX1 has 
previously been shown to result in apoptosis (DeGregorio-Rocasolano et al., 2001), it 
may be the case that an excess of this pentraxin builds up at the synapse when there is 
a decrease in the level of NPTXR to bind it in complex, which may therefore 
contribute to the pathological progression in AD, particularly in the presence of 
increasing levels of Aβ.  		
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Figure 7.1. NPTXR expression is dysregulated in the hippocampus of TASTPM mice. 
Gene expression changes (compared to WT) of NPTXR in the hippocampus from 
(www.Mouseac.org; Matarin et al., 2015) in the hippocampus of WT and TASTPM 
homozygous mouse models. Two-way ANOVA revealed a main effect of genotype. Sidak 
post hoc multiple comparison of control to normalized NPTX1 levels are indicated *p<0.05. 
Data presented as mean ± SEM. 
 
 
In the examination of a mouse model of AD pathology, the inability to detect SAP 
mRNA or protein in WT or TASTPM mice corroborates our understanding that in 
mice, SAP is most likely only expressed in the liver (Pepys et al., 1997), and that 
mouse SAP does not readily cross the blood brain barrier in mice under normal 
physiological conditions (Winkler et al., 2001). This is in line with recent evidence by 
(Bien-Ly et al., 2015) who reported no breakdown of the BBB in multiple mouse 
models of AD pathology using protein markers of multiple different sizes. Our results 
therefore suggest that BBB breakdown does not occur in mice to the extent that 
evidence suggests in humans (Blennow et al., 1990; Hartz et al., 2012; Kalaria and 
Grahovac, 1990). However, it is also important to consider that the pathology of 
sporadic AD in humans progressively builds over the course of several decades, 
whereas the pathological process in transgenic mouse models is accelerated via the 
insertion of human genes for familial AD. Transgenic mice therefore lack many key 
neurological features comprising the brain milieu that accumulate during the long 
course of the disease, including periphery molecules that may have entered the brain 
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during times of infection, which are common in the old age (Manepalli et al., 1990), 
or a buildup of damage caused by cerebrovascular lesions, another common 
observation in aged samples (Bridges et al., 2014; Farrall and Wardlaw, 2009), with 
one study reporting the presence of infarcts in 43% of elderly brains in their donation 
program (Beach et al., 2015).  
 
In the same TASTPM mouse model, although previous work has found NPTX1 
mRNA expression to be dysregulated and actually decreased at the ages of 4 and 18-
months (Matarin et al., 2015), we find no decrease in protein levels in the mice with 
advanced AD pathology at 18-months of age. As we also find a high degree of 
NPTX1 concentrated around Aβ plaques in these models, it is likely that the mRNA 
expression is being downregulated via a feedback mechanism detecting higher levels 
of this protein accumulating around plaques. Moreover, a study using the 
measurements of the absolute concentrations of mRNAs and proteins from various 
organisms, including mammalian cells, worms, flies, yeast and a few species of 
bacteria found that in both bacteria and eukaryotes, the cellular concentrations of 
proteins showed a squared Pearson correlation coefficient of ~0.40 with the 
abundances of their corresponding mRNAs (Vogel and Marcotte, 2012). This implies 
that only ~40% of the variation in protein concentration can be explained by knowing 
mRNA abundances, but that there is a remaining ~60% variation due to a 
combination of post-transcriptional regulation and measurement noise (ibid). An 
additional point to consider is that protein multimerization can influence a feedback 
circuit that regulates transcription/translation rates that can increase negative feedback 
strength (Singh, 2011; Singh and Hespanha, 2009; Thattai and van Oudenaarden, 
2001), and given NPTX1 is prone to multimerization, the downregulation of mRNA 
may be explained by NPTX1 forming a higher number of complexes at the synapse in 
AD.  	
Our interesting finding came with the examination of the TgSAP, TgSAPL38 and 3xTg 
mice expressing human SAP, where diffuse SAP staining could be seen throughout 
several regions of the brain, including the hippocampus, and around plaques in the 
mice with the TASTPM transgenes. Given that the affinity for the SAP antibody for 
its target is significantly higher than the affinity of the NPTX1 antibody that we used, 
it would lead us to conclude that the SAP concentration in the brains of these mice is 
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low, but at levels that are high enough to elicit impaired synaptic transmission with 
chronic exposure (Cummings, Benway et al., 2017). However, this still raises the 
question of how the SAP gets into the brain of the transgenic mice. The three lines of 
mice listed above are exposed to human SAP throughout life and so it is possible that 
the BBB is compromised from time to time during the life of the mouse and that this 
results in slightly higher levels in the brain, or that there is a leaky expression of the 
promoter in the brain. Corroborating evidence for these findings was shown in a 
recent study by Al-Shawi et al. (2016), in which the same 3xTg human SAP-
expressing mice were examined at 20 months of age. This study confirmed high 
levels of hSAP staining in the cerebrovasculature, at a level at least 1000-fold higher 
(in the case of the TgSAP, and even higher in the TgSAPL38 and 3xTg mice) than the 
plasma and extracerebral interstitial fluid concentration. This further supports the 
hypothesis that SAP is capable of penetrating the BBB across such a high 
concentration gradient and entering the brain. Finally, although we and others 
(Hawrylycz et al., 2012; Mulder et al., 2012) [www.brainmap. org]; (Matarin et al., 
2015)[www.mouseac.org]) find little or no evidence for expression of SAP within the 
brain, there still remains the possibility of local synthesis (Yasojima et al., 2000), 
which may be below detection thresholds in most studies.  
 
SAP crossing the BBB 
 
Our results using peripherally evoked LPS inflammation confirm the finding by 
Veszelka et al. (2013) that SAP can enter the brain under conditions of BBB 
breakdown. This result is compatible with the reported 1000-fold concentration 
gradient for SAP between the plasma and brain (Kolstoe et al., 2009; Nelson et al., 
1991b). While soluble SAP would be expected to be broken down or be otherwise 
removed from the brain (Veszelka et al. 2013), its ability to infiltrate the brain 
through a compromised BBB in AD suggests that it may possibly be binding to 
plaques and preventing their removal, thus reflecting the higher concentrations of 
SAP found in the brains of AD patients (Crawford et al., 2012). However, it is also 
possible that SAP is binding to dystrophic neurites or damaged synapses, where 
NPTX1 has previously been reported in the brains of AD patients (Abad et al., 2006), 
or even to NPTX1 on the plaque. The in vitro and in vivo evidence from Veszelka et 
al. (2013) shows that rapid efflux of SAP is greatly preferred at the BBB, with rapid 
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clearance following intrahippocampal administration and significantly higher release 
of SAP from endothelial cells to the luminal than that to the abluminal side. These 
findings support the hypothesis that the binding of SAP to amyloid may be what is 
preventing its removal from the brain and allowing levels, albeit low, to be 
maintained. 
 
The question arises as to what causes BBB disruption and preferential localization to 
the hippocampus in conditions of advanced age or disease (Montagne et al., 2015). As 
the hippocampus is a site of early pathology in aging and AD (Braak and Braak, 
1991), it would be logical to hypothesize that Aβ or tau might play a role. The 
accumulation of Aβ occurs earlier than tau (though tau cannot be completely 
excluded), is toxic to pericytes (Verbeek et al., 1997), and can induce cerebral 
endothelial dysfunction. Specifically, Aβ is able to increase BBB permeability via the 
activation of transient receptor potential melastatin-2 channels (TRPM-2) and through 
causing dysregulation of endothelial intracellular Ca2+ (Park et al., 2014). 
Importantly, SAP has also been shown to potentiate the BBB-weakening effect of Aβ, 
as their combination in vitro was found to increase BBB permeability (Veszelka et al., 
2013), suggesting that the crossing of SAP through the BBB could be capable of 
propagating the acceleration of BBB breakdown that has been shown to occur in AD 
(Montagne et al., 2015).  
 
SAP can interact with the neuronal pentraxins 
 
Interestingly, our coimmunoprecipitation results have shown a novel finding that SAP 
can bind to each of the neuronal pentraxins (NPTX1, NPTX2 and NPTXR), which 
suggests that SAP may be able to contribute to heteromultimeric complexes of 
NPTXs and, in doing so, possibly alter their activity. It is important to note however 
that they could also be pulled down together because they can simultaneously bind to 
other common partners, and so it is possible that SAP may therefore be able to 
compete for the same cell surface targets that the neuronal pentraxins bind to. 
Importantly, this result drastically expands the scope of SAP’s possible influence in 
the brain, beyond its interaction with plaques; if SAP can interact with each of the 
neuronal pentraxins, it is possible that this interaction could also cause disruption to 
the normal synaptic functions of the NPTXs in the brain (Fig. 7.2). However, it is 
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important to note that this would only be likely to occur under conditions of 
significant BBB breakdown, in order for the concentration of SAP to be high enough 
to exert any possible effects in the brain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. SAP is capable of interacting with the neuronal pentraxins and may be able 
to influence their function if high enough levels cross the BBB. Schematic depicting 
possible interactions that SAP could be having with the neuronal pentraxins at the synapse. 
Molecular biology data presented in this thesis has indicated that SAP can form part of the 
pentamer with the other neuronal pentraxins, and cell culture work has shown that SAP can 
also influence the function of NPTX1 on neurons and microglia.  
 
 
In summary, both SAP and NPTX1 are present around Aβ plaques in post-mortem 
brains of people with AD and, although mouse SAP is not present in the brains of 
TASTPM mice with advanced AD pathology, human SAP can be seen in the brains of 
mice when it is expressed at levels that are within a physiologically range in humans. 
The evidence presented here therefore strongly suggests that SAP is capable of 
entering the brain under some conditions of BBB breakdown, where it would have the 
opportunity to interact with the NPTXs and, as has been previously shown, influence 
central synaptic transmission (Cummings, Benway et al., 2017) in AD. 
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Spine density changes with treatment of SAP and/or NPTX1 
 
 
As changes in synapse function have been shown to occur before the onset of plaques 
in AD (Busche et al., 2012; Cao et al., 2012; Cummings et al., 2015), the examination 
of related factors that may play roles in the development of the disease is vital. Here, I 
have investigated the effects that increased levels of SAP and NPTX1 may be having 
on healthy neurons, representing what may be occurring in the brain prior to the 
development of plaques or the presence of increased levels of soluble Aβ. Developing 
a better understanding of how normal functions can go awry and contribute to disease 
pathology is key to the identification of targets for treatment and prevention of such 
disorders. 
 
Our finding that NPTX1 treatment at a concentration first found to elicit changes in 
synaptic transmission significantly decreased spine density in hippocampal neurons is 
in accordance with previous research by (Figueiro-Silva et al., 2015), where it was 
hypothesized that NPTX1 negatively regulates excitatory synapses. This role for 
NPTX1 was proposed based upon the results seen after its knockdown, which they 
found to cause: 1) an increase in the number of excitatory synapses, 2) a localization 
of extrasynaptic amino acid receptors to the new synapses, 3) higher frequency 
mEPSCs demonstrating functionality, and 4) an increase in the amplitude of 
spontaneous calcium oscillations. With this increase in excitatory synapse number 
from knockdown, they correspondingly found a significantly higher number of spine 
protrusions. As we found the opposite effect with chronic exposure of NPTX1, our 
results support this hypothesis. This role of NPTX1 as a limiting factor in excitatory 
synapses is further supported by the finding that overexpression of NPTX1 decreased 
the number of excitatory synapses (ibid). In the context of AD, given the increase in 
NPTX1 protein levels (Abad et al., 2006), it can be hypothesized that NPTX1 acts as 
a key mediator in driving the synaptic loss that is one of the hallmarks of the disease 
(Selkoe, 2002). Supporting this hypothesis, evidence from Abad et al. (2006) found 
that NPTX1 significantly contributes to synapse loss, neurite damage, and the 
subsequent apoptotic toxicity that is induced by Aβ in cortical neuronal cultures. 
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It was initially hypothesized that NPTX1 and SAP may be capable of inducing 
changes in synaptic density due to excitotoxicity produced as a result of their 
application at the same experimental concentrations that cause increases in glutamate 
release (Cummings, Benway et al., 2017). However, given only NPTX1 application 
caused a decrease in spine density and the finding that SAP co-application blocked, 
rather than augmented, the effect of NPTX1, an excitotoxic mechanism is therefore 
unlikely. Importantly, these results suggest that SAP may be capable of interacting 
with NPTX1 at the synapse and mediating the negative regulatory function that 
NPTX1 has been proposed to have on spines (Figueiro-Silva et al., 2015).  
 
While the application of SAP to hippocampal neurons did not cause a decrease in 
spine density, previous findings from our lab have shown that the long-term exposure 
of SAP that occurs in the brains of transgenic mice with human SAP can impair LTP 
(Cummings, Benway et al., 2017). While the latter results would seem to contradict 
the finding in the present study, given the correlation of spine formation with LTP 
(Segal, 2005), it may be the case that the concentration used and the extent of 
treatment time was not sufficient enough to produce changes in spine number. It 
should also be considered that LTP is associated with changes in the size of spine 
heads, as their enlargement is consistently reported to occur in response to the 
expansion of the postsynaptic density after LTP induction (Desmond and Levy, 1986; 
Fifkova and Anderson, 1981). It may therefore be the case that SAP could be causing 
changes in spine structure, rather than in density – at least at the concentration used. 
However, for NPTX1, the finding of spine density reduction with increased levels of 
NPTX1 correlates to the enhancement in LTP after NPTX1 knockdown that was 
reported by Figuero-Silva et al. (2015). Together, these results suggest that NPTX1 is 
likely to mediate more potent effects at the postsynaptic density than SAP. 
Additionally, the blocking effect of SAP when applied with NPTX1, rather than an 
additive effect, suggests SAP is interacting with NPTX1 or blocking the targets used 
by NPTX1 to regulate synapse formation. 
 
Effect of SAP and NPTX1 on microglia numbers and activation 
 
The functions of microglia in the CNS are inherently linked to the development, 
clearance and plasticity of synapses, which the pentraxins have also been shown to 
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influence (Osera et al., 2012; Cummings, Benway et al., 2017). The treatment of 
organotypic hippocampal slices with NPTX1 was found to cause a decrease in the 
number of microglia, and the co-treatment with SAP was again found to block the 
effect of NPTX1, which was the same effect that was observed with the hippocampal 
neurons. The blocking effect of SAP on NPTX1 in both cultured neurons and 
hippocampal slices further supports the hypothesis that SAP is interacting with 
NPTX1, and curiously poses the question of whether it may be capable of providing 
protection to cells by counteracting the negative effects elicited by NPTX1 or 
competing for binding to the same targets. If SAP is forming a complex with NPTX1, 
as I have shown is feasible, then it is possible that the binding of SAP to NPTX1 is 
preventing or decreasing the potency of the interaction that NPTX1 would otherwise 
be involved in at the synapse.  	
As NPTX1 has been found to contribute to the neuronal damage evoked by Aβ, it 
raises the possibility that this may also be the case in regard to microglia. It has been 
shown that transgene overexpression of NPTX1 reproduces the neurotoxic effects of 
Aβ, and that Aβ exposure to cultured microglia promotes their degeneration (Korotzer 
et al., 1993). If NPTX1 can mimic the effects of Aβ on neurons, the possibility that it 
may also be capable of mediating the same effects of Aβ on microglia is an important 
point for consideration. NPTX1 may therefore be a target worth further investigation 
for the treatment of AD. 
 
The activation of microglia requires a high level of metabolic energy from the cell, 
and prolonged periods of activation of aging microglia often result in senescence due 
to the strains placed on the cell (Streit, 2006). It was therefore hypothesized that 
NPTX1 may cause a decrease in microglia numbers as a result of the pentraxin 
inducing high levels of activation, given the report that NPTX1 binds to C1q (Stevens 
et al., 2007), the initiator of the complement cascade. Interestingly however, it was 
found that neither pentraxin had an effect on activation levels when applied on its 
own, but their co-application resulted in a decreased activation. This surprising 
finding indicates that the spine density changes that were observed from NPTX1 
application were unlikely to have been mediated via a microglia ‘pruning’ effect 
mediated by C1q, as previously suggested. It is possible however that the decreased 
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activation levels may in part be due to both pentraxins binding to C1q in a manner 
that instead prevents or reduces the potency of the activation of complement.  	
In relation to AD, increases in SAP and NPTX1 levels inhibiting microglial activation 
in key areas where phagocytosis of Aβ should be occurring may be a pathological 
feature of these two proteins that is important to consider. Moreover, these results 
suggest that an increase in NPTX1 level in the brain, as shown to occur in Abad et al., 
(2006), may be a factor that promotes dystrophy of aging microglial and subsequent 
death, further impeding the clearance of Aβ that microglia should be mediating. The 
latter point is particularly important considering that NPTX1 levels are clearly much 
higher around plaques and in dystrophic neurites than those of SAP in the brain (see 
Chapter 3), as the relatively small amount of SAP would be unlikely to block most of 
the effects of NPTX1. 
 
 
Spatial memory in mice expressing human SAP 
 
 
In our investigation into whether the synaptic effects of human SAP in the brains of 
transgenic mice would translate into memory problems, no spatial memory 
impairment could be detected up to an age of 14-months old, in any of the genotypes. 
This surprising finding raises the question of how mice with the AD transgenes were 
able to perform as well as WT in the task, particularly given the changes in LTP 
commonly observed in mouse models of AD pathology at earlier ages (Tozzi et al., 
2015)Jacobsen et al., 2006). Additionally, we have found that the magnitude of LTP 
is significantly smaller in hippocampal slices from TgSAP mice compared with WT 
mice (Cummings et al., 2017), and this model expresses only approximately (at least) 
half the amount of SAP as the TgSAPL38 mice (as described previously). However, 
sensitivity of the T-maze task has been confirmed in a previous experiment that used 
the Tg2576 mouse model of AD pathology in the task and found correlations between 
hippocampal plaque burden and behavioral performance (Cacucci et al., 2008). It is 
important to note that the aforementioned study examined older mice at 16 months of 
age, after significant impairments in LTP have been found in both the CA1 and DG 
(Chapman et al., 1999), and additional measures of response time and anxiety were 
not taken into account in the results. Despite the reports from Cacucci et al. (2008), a 
direct link between the amount of Aβ plaque deposits and behavioral deficits has not 
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been clearly identified in transgenic mouse models of AD or in patients, and that it is 
only synaptic loss that has been shown to correlate to cognitive impairment (Terry et 
al., 1991).  	
The training results of the TASTPM and TgSAPL38 mice beginning at such high 
levels may indicate the inability for these models to extinguish the memory of the 
task. The lack of extinction of fear memory has been shown in the TASTPM mice as 
early as 4 months of age (Pardon et al., 2009; Rattray et al., 2009), suggesting it may 
be a more sensitive measure for memory assessment that the explicit forced-choice T-
maze memory task. The extinction of fear memory is the learned inhibition of fear, 
and is a less explored but complex cognitive process. It is possible that the T-maze 
environment induces some level of fear in the animals, which would be expected to 
occur during habituation, but this should be followed by an inhibition of the acquired 
association by learning that the task is not aversive by the start of training (given their 
gained familiarity of the task and the reward provided). This would then suggest that 
the exposure to the maze can induce a reconsolidation of the learned behavior, rather 
than its extinction, thus demonstrating a reduction in cognitive flexibility (Pardon et 
al., 2009). It can therefore be suggested that the TgSAPL38 mice show similar memory 
extinction impairment as the TASTPM mice at 13-14 months of age, given both 
genotypes began training (following habituation) at such a high correct rate. However, 
the 3xTg display a learning curve similar to WT - an unexpected result, but one that 
has been supported by electrophysiological findings from our lab that have shown a 
decrease in paired pulse ratio and decreased LTP in TASTPM and TgSAPL38 mice, 
but no change in the 3xTg (Liu et al., unpublished data). Importantly, this could 
suggest that SAP may be capable of reducing the progression of, rather than 
negatively augmenting, the TASTPM phenotype. A possible explanation for this may 
be that SAP is promoting plaque formation and thus contributing to the removal of Aβ 
from the synapses, based upon the evidence from SAP knockdown mice that showed 
delayed and decreased amyloid plaque formation from experimentally induced 
amyloidosis (Botto et al., 1997). However, it is important to note that the findings 
from the aforementioned study were based upon plaques in the periphery, not in the 
brain, and therefore reflect very different physiological conditions. 
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Evidence supporting a protective function of amyloid aggregation has been shown by 
(Cohen et al., 2009) in a study that examined the effect of a reduction in insulin-like 
growth factor 1 (IGF-1) signaling in a mouse model of AD pathology with the human 
transgenes APPswe and presenilin-1 ΔE9. This study found that a reduction of IGF-1 
signaling resulted in an increased quantity of densely packed, larger fibrillar plaques 
later in life, which were found to protect from proteotoxicity associated with Aβ. The 
hyper-aggregation of Aβ was correlated with reductions in neuronal and synaptic loss, 
neuroinflammation, and behavioral impairment. These findings suggest that the 
accumulation of tightly packed and ordered plaques results in possible sequestering of 
the soluble Aβ oligomers that are consistently found to be more toxic than aggregated 
Aβ (Haass and Selkoe, 2007). This hypothesis has been supported in findings that 
enhanced Aβ fibrillization in mice by a different means (insertion of AβE22G 
mutation in hAPP mice) reduced Aβ toxicity (Cheng et al., 2007), and that small, 
oligomeric Aβ impairs LTP to a greater extent than fibrillar Aβ (Shankar et al., 2008).  
 
Another surprising result was found during the test phase of the task, with the 
introduction of long delays. With greater memory challenge, mice with the TASTPM 
transgene performed better with the 2.5-minute delay, but then performed at the same 
levels as WT when challenged with the two longer delays. This further suggests that 
the TASTPM mice may lack the ability to forget. These results may therefore indicate 
that the T-maze test may not be sensitive enough to detect explicit alteration in 
memory function, or that significant compensatory mechanisms exist in the brains of 
the mice that allow perceived normal functioning up to significantly advanced ages. 
This result is in line with recent findings from (Beglopoulos et al., 2016) that showed 
normal learning in the PDAPP mouse model of AD pathology (with the APPV717F 
mutation, exhibiting 10-fold higher human APP expression than endogenous murine 
APP) in the spatial memory-dependent water maze task. However, while the PDAPP 
mice showed no impairment in learning of the task at 3-4 months of age, the study 
reports that the transgenic mice had increased levels of forgetting the task, when long 
intervals of 7 days were introduced between trials (ibid). As this was a novel design 
feature of the maze, it is an important point to consider in animal behavior work that it 
may be necessary to incorportate such modifications for more sensitive detection of 
cognitive changes.	
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While no impairments in spatial memory were found, it was important to also 
determine whether any potentially confounding factors were apparent, particularly 
given that higher levels of anxiety are commonly reported in AD patients (Assal and 
Cummings, 2002; Brodaty and Low, 2003). An anxiogenic effect of the TASTPM 
transgenes was confirmed with these mice spending less time in the center of the open 
field than the WT and TgSAPL38 mice. This result correlates to previous findings in 
TASTPM mice tested at 7-8 months of age, where significantly higher levels of 
anxiety were observed using the same measurement in the open field task (Benway, 
MSc Dissertation). This effect was also demonstrated in the open field test in which 
mice with the AD transgenes spent significantly less time exploring than the WT or 
the TgSAPL38 mice, as measured by less distance travelled in the field. This finding is 
in agreement with increased levels of immobility observed in 5.5 month old TASTPM 
mice in retention and extinction trials in contextual fear conditioning experiments 
(Pardon et al., 2009). Additionally, hypoactivity has been displayed in 10-month old 
TASTPM mice previously, as measured using beam boxes and open field tests (Pugh 
et al., 2007a). It is important to note however that not all mouse models of AD 
pathology display increased levels of anxiety. While the Tg2576 and TgCRND8 
(Swe/Indiana APP mutations) mice both exhibit increased anxiety (Lee et al., 2004; 
Ognibene et al., 2005), and even a correlated increase in the expression of genes 
implicated in anxiety (for the latter model), other studies report no changes, such as in 
the APP23 models (Lalonde et al., 2002). While the observation that other measures, 
such as alterations in circadian rhythms, which are known to affect activity levels in 
mice, and may partially account for some of the variation observed, it is still unclear 
as to what accounts for the differences among transgenic animals. This therefore 
demonstrates that there is a variation between mouse models in the manifestation of 
different behaviors, making it important to assess what could be confounding factors 
when examining the phenotypes of the different transgenic models. A possible way of 
resolving this may be through the use of knock-in mice rather than transgenic models, 
which would avoid some of the issues related to overexpression and possible 
influences of transgene insertions.  
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Conclusion 
 
In the field of AD research, there is still a great deal yet to be understood about the 
underlying mechanisms that go awry and culminate in the tipping of the homeostatic 
balance in the brain towards disease. In this thesis I have investigated the influence of 
two members of the pentraxin family of proteins that have previously been implicated 
in AD, but focused my examination in a novel way that has considered not only the 
effects of each individually, but also their possible interaction, where possible, in 
relation to AD progression. Here I present evidence that the peripheral pentraxin SAP 
and the neuronal pentraxin NPTX1 can interact, and possibly affect the same targets 
within the brain.  
  
By thoroughly performing a series of tests to determine the specificity and affinities 
of multiple antibodies, I have been able to confirm the localization of SAP and 
NPTX1 in the brains of patients with AD and in mice with AD transgenes, with and 
without human SAP. From these histological examinations, it is clear that SAP is 
capable of infiltrating the brain, and can be found in key locations that are vulnerable 
in AD along with NPTX1, particularly co-localized around amyloid plaques. To 
investigate the possible implications of these findings, we considered the evidence 
that the neuronal pentraxins form complexes with one another and extended the 
possibility of this property to SAP, give the high degree of structural similarity. In our 
novel finding that SAP can bind to each of the neuronal pentraxins, we have 
broadened the lens through which SAP has been previously been viewed to mediate 
effects in the brain.  
 
With the evidence for the penetration of SAP into the brain and its potential for 
interaction with NPTX1 that was presented in Chapter 3, it was critical for our follow 
up work to further investigate this interaction and the effects that it may be exerting 
on different cell types. The finding in Chapter 4 that SAP not only fails to produce an 
additive effect, but can actually block the effect of NPTX1 on spine density 
demonstrates the possibility of a protective role for SAP in the brain. Moreover, this 
same effect was found with microglia in organotypic slices as described in Chapter 5, 
corresponding to the findings in spine density changes, but using a more 
physiologically relevant culture system and examining different cell types.  
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Apart from the interaction of SAP with NPTX1 or the downstream targets of the 
neuronal pentraxin, we have uncovered another possible protective function for SAP 
in the brain, in the examination of behavior in Chapter 6. While it may be the case 
that SAP is stabilizing Aβ plaques in the brain as it does in the periphery, the result of 
it doing so may be contributing to the removal of the toxic soluble Aβ species from 
the extracellular space, which is a mechanism that has previously been shown to be 
protective (Cohen et al., 2009). The finding that the mice with AD transgenes and 
human SAP performed similar to the WT mice suggests that SAP may be capable of 
moderating the effects of soluble Aβ, which is the toxic species most highly 
associated with cognitive impairment.  
 
However, in relating these results to humans, it is important to note that the likelihood 
of SAP being able to effectively block the effects of NPTX1 or stabilize Aβ plaques 
in the brain is quite low, given we have determined that qualitatively there is a much 
higher concentration of NPTX1 in the brain relative to SAP. Moreover, it is evident 
that SAP is also capable of exerting toxic effects on neurons as well, given the 
findings of it causing neuronal death in cell cultures (Duong et al., 1998; Urbanyi et 
al., 1994) and increasing glutamate release probability (Cummings, Benway et al., 
2017). In considering the data that has been presented throughout this thesis, the 
scope of the possible influence of SAP in the brain and in AD has been significantly 
broadened.  The interplay of SAP with the neuronal pentraxins has been shown here 
to be an important point for consideration in the future investigations of the functions 
of the NPTXs in the AD brain.  
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